Healthcare - associated infections: classification, epidemiology and treatment by Teresa Maria da Costa Cardoso


HEALTHCARE-ASSOCIATED 
INFECTIONS: CLASSIFICATION,
EPIDEMIOLOGY AND TREATMENT
TERESA MARIA DA COSTA CARDOSO
PORTO | 2013
HEALTHCARE-ASSOCIATED INFECTIONS: 
CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
PhD thesis, Medical Faculty, University of Oporto
The research described in this thesis and its publication was supported by: a PhD research grant from the Teaching
and Research Department (Departamento de Formação, Ensino e Investigação) of Oporto Hospital Centre (reference
number 069/07(051-DEFI/084-CES)) and ASSUCIP (Associação de Apoio à Unidade de Cuidados Intensivos Polivalente
- UCIP, Hospital de Santo António, Porto, Portugal). The funders had no role in the study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
ISBN: 978-989-20-3403-4
Design and layout: Isabel Pereira Monteiro
Printing: Next Color – Soluções Digitais, Lda.
Copyright 2013 © Teresa Cardoso | Porto | Portugal
All rights reserved. No part of this thesis may be reproduced, stored or transmitted in any form or by any means without the prior permission of
the author. The copyright or the articles that have been accepted for publication or that have been published, has been transferred to the
respective journals.
HEALTHCARE-ASSOCIATED 
INFECTIONS: CLASSIFICATION,
EPIDEMIOLOGY AND TREATMENT
A thesis submitted by
TERESA MARIA DA COSTA CARDOSO
to the Medical Faculty of Porto University for the degree in 
Doctor in Clinical and Health Services Research
PhD supervisor: 
Professor Doutor António Sarmento
Medical Faculty of Porto University
PhD co-supervisor: 
Professor Doutor Altamiro Costa Pereira
Medical Faculty of Porto University 
JURI
PRESIDENTE:
Doutor José Agostinho Marques Lopes, 
professor catedrático da Faculdade de Medicina da Universidade do Porto 
(em representação do Reitor da Universidade do Porto)
VOGAIS:
Doutor António Carlos Megre Eugénio Sarmento, 
professor catedrático convidado da Faculdade de Medicina da Universidade do Porto
Doutor José Gabriel Saraiva da Cunha, 
professor associado com agregação da Faculdade de Medicina da Universidade de Coimbra
Doutor Pedro Manuel Sarmento Rodrigues Póvoa, 
professor auxiliar da Faculdade de Ciências Médicas da Universidade Nova de Lisboa
Doutor José Artur Osório de Carvalho Paiva, 
professor associado convidado da Faculdade de Medicina da Universidade do Porto
Doutro Pedro Pereira Rodrigues, 
professor auxiliar convidado da Faculdade de Medicina da Universidade do Porto
PROFESSORES CATEDRÁTICOS:
MANUEL ALBERTO COIMBRA SOBRINHO SIMÕES
MARIA AMÉLIA DUARTE FERREIRA 
JOSÉ AGOSTINHO MARQUES LOPES
PATRÍCIO MANUEL VIEIRA ARAÚJO SOARES SILVA
DANIEL FILIPE LIMA MOURA
ALBERTO MANUEL BARROS DA SILVA
JOSÉ MANUEL LOPES TEIXEIRA AMARANTE
JOSÉ HENRIQUE DIAS PINTO DE BARROS
MARIA FÁTIMA MACHADO HENRIQUES CARNEIRO
ISABEL MARIA AMORIM PEREIRA RAMOS
DEOLINDA MARIA VALENTE ALVES LIMA TEIXEIRA
MARIA DULCE CORDEIRO MADEIRA
ALTAMIRO MANUEL RODRIGUES COSTA PEREIRA
RUI MANUEL ALMEIDA MOTA CARDOSO
ANTÓNIO CARLOS FREITAS RIBEIRO SARAIVA
JOSÉ CARLOS NEVES DA CUNHA AREIAS
MANUEL JESUS FALCÃO PESTANA VASCONCELOS
JOÃO FRANCISCO MONTENEGRO ANDRADE LIMA BERNARDES
MARIA LEONOR MARTINS SOARES DAVID
RUI MANUEL LOPES NUNES
JOSÉ EDUARDO TORRES ECKENROTH GUIMARÃES
FRANCISCO FERNANDO ROCHA GONÇALVES
JOSÉ MANUEL PEREIRA DIAS DE CASTRO LOPES
ANTÓNIO ALBINO COELHO MARQUES ABRANTES TEIXEIRA
JOAQUIM ADELINO CORREIRA FERREIRA LEITE MOREIRA
RAQUEL ÂNGELA SILVA SOARES LINO
PROFESSORES CATEDRÁTICOS JUBILADOS E APOSENTADOS:
ABEL JOSÉ SAMPAIO DA COSTA TAVARES
ABEL VITORINO TRIGO CABRAL
ALEXANDRE ALBERTO GUERRA SOUSA PINTO
AMÂNDIO GOMES SAMPAIO TAVARES
ANTÓNIO AUGUSTO LOPES VAZ
ANTÓNIO CARVALHO ALMEIDA COIMBRA
ANTÓNIO FERNANDES DA FONSECA
ANTÓNIO FERNANDES OLIVEIRA BARBOSA RIBEIRO BRAGA
ANTÓNIO GERMANO PINA SILVA LEAL
ANTÓNIO JOSÉ PACHECO PALHA
ANTÓNIO MANUEL SAMPAIO DE ARAÚJO TEIXEIRA
 
BELMIRO DOS SANTOS PATRÍCIO
CÂNDIDO ALVES HIPÓLITO REIS 
CARLOS RODRIGO MAGALHÃES RAMALHÃO
CASSIANO PENA DE ABREU E LIMA
DANIEL SANTOS PINTO SERRÃO
EDUARDO JORGE CUNHA RODRIGUES PEREIRA 
FERNANDO DE CARVALHO CERQUEIRA MAGRO FERREIRA
FERNANDO TAVARELA VELOSO
FRANCISCO DE SOUSA LÉ
HENRIQUE JOSÉ FERREIRA GONÇALVES LECOUR DE MENEZES
JOSÉ AUGUSTO FLEMING TORRINHA
JOSÉ CARVALHO DE OLIVEIRA
JOSÉ FERNANDO BARROS CASTRO CORREIA
JOSÉ LUÍS MEDINA VIEIRA
JOSÉ MANUEL COSTA MESQUITA GUIMARÃES
LEVI EUGÉNIO RIBEIRO GUERRA
LUÍS ALBERTO MARTINS GOMES DE ALMEIDA
MANUEL AUGUSTO CARDOSO DE OLIVEIRA
MANUEL MACHADO RODRIGUES GOMES
MANUEL MARIA PAULA BARBOSA
MARIA DA CONCEIÇÃO FERNANDES MARQUES MAGALHÃES
MARIA ISABEL AMORIM DE AZEVEDO
MÁRIO JOSÉ CERQUEIRA GOMES BRAGA
SERAFIM CORREIA PINTO GUIMARÃES
VALDEMAR MIGUEL BOTELHO DOS SANTOS CARDOSO
WALTER FRIEDRICH ALFRED OSSWALD
ÁLVARO JERONIMO LEAL MACHADO DE AGUIAR
MANUEL ANTÓNIO CALDEIRA PAIS CLEMENTE
JORGE MANUEL MERGULHÃO CASTRO TAVARES
To my family:
Ana, Simão e Joaquim
Maria e Maximino
Filomena e Lourenço 

TABLE OF CONTENTS
Page
Acknowledgements XI
Summary / Sumário XIII / XV
List of figures and tables XVII
Abbreviations XIX
Outline and outcomes of this thesis XXI
Scientific and clinical outputs of this thesis XXIII
CHAPTER 1 Introduction 3
1.1. Rationale 3
1.2. Aims 4
CHAPTER 2 Healthcare-associated infections: a systematic review 7
2.1. Classification of healthcare-associated infections 9
2.2. Microbiological profile of healthcare-associated infections 
and therapeutic implications 29
2.3. Healthcare-associated infections and inadequate initial antibiotic therapy 47
2.4. Healthcare-associated infections and mortality 59
CHAPTER 3 Patients and general methods 71
CHAPTER 4 Results 83
4.1. Additional risk factors for infection by multidrug-resistant 
pathogens in healthcare-associated infections 85
4.2. Differences in the microbiological profile between community-acquired, 
healthcare-associated and hospital-acquired infections 97
4.3. The impact of healthcare-associated infections on mortality: 
failure in clinical recognition is related with inadequate antibiotic therapy 111
4.4. Predisposition, Insult/Infection, Response and Organ dysfunction (PIRO): 
a pilot clinical staging system for hospital mortality in patients with infection 123
CHAPTER 5 General discussion and conclusions 139
5.1. General discussion 141
5.2. Conclusions and suggestions for further research 147
Bibliography 153

ACKNOWLEDGMENTS
To Professor António Sarmento and Professor Altamiro da Costa Pereira goes my deepest grati-
tude for accepting the challenge to guide me through this long way with their knowledge and,
most of all, with their friendship.
To Dr. Irene Aragão goes my unconditional loyalty to her leadership, my deepest respect for her
strength and my huge debt for her critical appraisal of my work and most of all for her infinite
patience with all my pumping ideas. 
To Professor Fiona Lecky, Professor at the University of Manchester and consultant in the
Emergency Department of Hope Hospital, for her critical appraisal of this work.
To Professor Brun-Buisson, Chair of the National Infection Control Program at Hospital Henri
Mondor, for his priceless suggestions and availability to answer my questions.
From the Clinical and Health Services Research Doctoral Programme I have to thank two special
professors: 
– Professor Armando Teixeira-Pinto for the challenges made, that led to a special award and for his
precious help in the development of the clinical staging system - it would not be possible with-
out him;
– Dr. Luís Azevedo, for believing in my work and for his constant support, fundamental to keep me
on track, pursuing a difficult goal and to help in its concretization.
To Dr. Heloísa Castro, my colleague and my friend, my deepest thanks for her super support in the
final track. She created the conditions to make this real. We will continue to walk through numer-
ous challenges together.
This research is the answer to a challenge made by Dr. António Carneiro – thank you.
To Ernestina Gomes who accepted that challenge earlier: thank you for sharing your knowledge
and difficulties with me. 
I believe I have very good data - that would not be possible without the priceless help of Sr.
Manuel Bernardo, from the archives of Hospital de Santo António.
To my family: Joaquim, Simão e Ana, all my love and deepest proud for your trust in our family!
Together we can make anything possible!
| XI

SUMMARY
Background: Healthcare-associated infections (HCAI) have now been a subject of scientific
debate for more than a decade regarding the need to be included in the classification of infection
according to place of acquisition.
Objectives: To review additional risk factors for infection by multidrug resistant (MDR) pathogens
not included in the adopted definition; to describe the microbiological profile associated with
HCAI by focus of infection, comparing with community (CAI) and hospital-acquired (HAI) infec-
tions; to determine the impact of HCAI in inadequate empiric antibiotic therapy and mortality and
to develop a clinical staging system based on the PIRO concept (Predisposition, Insult/Infection,
host Response and Organ dysfunction) and determine the role of HCAI in it.
Methods: Prospective cohort study including all patients with infection admitted to a large, tertiary
care, university-affiliated hospital, over one year. All consecutive adult patients with intra-abdominal,
urinary, respiratory or bloodstream infections were included. Infections were classified according to
place of acquisition in – CAI, HCAI or HAI. The HCAI definition adopted was the one proposed by
Friedman et al. an infection present at hospital admission or within 48 hours of admission in patients
that fulfilled any of the following criteria: received intravenous therapy at home, wound care or spe-
cialized nursing care in the previous 30 days; attended a hospital or hemodialysis clinic or received
intravenous chemotherapy in the previous 30 days; were hospitalized in an acute care hospital for
≥2 days in the previous 90 days or resided in a nursing home or long-term care facility.
Main outcomes were: to determine additional risk factors for infection by MDR pathogens, not
included in the adopted definition, among patients admitted from the community; description of
the microbiological profile of HCAI according to focus of infection, to determine the impact of
HCAI in inadequate initial empiric antibiotic therapy and hospital mortality and determine its role
in a new clinical staging system for patients with severe infection. A staging system will be devel-
oped according to the proposal of 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis
Definitions Conference according to the patient characteristics at presentation, namely:
Predisposition, the Insult/Infection, the host Response and Organ dysfunction, in this cohort of
patients. The system will be validated in an independent cohort.
Results: During the study period a total of 1035 patients met the inclusion criteria: 493 (48%) were
diagnosed with CAI, 225 (22%) with HCAI and 317 (30%) with HAI. 
There were 718 patients admitted from the community (with CAI or HCAI); 439 (61%) had micro-
biologic documentation of infection; of those 123 (28%) were caused by MDR pathogen.
Independent risk factors, not included in the definition proposed by Friedman et al. and associat-
ed with infection by MDR-gram negatives infection were: age>60 years [adjusted OR (CI 95%) = 1.5
(1.1-2.1), per category] and hospitalization in the previous year (between 4 and 12 months previ-
ously) [adjusted OR (CI 95%) = 1.7 (1.0-3.0)]. Infection by a pathogen from the ESKAPE group was
independently associated with previous antibiotic therapy [adjusted OR (CI 95%) = 17.2 (3.1-17.0)]
and a Karnofsky index<70 [adjusted OR (CI 95%) = 3.7 (1.6-8.6)].
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The microbiological profile, including resistance rates, was different either globally or by focus of
infection, according to the place of acquisition. 
HCAI [adjusted OR (CI 95%) = 2.1 (1.2-3.8)], HAI [adjusted OR (CI 95%) = 2.2 (1.4-3.6)] and a Karnofsky
index<70 [adjusted OR (CI 95%) = 2.2 (1.5-4.4)] were independently associated with inadequate
empiric antibiotic therapy. 
Hospital mortality was independently associated with age [adjusted OR (CI 95%) = 1.05 (1.03-1.07),
per year], severe sepsis [adjusted OR (CI 95%) = 1.9 (1.0-3.6)], septic shock [adjusted OR (CI 95%) = 8.1
(3.8-17.2)] and inadequate antibiotic therapy [adjusted OR (CI 95%) = 2.0 (1.2-3.3)] 
HCAI was retained in final model that lead to the development of the new clinical staging system
based on PIRO. The validation in an independent cohort (n=186) with the same inclusion criteria
as the development cohort provided similar results: both had a good discrimination power with
an area under the ROC curve (CI 95%) of 0.85 (0.82-0.88) and 0.84 (0.76-0.91), respectively. This stag-
ing system allowed stratification of patients into four stages of increasing hospital mortality rates:
stage I ≤5%, II 6-20%, III 21-50% and IV>50%, based on the Predisposition, type Infection, host
Response and Organ dysfunction characteristics at clinical presentation. 
Conclusions: There are additional risk factors for MDR pathogens not included in the adopted
definition. HCAI has a unique microbiological profile providing further evidence for its inclusion
in infection classification according to place of acquisition. HCAI was an independent risk factor
for higher rate of inadequate initial antibiotic therapy but not for higher hospital mortality. The
clinical staging system developed ads to previous ones the inclusion of HCAI and its applicability
to a cohort of mostly non-critically ill patients.
KEY WORDS: Healthcare-associated infection, classification, risk factors, epidemiology, multi-drug
resistant pathogens, treatment, inadequate antibiotic therapy, hospital mortality, PIRO clinical
staging system.
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SUMÁRIO
Introdução: As infecções associadas a cuidados de saúde (ICAS) têm sido alvo de aceso debate
científico, particularmente na última década relativamente à necessidade ou não da sua inclusão
na classificação de infecção de acordo com o local de aquisição.
Objectivos: Identificar os factores de risco para infecção por microorganismos multirresistentes,
não contemplados na definição adoptada; descrever o perfil microbiológico das IACS
comparando com as infecções da comunidade e as nosocomiais; determinar o impacto das IACS
na antibioterapia inicial inadequada e na mortalidade hospitalar e desenvolver um sistema de
estadiamento clínico baseado no conceito PIRO (Predisposição, Infecção, Resposta e disfunção de
Orgão) determinando o papel das IACS nesete sistema. 
Métodos: Estudo de coorte prospectivo, incluindo todos os doentes hospitalizados com infecção
num hospital universitário ao longo de um ano. Foram incluídos de forma consecutiva todos os
doentes com infecção intra-abdominal, urinária, respiratória ou bacteriemia. Classificaram-se as
infecções de acordo com o local de aquisição em infecções da comunidade, IACS ou nosocomiais.
A definição de IACS adoptada foi a proposta por Friedman et al. – infecção presente na admissão
hospitalar ou nas primeiras 24 horas em doentes com pelo menos um dos seguintes critérios:
submetidos a cuidados de pensos, terapêutica endovenosa ou cuidados de enfermagem
diferenciados nos 30 dias prévios; observados num hospital ou centro de hemodiálise, ou
submetidos a quimioterapia nos 30 dias anteriores; admitidos num hospital de agudos durante 2
ou mais dias nos 90 dias anteriores; residentes lares ou instituições. 
As principais medidas de resultado consistiam em: determinar factores de risco adicionais para
infecção por microorganismos multirresistentes não incluídos na definição de IACS adoptada entre
os doentes admitidos a partir da comunidade; descrição do perfil microbiológico das IACS de
acordo com o foco de infecção; determinar o impacto das IACS na inadequação da antibioterapia
inicial e na mortalidade hospitalar e qual o seu papel num novo sistema de estadiamento clínico
dos doentes com infecção grave. Será desenvolvido neste coorte, um sistema de estadiamento de
acordo com a proposta da Conferência Internacional de Consenso sobre as definições de sepsis de
2001 da SCCM/ESICM/ACCP/ATS/SIS, de acordo com as características apresentadas pelo doente,
nomeadamente: a Predisposição, o Insulto/Infecção, a Resposta do hospedeiro e a disfunção de
Orgão. Este sistema será validado num coorte independente. 
Resultados: Durante o período de estudo foram incluídos no estudo 1035 doentes: 493 (48%) com
infecção adquirida na comunidade, 225 (22%) com IACS e 317 (30%) com infecção nosocomial. 
Entre os 718 doentes admitidos da comunidade (com infecção adquirida na comunidade ou
IACS), 439 (61%) tinham documentação microbiológica, sendo 123 (28%) por microorganismos
multirresistentes. Os factores de risco associados de forma independente à infecção por micro-
organismos multirresistentes foram: idade> 60 anos [OR ajustado (IC 95%) = 1,5 (1,1-2,1), por
categoria] e a hospitalização no último ano (entre 4 e 12 meses) [OR ajustado (IC 95%) = 1,7 (1,0-
3,0)]. A infecção por um patogéneo do grupo ESKAPE associou-se de forma independente a
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antibioterapia prévia) [OR ajustado (IC 95%) = 17,2 (3,1-17,0)] e a um índice de Karnofsky<70 [OR
ajustado (IC 95%) = 3,7 (1,6-8,6)]. 
O perfil microbiológico, incluindo as taxas de resistência, foram diferentes globalmente e por foco
de infecção, de acordo com o local de aquisição da infecção.
A IACS [OR ajustado (IC 95%) = 2,1 (1.2-3.8)], a infecção nosocomial) [OR ajustado (IC 95%) = 2,2 (1,4-
3,6)] e um índice de Karnofsky <70) [OR ajustado (IC 95%) = 2,2 (1,5-4,4)] associaram-se de forma
independente à antibioterapia inicial inadequada. 
A mortalidade hospitalar associou-se de forma independente à idade [OR ajustado (IC 95%) = 1,05
(1,03-1,07), por ano], à existência de sepsis grave [OR ajustado (IC 95%) = 1,9 (1,0-3,6)], de choque
séptico [OR ajustado (IC 95%) = 8,1 (3,8-17,2)] e antibioterapia inadequada [OR ajustado (IC 95%) =
2,0 (1,2-3,3)].
A IACS foi retida no modelo final que conduziu ao desenvolvimento do novo sistema de
estadiamento clínico baseado no PIRO. A validação no coorte independente (n=186) com os
mesmos critérios de inclusão que o coorte de desenvolvimento forneceu resultados semelhantes;
ambos apresentaram um bom poder discriminativo com uma área debaixo da curva ROC (IC 95%)
de 0,85 (0,82-0,88) e 0,84 (0,76-0,91), respectivamente. Este sistema de estadiamento permitiu a
estratificação dos doentes em quatro estádios de mortalidade hospitalar crescente: estadio I≤5%,
II 6-20%, III 21-50% e IV>50% de acordo com as características da Predisposição, tipo de Infecção,
Resposta do hospedeiro e disfunção de Orgão à admissão hospitalar.
Conclusões: Existem factores de risco para infecção por microorganismos multirresistentes não
incluídos na definição adoptada. As IACS apresentaram um perfil microbiológico único
fornecendo evidência adicional para a sua inclusão na classificação de infecção de acordo com o
local de aquisição. As IACS constituem um factor de risco independente para maior taxa de
antibioterapia inicial inadequada, mas não para maior mortalidade hospitalar. O sistema de
estadiamento clínico desenvolvido acrescenta aos anteriores a inclusão das IACS e a sua
aplicabilidade a um coorte de doentes maioritariamente não críticos.
PALAVRAS-CHAVE: Infecção associada a cuidados de saúde, classificação, factores de risco,
epidemiologia, microorganismos multirresistentes, tratamento, antibioterapia inadequada,
mortalidade hospitalar, sistema de estadiamento clínico PIRO.
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OUTLINE AND OBJECTIVES OF THE THESIS
The main objectives of this thesis are:
1. to globally understand what is the role played by healthcare-associated infections (HCAI) in the
classification of infections by place of acquisition,
2. to know if there are significant differences in HCAI epidemiology, when compared with commu-
nity-acquired and hospital-acquired infections, namely regarding microbiological profiles and
resistances,
3. to determine the impact of HCAI in the adequacy of empiric antibiotic therapy,
4. to determine the impact of HCAI in hospital mortality,
5. to understand the role of HCAI in a clinical staging system based in the PIRO concept
(Predisposition, Insult/Infection, host Response and Organ dysfunction).
The first chapter focuses on the thesis rational and presents the research questions.
The second chapter provides a systematic review on the main topics of the thesis: classification of
healthcare-associated infection, its epidemiology focusing mainly on microbiological data and
the impact of HCAI on inadequate initial antibiotic therapy and on mortality.
The third chapter describes general methodology.
The fourth chapter lays out the research results: 
1. Description of additional risk factors not included in the definition by Friedman et al., independ-
ently associated with infection by multi-drug resistant organisms and its impact on the adequa-
cy of antibiotic therapy and hospital mortality;
2. Description of the microbiological profile including resistance rates for the four major focus of
infection that drives patients into hospital care: intra-abdominal, urinary, respiratory and bac-
teremia; making a thorough comparison according to place of acquisition: community, health-
care-associated or hospital-acquired;
3. Determination of the impact of HCAI in initial inadequate antibiotic therapy and hospital mor-
tality;
4. Development of a clinical staging system based on the patients characteristics at clinical pres-
entation: Predisposition, type of Infection, host Response and Organ dysfunction (the PIRO con-
cept), on a cohort of mainly non-critically ill patients, including healthcare-associated infection
in the model as a new variable. The staging system is then validated in an independent cohort
of patients.
Finally in chapter five, the results of the different studies are summarized and the implications for
further research are discussed. 
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INTRODUCTION
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1. INTRODUCTION
1.1.RATIONALE
Traditionally infections have been classified as community or hospital-acquired, according to their
place of acquisition, and this classification is still used to guide diagnosis and treatment decisions [1, 2].
However, over the last decade the massive increase in outpatient clinical care has led to a new
context for the emergence of healthcare-associated infections. This is a new name for the new
group of infections appearing among patients that come from the community but with a history
of previous exposure to the healthcare not fitting the nosocomial infection criteria. The propor-
tion of patients hospitalized with healthcare-associated infections among those admitted from
the community setting can be as high as 50% [3-6].
In 2002, Deborah Friedman and et al. [3] proposed a new classification of infection according to
place of acquisition, adding healthcare-associated infections (HCAI) to the dichotomy of com-
munity (CAI) and hospital-acquired (HAI) infections. She proposed HCAI to be defined as an infec-
tion present at hospital admission or within 48 hours of admission in patients that fulfilled any of
the following criteria:
– received intravenous therapy at home, wound care or specialized nursing care through a
healthcare agency, family or friends; or had self-administered intravenous medical thera-
py in the 30 days before the infection. Patients whose only home therapy was oxygen use
were excluded;
– attended a hospital or haemodialysis clinic or received intravenous chemotherapy in the
previous 30 days;
– were hospitalized in an acute care hospital for 2 or more days in the previous 90 days,
– resided in a nursing home or long-term care facility.
The definition proposed by Deborah Friedman et al. [3] despite being one of the most frequently
used in clinical studies [7-12] is not consensual. More recent studies have included additional risk
factors such as immunosuppression [13, 14], elderly person or physical disable persons who need
healthcare [15, 16], previous submission to invasive procedures or surgery [17, 18] and prior antibiotic
therapy [14]. There is a need to review all situations involved in the community setting that imply
close contact to healthcare services and that might represent an increased risk for infection by
multidrug resistant pathogens, not included in the original definition [3].
The studies that followed using the original definition [3] were mainly dedicated to single focus of
infection, specially bloodstream infections and pneumonia, not addressing other major focus that
drive patients into hospital care creating the need for new and more extensive epidemiologic
studies that would include other foci of infection [19].
A non-consensual definition may lead to poor recognition. If not recognized these patients may be
treated according to community-acquired infections recommendations. The impact of healthcare-
associated infections in the adequacy of initial antibiotic therapy and mortality needs to be deter-
mined. 
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In the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [20] John
Marshall proposed a theoretical concept to stratify patients with sepsis according to their charac-
teristics at presentation, namely: Predisposition, the Insult/Infection, the host Response and Organ
dysfunction (the PIRO concept). HCAI will be added to the domain of Infection in the PIRO con-
cept and from the concept a new staging system will be developed in a cohort of mainly non-crit-
ically ill patients. The system will be validated in an independent cohort.
1.2. AIMS
1. To explore all the definitions used in clinical studies regarding healthcare-associated infections:
a. Research question:
i. Are there aditional criteria not included in the adopted definition of HCAI [3] that
represent risk factors for infection by multi-drug resistant microorganisms? 
2. Considering the definition of healthcare-associated infections proposed by Friedman et al. [3]:
a. Research questions:
i. Do healthcare-associated infections represent a separate group with unique micro-
biology and resistance profiles for the main focus of infection, among hospitalized
patients, when compared with CAI and HCAI?
ii. Are HCAI an independent risk factor for inadequate initial antibiotic therapy and
hospital mortality?
3. In the developing of a new clinical staging system based on the PIRO concept, applied to hos-
pitalized patients with severe infection
a. Research question:
i. What is the role of HCAI in the Infection category?
4 | HEALTHCARE-ASSOCIATED INFECTIONS: CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
C
H
A
PTER 1
REFERENCES
1. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect
Control 1988, 16(3):128-140.
2. Directors ATSB, Comm IG: Guidelines for the management, of adults with hospital-acquired, ventilator-associ-
ated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2005,
171(4):388-416.
3. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL et al:
Health care-associated bloodstream infections in adults: a reason to change the accepted definition of com-
munity-acquired infections. Annals of internal medicine 2002, 137(10):791-797.
4. Park SC, Kang YA, Park BH, Kim EY, Park MS, Kim YS, Kim SK, Chang J, Jung JY: Poor prediction of potentially drug-
resistant pathogens using current criteria of health care-associated pneumonia. Respiratory Medicine 2012,
106(9):1311-1319.
5. Benito N, Miro JM, de Lazzari E, Cabell CH, del Rio A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou
H et al: Health Care-Associated Native Valve Endocarditis: Importance of Non-nosocomial Acquisition. Annals
of Internal Medicine 2009, 150(9):586-U585.
6. Aguilar-Duran S, Horcajada JP, Sorlí L, Montero M, Salvadó M, Grau S, Gómez J, Knobel H: Community-onset health-
care-related urinary tract infections: Comparison with community and hospital-acquired urinary tract infec-
tions. Journal of Infection 2012, 64(5):478-483.
7. Catarralà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, Manresa F, Gudiol F: Health care-asso-
ciated pneumonia requiring hospital admission. Arch Intern Med 2007, 167(13):1393-1399.
8. Park HK, Song JU, Um SW, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Jeon K: Clinical characteristics of health
care-associated pneumonia in a Korean teaching hospital. Respir Med 2010:1-7.
9. Vallés J, Calbo E, Anoro E, Fontanals D, Xercavins M, Espejo E, Serrate G, Freixas N, Morera M, Font B et al:
Bloodstream infection in adults: importance of healthcare-associated infections. Journal of infection 2007,
56:27-34.
10. Cheong HS, Kang C, Kwon KT, Heo ST, Wi YM, Kim ES, Lee JS, Ko KS, Chung DR, Lee NY et al: Clinical significance of
healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrob Chemother
2007, 60:1355-1360.
11. Rello J, Luján M, Gallego M, Vallés J, Belmonte Y, Fontanals D, Diaz E, T L, Group aftPS: Why mortality is increased in
health-care-associated pneumonia: lessons from Pneumococcal Bacteremic Pneumonia. Chest 2010,
137:1138-1144.
12. Stryjewski ME, Kanafani ZA, Chu VH, Pappas PA, Harding T, Drew LA, Benjamin DK, Reller LB, Lee BA, Corey GR et al:
Staphylococcus aureus bacteremia among patients with health care-associated fever. Am J Med 2009, 122:281-289.
13. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH: Health care-associated pneumonia and community-
acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007, 51(10):3568-3573.
14. Schreiber MP, Chan CM, Shorr AF: Resistant Pathogens in Nonnosocomial Pneumonia and Respiratory Failure Is
It Time To Refine the Definition of Health-care-Associated Pneumonia? Chest 2010, 137(6):1283-1288.
15. Ishida T, Tachibana H, Ito A, Yoshioka H, Arita M, Hashimoto T: Clinical characteristics of nursing and healthcare-
associated pneumonia: a Japanese variant of healthcare-associated pneumonia. Internal medicine (Tokyo,
Japan) 2012, 51(18):2537-2544.
16. Miyashita N, Kawai Y, Akaike H, Ouchi K, Hayashi T, Kurihara T, Okimoto N: Clinical Features and the Role of Atypical
Pathogens in Nursing and Healthcare-associated Pneumonia (NHCAP): Differences between a Teaching
University Hospital and a Community Hospital. Internal Medicine 2012, 51(6):585-594.
17. Ha YE, Kang C-I, Joo E-J, Park SY, Kang SJ, Wi YM, Chung DR, Peck KR, Lee NY, Song J-H: Clinical implications of
healthcare-associated infection in patients with community-onset acute pyelonephritis. Scandinavian Journal
of Infectious Diseases 2011, 43(8):587-595.
INTRODUCTION | 5
C
H
A
PT
ER
 1
18. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, Ridola L, Attili AF, Venditti M: Cirrhotic Patients Are at
Risk for Health Care-Associated Bacterial Infections. Clinical Gastroenterology and Hepatology 2010, 8(11):979-
985.
19. Kollef MH, Napolitano LM, Solomkin JS, Wunderink RG, Bae IG, Fowler VG, Balk RA, Stevens DL, Rahal JJ, Shorr AF et
al: Health care-associated infection (HAI): a critical appraisal of the emerging threat - proceedings of the HAI
Summit. Clin Infect Dis 2008, 47:S55-99.
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G et al: 2001
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31(4):1250-1256.
6 | HEALTHCARE-ASSOCIATED INFECTIONS: CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
C
H
A
PTER 1
C
H
A
PT
ER
 2
C
H
A
PT
ER
 2
.2
C
H
A
PT
ER
 2
.3
C
H
A
PT
ER
 2
.4
CHAPTER 2
HEALTHCARE-ASSOCIATED 
INFECTIONS: 
A SYSTEMATIC REVIEW
Foto by Virginia Lopes
Submitted
Teresa Cardoso1, Mónica Almeida2, N. Deborah Friedman3, Irene Aragão4, Altamiro Costa-Pereira5,
António E. Sarmento6, Luís Azevedo7
1 MD, Internal Medicine Consultant and Researcher at Intensive Care Unit – Unidade de Cuidados Intensivos
Polivalente – Hospital de Santo António, Lecturer at University of Porto, Porto – Portugal
2 MD, Internal Medicine Register at Internal Medicine Department – Hospital de Braga, Braga – Portugal 
3 MBBS, FRACP, MD, MPD – Infectious Diseases Physician and Principal Research Fellow, Department of Medicine,
Barwon Health, Geelong, Victoria – Australia
4 MD, Director of the Intensive Care Unit – Unidade de Cuidados Intensivos Polivalente – Hospital de Santo António,
University of Porto, Porto – Portugal
5 MD, PhD, Director of the Department of Health Information and Decision Sciences, Center for Research in Health
Technologies and Information Systems (CINTESIS), Faculty of Medicine, University of Porto, Porto – Portugal
6 MD, PhD, Director of Department of Infectious Diseases, Hospital de São João, University of Porto, Porto – Portugal; 
7 MD, Lecturer at Faculty of Medicine, University of Porto and Researcher at Department of Health Information and
Decision Sciences, Center for Research in Health Technologies and Information Systems (CINTESIS), Porto – Portugal
8 | HEALTHCARE-ASSOCIATED INFECTIONS: CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
C
H
A
PTER 2.1
2.1. CLASSIFICATION OF HEALTHCARE-ASSOCIATED INFECTIONS: 
A SYSTEMATIC REVIEW 10 YEARS AFTER THE FIRST PROPOSAL
ABSTRACT 
Background: Ten years after the first proposal, a consensus definition of healthcare-associated
infection (HCAI) has not been reached preventing the development of specific treatment recom-
mendations. A systematic review of all definitions of HCAI used in clinical studies is made.
Methods: The search strategy focused on HCAI definition. MEDLINE, SCOPUS and ISI Web of
Knowledge were searched for articles published between 1968 and November 2012. Abstracts
from scientific meetings were searched for relevant abstracts along with a manual search of ref-
erences from reports, earlier reviews and retrieved studies. 
Findings: The search retrieved 49,405 references: 15,311 were duplicates and 33,828 were exclud-
ed based on title and abstract. Of the remaining 266, 43 met the inclusion criteria. The definition
more frequently used was the initial proposed in 2002-an infection present at hospital admission
or within 48 hours of admission in patients that fulfilled any of the following criteria: received
intravenous therapy at home, wound care or specialized nursing care in the previous 30 days;
attended a hospital or hemodialysis clinic or received intravenous chemotherapy in the previous
30 days; were hospitalized in an acute care hospital for ≥2 days in the previous 90 days, resided in
a nursing home or long-term care facility. Additional criteria founded in other studies were:
immunosuppression, active or metastatic cancer, previous radiation therapy, transfer from anoth-
er care facility, elderly or physically disabled persons who need healthcare, previous submission to
invasive procedures, surgery performed in the last 180 days, family member with a multi-drug
resistant microorganism and recent treatment with antibiotics.
Conclusions: Based on the evidence gathered we conclude that the definition initially proposed
is widely accepted. In a future revision, hospitalization in the last year, recent invasive procedures
or previous antibiotic treatment should be considered for inclusion in the definition. The role of
immunosuppression still requires ongoing discussion. 
KEY WORDS: Healthcare-associated infection, classification, multidrug resistant pathogens preva-
lence, pneumonia, bloodstream infections
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INTRODUCTION
Traditionally, infections have been classified as community or hospital-acquired, according to
their place of acquisition, and this classification is still used to guide treatment decisions [1, 2].
Over the last decade the massive increase in outpatient clinical care has led to a new context for the
emergence of healthcare-associated infections (HCAI). This is a new name for a new group of infec-
tions emerging among patients that come from the community with a history of previous exposure
to healthcare who do not fit the nosocomial infection criteria. The proportion of patients hospital-
ized with HCAI among those admitted from the community setting can be as high as 50% [3-6].
The first proposals of HCAI and its inclusion in infection classification along with community-
acquired infection (CAI) and hospital-acquired infection (HAI) were made in 2002 by Siegman-Igra
et. al [7] and Friedman et. al [3]. Different one from another, the definition from Friedman et. al [3] has
been used in numerous clinical studies and will be referred to in this review as the initial defini-
tion; it is defined as an infection present at hospital admission or within 48 hours of admission in
patients that fulfilled any of the following criteria:
– received intravenous therapy at home, wound care or specialized nursing care through a
healthcare agency, family or friends; or had self-administered intravenous medical therapy in
the 30 days before the infection;
– attended a hospital or hemodialysis clinic or received intravenous chemotherapy in the pre-
vious 30 days;
– were hospitalized in an acute care hospital for 2 or more days in the previous 90 days,
– resided in a nursing home or long-term care facility.
Although widely accepted [5, 8-10] numerous alternative definitions have also been used in clinical
studies [11-14]. This heterogeneity has raised more confusion than understanding in determining
likely microbiological resistance patterns and making decisions about empiric antibiotic treat-
ment. A correct recognition of all risk factors for HCAI is crucial in guaranteeing optimal empiric
antibiotic choice to adequately treat likely pathogens while avoiding selective pressure that con-
tributes to the development of multidrug-resistant (MDR) organisms.
The objective of the current study is to present a systematic review of all definitions of HCAI used
in clinical studies in order to compare and contrast the criteria they include.
METHODS
Data sources and Searches 
This search was performed in accordance with the recommendations of the Cochrane collabora-
tion using MEDLINE/PubMed (from 1989 - present), SCOPUS (from 1974 - present) and ISI Web of
Knowledge (from 1968 –present) from earliest achievable data until November 2012. A manual
search of references from reports, earlier reviews and retrieved studies was also performed.
Abstract books and CD-ROMs from several annual scientific meetings were searched for relevant
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abstracts (Figure 2.1.1). No language restriction was applied and papers written in a foreign lan-
guage were translated.
The electronic search strategy covered the main subject areas: ((((“healthcare” [All Fields] OR “health
care” [All Fields] OR “health-care” [All Fields]) AND (“related” OR “associated” [All Fields])) OR “health-
care-related” [All Fields] OR “healthcare-associated” [All Fields] OR “health care-related” [All Fields]
OR “health care-associated” [All Fields]) AND (“Infection” [MeSH Terms] OR “bacteremia” [MeSH
Terms] OR “endotoxemia” [MeSH Terms] OR “bacteraemia” [All Fields] OR “sepsis” [MeSH Terms] OR
“severe sepsis” [MeSH Terms] OR “septicemia” [MeSH Terms] OR “pyohemia” [MeSH Terms] OR
“pyemia” [MeSH Terms] OR “pyaemia” [MeSH Terms] OR “poisoning, blood” [MeSH Terms] OR “blood
poisoning” [MeSH Terms] OR “pneumonia” [MeSH Terms] OR “pneumonia lobat” [MeSH Terms] OR
“lobar, pneumonia” [MeSH Terms] OR “pneumonitis” [MeSH Terms] OR “pulmonary inflamation”
[MeSH Terms] OR “lung inflamation” [MeSH Terms] OR “bronchopneumonia” [MeSH Terms] OR “peri-
tonitis”[MeSH Terms] OR “cystitis”[ MeSH Terms] OR “pyelonephritis”[ MeSH Terms] OR “pyelocysti-
tis”[ MeSH Terms]) AND “adult”[Filter]) was applied. The last search was done on 8th November 2012.
Study selection
The inclusion criteria were all observational studies (cohort, cross-sectional or case-control) on
adult patients admitted to hospital that provided microbiology results according to place of
Figure 2.1.1 – Flow diagram of study selection
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acquisition of infection. The following definitions of infection by setting were used:
– CAI - infection detected within 48 hours of hospital admission in patients without previous
contact with healthcare service. 
– HAI - localized or systemic condition: 1) that results from adverse reaction to the presence of
an infectious agent(s) or its toxin(s) and 2) that was present 48 hours or more after hospital
admission and not incubating at hospital admission time [15]. 
– HCAI - infection detected within 48 hours of hospital admission in patients that had previous
contact with healthcare service.
Data extraction and quality assessment
The results of the literature search were accessed by two reviewers (TC, MA) and non-relevant
studies were excluded based on title and abstract. For potentially relevant studies, the full text was
obtained, and two investigators (TC, MA) independently assessed study eligibility and extracted
data on study design, objectives, HCAI definitions and multi-drug resistant pathogens (MDR)
prevalence [Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa,
Acinectobacter, Stenotrophomas maltophilia, Extended-spectrum beta lactamases producer
(ESBL)], using a data extraction protocol; disagreements were resolved through consultation with
a third reviewer (LA).
Each selected study was independently evaluated by two reviewers (TC, MA) for the strength of
evidence through examination of the study design and quality of data. 
Potential threats to the internal validity of included studies were evaluated considering the fol-
lowing criteria:
– The authors define inclusion criteria, 
– The authors define an adequate selection method,
– The selection of participants was consecutive,
– The outcome data was complete (no attrition bias) and 
– All results were reported (reporting bias).
Studies that met all of the above 5 criteria, were classified as “low risk of bias”. Studies that partial-
ly met one or more criteria were classified as “moderate risk of bias”. Studies were classified as “high
risk of bias” if one or more of these criteria was not met.
Data analysis 
Data on individual studies included are provided in tables 2.1.1 and 2.1.2. A meta-analysis was not
performed due to the nature of the objectives of this review and the heterogeneity of the studies
included.
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RESULTS
The search retrieved a total of 49,405 references, among which 15,311 duplicates were identified;
33,828 were excluded based on title and abstract and full texts were obtained for the remaining
266 articles. Of those: 106 were review articles or opinion pieces and 108 did not meet inclusion
criteria. Of the remaining 52 studies: 30 used the initial definition of Friedman et. al [3], but only 21
provided data on microbiology and were included along with 22 additional studies that used
alternative definitions and met the inclusion criteria totalizing 43 studies included in this system-
atic review (figure 2.1.1): 18 were prospective (7 multicenter and 11 single center) and 25 were ret-
rospective (9 multicenter and 16 single center); involving 42,611 patients. 
Characteristics of included studies that used the initial definition are shown in table 2.1.1. and of
those that used alternative definitions in table 2.1.2.
Infections by Source
In bloodstream HCAIs, six studies used the initial definition [3] (table 2.1.1) and six did not (table
2.1.2), all found an increasing prevalence of MDR organisms from CAI to HCAI and HAI, regardless
of the definition used.
The majority of the included studies were about pneumonia (22 studies of 43). Most of these stud-
ies only compared community-acquired pneumonia (CAP) with healthcare-associated pneumo-
nia (HCAP) and revealed a higher prevalence of MDR pathogens among HCAP patients compared
with CAP patients. There were three studies comparing CAP and HCAP with hospital acquired
pneumonia (HAP) [13, 16, 17] but they used different definitions of HCAP achieving different results
regarding MDR prevalence according to place of acquisition of infection (tables 2.1.1 and 2.1.2).
There were 3 studies of healthcare-associated infective endocarditis [5, 18, 19]. Two found an increas-
ing rate of MDR organisms from community-acquired to healthcare-associated and hospital-
acquired infective endocarditis (table 2.1.1). A third study compared healthcare-associated infec-
tive endocarditis with non- healthcare-associated infective endocarditis (that is, community-
acquired plus hospital-acquired infective endocarditis) and found a higher prevalence of MDR in
healthcare-associated infective endocarditis than in non- healthcare-associated infective endo-
carditis (table 2.1.2).
Studies regarding urinary tract [6, 20] and intra-abdominal [21] infections also found a higher preva-
lence of MDR organisms, among HCAIs when compared to CAIs (tables 2.1.1 and 2.1.2). 
The initial definition [3] was the most widely used in clinical studies (30 studies among 51). Overall,
different HCAI definitions comprised 17 different criteria, of which 7 were equivalent to those
used by Friedman et. al [3], but leading to a different final definition due to the addition or subtrac-
tion of criteria (table 2.1.3).
An analysis of the risk of bias of the 43 included studies revealed that 24 presented a low-risk of
bias, 7 presented a moderate-risk of bias, and 12 presented a high-risk of bias, according to previ-
ously defined criteria (table 2.1.4).
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Table 2.1.1 – Characterization of the studies included that use the initial [3] definition of HCAI by focus of infection
Study Study design Nº of blood
culture 
isolates
Isolation rate by 
category, n (%)
MDR* organisms Risk of
bias
CAI HCAI HAI CAI HCAI HAI
BLOODSTREAM INFECTIONS
Friedman [3] Prospective, multi-center, in 504
patients, USA, 4-5 months
504 143 
(28)
186 
(37)
175 
(35)
Not mentioned High
Marschall [50] Prospective, single center, in 250
patients with Gram-negative bac-
teremia, USA, 6 months
250 28 
(11)
132
(53)
90
(36)
0
(0) 
9
(7)
10
(11)
Low
Son [51] Prospective, multicenter study, in 
1144 patients, Korea, 12 months
1144 380 
(33)
558 
(49)
206 
(18)
29 
(8)
38
(7)
162
(79)
Low
Evans [52] Retrospective, multicenter, bacteremia
episodes in 223 patients with spinal
cord injury, USA, 7 years
413 36
(9)
110
(27)
267
(64)
6 
(17)
34 
(31)
111
(42)
High
Rodriguez-
Bano [53]
Prospective, multicenter, 821 bacteremia
episodes including potential contami-
nants, Spain, 2-5 months
821 150 
(18)
195 
(24)
476
(58)
7 
(5)
29 
(15)
99
(21)
Moderate
Vallés [8] Prospective, multicenter, in 726 patients,
Spain and Argentina, 12 months
720 343 
(47)
131 
(18)
252 
(35)
7 
(2)
11 
(8)
29 
(12)
High
PNEUMONIA
Umeki [54] Prospective, single center, in 202
patients, Japan, 2 years
Not 
mentioned
48 
(39)
48 
(61)
10
(21)
12
(25)
Moderate
Park [4] Prospective, single center, in 339
patients with positive microbiology,
Korea, 2 years
339 172
(100)
167
(100)
35
(20)
52
(31)
Low
Shindo [46] Retrospective, single center, in 371
patients, Japan, 1 year and 3 months
186 109
(47)
77
(55)
6 
(6)
17 
(22)
Low
Seki [55] Retrospective, single center, in 34
patients Japan, 4 months
Not mentioned but the nº of isolates
is higher than the number of patients 
0 
(0)
6 
(43)
Moderate
Garcia-Vidal [56] Prospective, single center, in 2153
patients, those with more than one con-
dition of HCAI, with neutropenia, AIDS,
after transplantation and chronic corti-
costeroid treatment were excluded,
Spain, 8 years and 9 months
1388 1066
(64)
322 
(66)
19 
(2)
7 
(2)
Low
Jung [57] Retrospective, single center, in 527
patients, Korea, 1 year
162 83 
(28)
79 
(34)
15 
(18)
30 
(38)
Low
Park [9] Retrospective, single center, in 345
patients, time frame for defining CAI and
HCAI was 72 h after hospital admission,
patients with neutropenia, AIDS and
after transplantation were excluded,
Korea, 1 year
111 46 
(28)
65 
(36)
7 
(15)
21 
(32)
Moderate
Carratalà [10] Prospective, single center, in 727
patients, those with neutropenia, AIDS
and after transplantation were excluded,
Spain, 4 years
422 337 
(56)
85 
(67)
3 
(1)
2 
(2)
Low
Jeon [58] Retrospective, multicenter, in 210 patients
older than 60 years, Korea, 2 years
93 63 
(36)
30 
(57)
10 
(16)
20 
(67)
Low
Lee [59] Retrospective, multicenter study, in 250
patients, Korea, 21 months
139 84 
(41)
55 
(57)
3 
(4)
17 
(31)
Low
Depuydt [60] Retrospective, single center, in 269
patients, those with neutropenia, trans-
plantation or transferred from another
hospital were excluded, Belgium , 1 year
34 14 
(25)
20 
(16)
0 
(0)
6 
(30)
Low
Pascual [17] Retrospective, single center, in 308
patients with bacteriemic pneumonia,
Spain, 6 years
308 206
(100)
60
(100)
42
(100)
(2) (12) (31) High
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Table 2.1.1 – Characterization of the studies included that use the initial [3] definition of HCAI by focus of infection
(continuation)
*MDR = MRSA, Pseudomonas sp, Acinectobacter, Stenotrophomonas maltophilia, ESBL.
Study Study design Nº of blood
culture 
isolates
Isolation rate by 
category,
n (%)
MDR* organisms Risk of
bias
CAI HCAI HAI CAI HCAI HAI
OTHER FOCI
Wu [18] Retrospective, single center, in 192
patients with ENDOCARDITIS, Taiwan, 
5 years
200 141 
(95)
30 
(100)
21 
(95)
15 
(11)
13 
(43)
17 
(81)
Moderate
Benito [5] Prospective, single center, in 1622
patients with ENDOCARDITIS, compar-
ing CAI with healthcare associated that
included non-nosocomial and nosoco-
mial, intra-venous drug users and pros-
thetic valves were excluded, USA, 
6 months
1474 947 
(89)
238 
(94)
289 
(95)
25 
3)
41 
(17)
76 
(26)
Low
Aguilar-
Duran [6]
Prospective, single center, in 251
patients with URINARY INFECTION,
Spain, 7-8 months
251 88 
(35)
97 
(13)
66 
(26)
2 
(2)
15 
(15)
9 
(14)
High
Table 2.1.2 – Characterization of the studies included that did not use the initial [3] definition of HCAI by focus of infection
Study Study design HCAI criteria MDR* organisms Risk of
biasCAI HCAI HAI
BLOODSTREAM INFECTIONS
Al-Hasan [31] Retrospective, multicenter, 
in 733 episodes of gram 
negative bacteremia;
excludes polymicrobial,
nosocomial and recurrent
episodes; USA, 10 years
1. Hospitalized for 2 or more days in the previous
90 days
2. Residents in a nursing home or long-term care
facility
3. Received intravenous therapy including ATB and
chemotherapy
4. Hemodialysis in the previous 30 days
12 
(4)
28 
(7)
Moderate
Shorr [11] Retrospective, multicenter,
in 6697 patients; USA, 
2 years
1. Prior hospitalization within 30 days
2. Transfer from another healthcare facility
3. Chronic hemodialysis
4. Immunosuppression medication or metastatic
cancer
152
(2)
397
(11)
62
(13)
Low
Lenz [41] Retrospective, multicenter,
in 7712 patients; only sam-
ples obtained in the first 5
days of hospital admission;
Canada, 8 years
1. Hospitalized for 2 or more days in the previous
90 days
2. Nursing home or long term-care facility
3. Visit a hospital, clinic or emergency department
within the prior 5-30 days
4. Hemodialysis
5. Active cancer
59
(2)
158
(6)
202
(9)
Low
Siegman-Igra [7] Prospective, single center,
of 1028 infections in 912
patients; Israel, 1 year
1. Discharge from hospital 2 to 30 days previously
2. Nursing-home acquired
3. Patients with long-term intravenous devices, for
hemodialysis, chemotherapy or parenteral nutrition
4. Chronic hemodialysis
5. Invasive procedure previously or at hospital
admission
8
(2)
24
(10)
71
(17)
Moderate
Kao [32] Prospective, single center,
of 890 infections in 831
patients older than 14
years; Taiwan, 1 year
1. Hospitalized for 2 or more days in the previous
90 days
2. Resided in a nursing home
3. Hemodialysis, intravenous chemotherapy or
invasive procedures in the previous 90 days
11
(2)
41
(16)
42
(41)
High
Kollef [12] Prospective, multicenter, in
1143 patients; USA, 1 year
1. Prior hospitalization within 6 months
2. Admission from a skilled nursing facility
3. Hemodialysis
4. Immunosuppression
79
(19)
242 
(33)
Low
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Study Study design HCAI criteria MDR* organisms Risk of
biasCAI HCAI HAI
PNEUMONIA
Chalmers [33] Prospective, single center, 
in 1348 patients; Scotland, 
4 years and 5 months
1. Hospitalization for 2 days or more in the preced-
ing 90 days
2. Resident of a nursing home or 
extended-care facility
3. Home infusion therapy (including antibiotics
and long-indwelling devices has catheters)
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug 
resistant pathogen
3
(1)
5
(6)
High
Table 2.1.2 – Characterization of the studies included that did not use the initial [3] definition of HCAI by focus of infection
(continuation)
Ishida [34] Retrospective, single 
center, in 893 patients; 
Japan, 3 years
1. Discharged from a hospital in the preceding 90
days 
2. Resident in a nursing home or extended-care ward
3. A patient who regularly requires vascular access
for dialysis, antimicrobial treatment, chemother-
apy or immunosuppressive therapy in an outpa-
tient setting
4. Elderly or handicap who needs long-term care
with an ECOG of 3 or 4
6
(3)
37
(21)
Low
Micek [27] Retrospective, single 
center, in patients with 
positive cultures, in 
639 patients older than 
16 years, Spain, 2 years
1. Hospitalization in the past 12 months
2. Resident in a nursing home or long-term care
facility or rehabilitation hospital
3. Outpatient hemodialysis, peritoneal dialysis or infu-
sion therapies requiring regular visits to a clinic
4. Immunosuppression
35
(17)
242
(56)
Low
Miyashita [36] Prospective, multicenter, in
1385 patients; CAI and HCAI
are considered until 72h
after hospital admission,
Japan, 6 years
1. Discharged from a hospital in the preceding 90
days
2. Resident in a long-term nursing home setting or
healthcare home
3. Continuous receiving endovascular therapy in an
ambulatory setting (including dialysis, antibi-
otics, anticancer drugs and immunosuppression)
4. Elderly persons or physical disable persons who
need healthcare
21
(4)
78
(20)
High
Giannella [16] Prospective, multicenter, in
1002 patients admitted into
internal medicine depart-
ments, includes patients
older than 16 years, Spain, 2
weeks
1. Hospitalization in the past 180 days
2. Resident in a nursing home or extended-care
facility
3. Attending a hospital regularly because of chron-
ic underlying disease
4. Undergoing hemodialysis
5. Wound care or specialized nursing care in the
past 30 days
6. Chemotherapy in the past 30 days
7. Surgery in the past 180 days
6
(4)
19
(29)
11
(52)
Low
Kollef [13] Retrospective, multicenter,
in 4543 patients with posi-
tive cultures within 5 days
of hospital admission, 
USA, 2 years
1. Prior hospitalization within 30 days
2. Admission from another care facility
3. Receiving long-term hemodialysis
624
(28)
537
(54)
362
(43)
High
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Tasbakan [37] Retrospective, single center
study, in 187 patients,
Turkey, 1 year
1. Hospitalization for 2 days or more in the 
preceding 90 days
2. Resident of a nursing home or extended-care
facility
3. Home infusion therapy (including antibiotics)
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug resistant
pathogen
1
(13)
17
(44)
Low
Guimarães [38] Retrospective, single center
study, in 197 patients,
Portugal, 1 year
1. Hospitalization for 2 days or more in the preced-
ing 90 days
2. Resident of a nursing home or extended-care
facility
3. Intravenous antibiotic therapy or chemotherapy
within 30 days
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug resistant
pathogen 
2
(18)
9
(82) 
High
Schreiber [40] Retrospective, single center
study, in 190 patients need-
ing mechanical ventilation
more than 24 hours after
hospital admission, patients
without evidence of bacter-
ial infection and patients
transferred from other hos-
pitals were excluded, USA, 
4 years
1. Recent hospitalization (90 days)
2. Admission from a long-term facility
3. Recent treatment with broad spectrum antibi-
otics (30 days)
4. Chronic hemodialysis
5. Wound care
6. Immunosuppression
17
(18)
48
(48) 
Low
Grenier [14] Retrospective, single center
study, in 3295 patients,
those transferred from
other hospitals or dis-
charged from an acute care
facility within 14 days were
excluded, Canada, 12 years
1. Hospitalization in the past 90 days, but not in
the last 14 days
2. Resident of a nursing home or long-term care
facility
3. Outpatient intravenous therapy or cancer thera-
py within the previous month
4. Long term hemodialysis
42
(4)
21
(10) 
Low
Sugisaki [39] Retrospective, single center
study, in 526 patients,
Japan, 4 years
1. Hospitalization for 2 days or more in the preced-
ing 90 days
2. Resident of a nursing home or extended-care
facility
3. Home infusion therapy (including antibiotics
and long indwelling devices or catheters)
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug resistant pathogen
50
(15)
72
(40)
Low
Wu [22] Retrospective, multicenter
study, in 1646 patients with
pneumonia developing 2
days after admission or less
than 14 days after the last
hospitalization those with
lung cancer obstructive
pneumonia or HIV 
positive status with CD4+
count<200 were excluded,
Taiwan, 1 year.
1. Undergoing repeated hospitalization within 90
days before
2. Residing in a nursing home
3. Receiving radiation therapy or chemotherapy at
an outpatient clinic
4. Received regular dialysis at an out patients clinic
122
(15)
169
(28)
Low
MDR* organisms Risk of
biasCAI HCAI HAI
Table 2.1.2 – Characterization of the studies included that did not use the initial [3] definition of HCAI by focus of infection
(continuation)
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OTHER FOCI
Sy [19] Retrospective, multicenter
study, in 1536 patients with
ENDOCARDITIS; patients
transferred from another
hospital, recurrent admis-
sions or day-stay admis-
sions were excluded,
Australia, 6 years
1. Hospitalization for 2 days or more in the preced-
ing 90 days
2. Resident of a nursing home or in a long-term
facility
3. Attended a hemodialysis clinic or received intra-
venous therapy in the 30 days before
40
(26)
61
(18)
High
Study Study design HCAI criteria MDR* organisms Risk of
biasHCAI Non-
HCAI
MDR* organisms
CAI HCAI HAI
Table 2.1.2 – Characterization of the studies included that did not use the initial [3] definition of HCAI by focus of infection
(continuation)
Ha [20] Retrospective, single center
study, in 319 patients with
URINARY INFECTION;
Korea, 1 year
1. Hospitalization for 2 or more days in an acute
care hospital in the preceding 90 days
2. Resident of a nursing home or long-term care
facility
3. Received intravenous therapy, wound care or
specialized nursing care at home in the previous
30 days
4. Attended a hospital or hemodialysis clinic or
received intravenous chemotherapy in the 30
days before
5. Received an invasive procedure, urological sur-
gery or urethral catheterization in the previous 
7 days
1
(1)
28
(14)
Low
Swenson [21] Retrospective, single 
center study, 2049 INTRA-
ABDOMINAL INFECTIONS;
Canada, 10 year
1. Patients with a story of any 
hospitalization in the previous 30 days
2. Resident of a nursing home or rehabilitation
facility in the previous 30 days
27
(7)
221
(28)
High
Merli [26] Prospective, single center
study, in 54 patients with
cirrhosis, patients with HVI
infection, under high dose
of corticosteroid treatment
or immunosuppressive 
therapy were excluded,
Italy, 9 months
1. Hospitalization for 2 or more days or had 
undergone surgery during the preceding 
180 days
2. Resident of a nursing home or long-term care
facility
3. Attended a hospital or hemodialysis clinic or
received intravenous chemotherapy in the 30
days before
2
(50)
9
(82)
5
(45)
Low
*MDR = MRSA, Pseudomonas sp, Acinectobacter, Stenotrophomonas maltophilia, ESBL.
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Table 2.1.3 – List of all different criteria used to compose different classifications of HCAI 
Criteria for HCAI Low risk 
of bias
Moderate risk 
of bias
High risk 
of bias
All studies
Criteria included in the initial definition [3] number of studies (number of patients)
Received intravenous therapy 16 (13082) 7 (3239) 8 (6284) 31 (22605)
Received wound care or specialized nursing care 
(One study considered in the previous 30 days)
16 (10086) 5 (1594) 7 (3560) 28 (15240)
Attended a hospital or a clinic in the last 30 days 16 (17588) 5 (1594) 5 (2015) 26 (21197)
Received chemotherapy in the last 30 days (4 studies did not 
specify a time frame)
15 (10883) 6 (2506) 7 (3043) 28 (16432)
Receiving hemodialysis (8 studies specify in the previous month, 
1 in the previous 90 days)
23 (31272) 7 (2639) 10 (10470) 40 (44381)
Prior hospitalization (in the last year) (3 studies did not specify 
a time frame, 2 exclude patients discharged in the previous 14 days)
24 (32165) 7 (3239) 12 (13904) 43 (49308)
Resident in a nursing home or long term-care facility 23 (25468) 7 (3239) 11 (9361) 41 (38068)
Criteria NOT included in the initial definition [3]
Transfer from another care facility 1 (6697) 1 (4543) 2 (11240)
Immunosuppression 4 (8669) 4 (8669)
Active or metastatic cancer 1 (7712) 1 (7712)
Submitted to invasive procedures previously (One study specify 
in the last 90 days and another in the last 7 days)
1 (319) 1 (912) 1 (831) 3 (2062)
Family member with a multi-drug resistant microorganism 2 (713) 2 (1545) 4 (2258)
Elderly person or physical disable persons who need healthcare 1 (893) 1 (1385) 2 (2278)
Surgery in the last 180 days 2 (1056) 2 (1056)
Received radiation therapy 1 (1646) 1 (1646)
Recent (30 days) treatment with antibiotics 1 (190) 1 (733) 1 (197) 3 (1120)
DISCUSSION
Ten years after the first descriptions [3, 7], this is the first systematic review of HCAI classification. It
incorporates all published studies on HCAI that provided original data. The majority of the includ-
ed studies had a low risk of bias, resulting in good quality of the evidence assembled.
The following criteria that were used in various studies to define HCAI in patients with an infec-
tion present at hospital admission or within 48 hours of admission are the ones that we believe to
be most important:
– received invasive procedures in the 30 days before the infection, including intravenous ther-
apy, wound care or specialized nursing care; 
– recent treatment with broad spectrum antibiotics;
– attended a hospital or hemodialysis clinic in the previous 30 days;
– were hospitalized in an acute care hospital for 2 or more days in the previous 30 days to 1 year;
– resided in a nursing home or long-term care facility.
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Table 2.1.4 – Studies with moderate or high risk of bias according to pre-defined criteria
Study Defines 
inclusion 
criteria
Defines 
selection
method
Consecutive
selection of
patients
Attrition 
bias
Reporting 
bias
Overall
Rodriguez-Bano [53] yes yes Not mentioned partial Moderate
Umeki [54] yes yes yes no partial Moderate
Seki [55] yes yes yes no partial Moderate
Park [9] yes yes yes no partial Moderate
Wu [18] yes yes yes no partial Moderate
Al-Hasan [31] yes yes Not mentioned no no Moderate
Siegman-Igra [7] yes yes yes partial no Moderate
Friedman [3] yes yes yes yes yes High
Evans [52] yes yes Not mentioned yes yes High
Vallés [8] yes yes yes yes yes High
Pascual [17] yes yes yes yes yes High
Aguilar-Duran [6] yes yes yes yes yes High
Chalmers [33] yes yes yes yes yes High
Kollef [13] yes yes yes no yes High
Miyashita [36] yes yes yes no yes High
Swenson [21] yes yes no no partial High
Kao [32] yes yes yes no yes High
Guimarães [38] yes yes yes no yes High
Sy [19] yes yes yes no yes High
The inclusion of immunosuppression as a criteria either secondary to chemotherapy, treatment
with high dose of corticosteroids or other types of immunosuppressive therapy or HIV infection,
needs further evidence due to the clear heterogeneity among these patients. However, many
immunosuppressed patients, including cancer patients would fulfill other criteria for HCAI such as
invasive procedures, recently attending a hospital clinic, recent hospitalization and/or recent
treatment with broad spectrum antibiotics
Most of the criteria not included in the initial definition [3] are either not evidence based (close
contact with family members with MDR microorganism) or represent different descriptions of the
same criteria (active or metastatic cancer, submission to invasive procedures or transfer from
another care facility). 
This systematic review provides the clinician with a thorough description of all criteria available in
order to include an infected patient in the category of HCAI, in the hope that it leads to an optimal
selection of empiric antibiotic therapy in this group of patients and consequently an improvement
in outcome. It is expected that a consensus definition of HCAI can be developed to be used in
future research in order to develop specific antibiotic treatment recommendations for this group
of patients.
Clearly, a major hindrance in moving forward with specific therapeutic recommendations is the
lack of a consensus definition of HCAI to allow for drawing conclusions based on different studies.
The review of all definitions of HCAIs that have been used in clinical studies has revealed a huge
variation dependent on multiple combinations of criteria to achieve the final definition. 
The disparities in criteria that have been found in this review range from studies that include hos-
pitalization in the previous 30 days as a criteria for HCAI [7, 11, 13, 21] while other studies excluded
patients discharged from the hospital within the last 14 days from this group of infections [14, 22].
Regarding previous hospitalization, we believe that this criterion must be retained in any defini-
tion of HCAI .The presence of MDR organisms (gram positives or gram negatives) has been docu-
mented between 6 months to one year after hospital discharge [23-25]. This risk of long lasting col-
onization of both the respiratory tract and gastrointestinal tract with pathogens not present in
the community following hospitalization has led some authors to alter this criteria to hospitaliza-
tion in the previous 6 months [12, 16, 26] or even one year [27]. However, the classification of infections
that develop among patients recently discharged from the hospital (in the previous 14 days) is
somewhat contentious. Some authors consider these infections occurring within 14 days of hos-
pital discharge nosocomial infections [28-30], while others consider infections among those hospi-
talized in the last month as HCAIs. Therefore among different studies, depending on the definition
of the criteria of prior hospitalization, an infection occurring in the 2 weeks after hospitalization
could potentially be defined as HCAI or HAI [11, 14]. 
The initial HCAI definition [3] included treatments delivered at home or in an outpatient clinic and
these criteria have been widely adopted in other studies. The receipt of intravenous therapy [7, 14,
19, 20, 31-39], wound care or specialized nursing care [16, 20, 33, 37-40], and hemodialysis [7, 11-14, 16, 19, 20, 22, 26, 27, 31,
33, 34, 36-41], as well as attendance to a hospital or clinic [16, 20, 26, 41] are important factors as this group
of patients have documented higher rates of colonization and infection with MDR microorgan-
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isms [29, 30, 42]. Three additional studies have included the criteria of other previous invasive proce-
dures [7, 20, 32], like urological procedures [20]. There is no reason to believe that this last group of
patients is different from the previous ones in regards to the risks of infection by MDR organisms. 
Another criterion in the initial definition [3] is receiving chemotherapy in the last 30 days. This is a
criteria frequently used among alternative definitions [7, 14, 16, 20, 22, 26, 31, 32, 34, 36, 38] along with having
active or metastatic cancer [11, 41] that suggest receipt of some kind of anti-cancer therapy. These
are a special group of patients due to underlying immunosuppression. Immunosuppression,
including HIV infection and treatment with immunosuppressive agents is a criteria considered by
several authors [11, 12, 27, 34, 36, 40], but specifically excluded by others [22, 26]. The variety of potential
opportunistic pathogens that may occur among this group of patients varies largely according to
the underlying cause of immunosuppression, for example empiric antimicrobial recommenda-
tions for a patient with advanced HIV infection [43] is distinct from therapies used in patients with
acute febrile neutropenia [44]. The inclusion of these groups of patients in a HCAI definition is pos-
sibly one of the most controversial issues.
Patients admitted from nursing homes with infection have been extensively studied and may
constitute more than 50% of cases of healthcare-associated pneumonia [42]. This criterion has been
considered by almost all studies; however caution is needed with this approach. Patients with
non-severe nursing home-acquired pneumonia (NHAP) have a pathogen distribution similar to
those expected in CAP [45]. Among, patients with severe NHAP, with organ dysfunction, resistant
pathogens have been seen [10, 33, 45]. Poor functional status and increased age have been linked to
an increased risk of infection with a MDR pathogen among NHAP patients [46, 47], and are linked to
the level of care provided in these facilities. Nursing homes with hospital-like wards carry the
same infection risk by resistant pathogens as hospitals, and should best be considered as the anal-
ogous to HAIs. Clinicians should consider factors such as functional status and level of care
required in selecting treatments for patients who reside in nursing homes. 
Patients with close contact with a family member with a MDR microorganism are part of the ATS
definition of HCAP [2]. Currently, there are no epidemiological studies assessing the microbiologi-
cal features of this particular group of patients [30].
In addition, recent treatment with broad spectrum antibiotics has been identified as a risk factor
for infection or colonization by MDR pathogens [48] and should also be considered both in the def-
inition of HCAI and in selection of empiric antibiotics. 
There has only been one previous review on HCAI to our knowledge. It concerns healthcare-asso-
ciated pneumonia and is focused mainly on epidemiology [49]. The authors performed the search
in PubMed, and included 8 studies regardless of the definition used. No assessment of bias was
made. A description of the definitions of HCAP used was not made. Five of those studies focused
only on nursing-home acquired pneumonia. The remaining 3 studies of HCAP included by the
authors were also included in the current analysis.
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Limitations
The research method was exhaustive leading to a huge number of retrieved studies and a very
long process of selection; this type of sensitive electronic search in several databases, including
relevant conference proceedings and a hand search of additional sources ensures that no relevant
study was excluded. 
The permissive criteria for inclusion in this study were essential to achieve the main goal: gather-
ing all definitions of HCAI used in clinical studies. 
We found a high rate of studies with low risk of bias, probably related to the simplicity of the eval-
uation. The criteria used were: clear definition of inclusion criteria and selection method, consec-
utive selection of patients, and no attrition or reporting bias. Considering that we only found
observational studies we think that those are the most adequate criteria to evaluate risk of bias in
this type of studies.
CONCLUSIONS AND RECOMMENDATIONS
The initial definition of HCAI [3] seems to be widely accepted; some of the included criteria, such as
the precise time from the last hospitalization are still controversial but probably should be
extended to one year. In addition, other criteria such as recent invasive procedures and receipt of
broad-spectrum antibiotics should be considered for inclusion in a future definition of HCAI.
The inclusion/exclusion of immunosuppressed patients in the definition of HCAI requires ongo-
ing discussion.
It is expected that a consensus definition of HCAI can be developed soon to be used in future
research in order to develop specific antibiotic treatment recommendations for this group of
patients, with an influence from local antibiograms. 
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2.2. MICROBIOLOGICAL PROFILE OF HEALTHCARE-ASSOCIATED
INFECTIONS AND THERAPEUTIC IMPLICATIONS: A SYSTEMATIC
REVIEW
ABSTRACT 
Background: Patients with healthcare associated infections (HCAI) can represent a proportion as
high as 50% of all patients admitted from the community setting. Doctors need to know the
microbiology involved by focus of infection in order to plan adequate antibiotic therapy. The pur-
pose of the current study is to present a systematic review of the microbiological profile involved
in HCAI by focus of infection, comparing with community (CAI) and hospital-acquired infection
(HAI) microbiological profiles.
Methods: The search strategy focused on healthcare-associated infection. MEDLINE, SCOPUS and
ISI Web of Knowledge were searched for articles published from the earliest achievable data until
November 2012. Abstracts from scientific meetings were searched for relevant abstracts along
with a manual search of references from reports, earlier reviews and retrieved studies. All studies
that used Friedman et al. definition of HCAI and that provide a detailed microbiologic profile by
focus of infection were included. 
Findings: On healthcare-associated pneumonia 12 studies were included, involving 1744 patients
with an isolation rate of 59%; the most frequent microorganisms involved were: Streptococcus
pneumoniae in 389 (38%), Staphylococcus aureus in 116 (11%), Klebsiella pneumoniae in 113 (11%),
Pseudomonas aeruginosa in 98 (10%). MRSA was isolated in 72 (7%) and ESBL strains in 17 (2%). If
these patients were treated according to ATS/IDSA guidelines for the treatment of community-
acquired pneumonia 75%-77% would get adequate antibiotic therapy. If they were treated
according to ATS /IDSA guidelines for the treatment of healthcare-associated pneumonia and
hospital-acquired pneumonia, 92% would receive adequate antibiotic therapy but 77% will be
over treated. If piperacillin-tazobactam or aztreonam plus azithromycin were used, the rate of ade-
quate antibiotic therapy would increase to 88%.
There were only two studies on endocarditis, one on urinary infections and five on bloodstream
infections (BSI). None of the studies concerning BSI described the microbiological profile of pri-
mary BSI, turning the described microbiology dependent on the primary focus of infection.
Overall HCAI when compared with CAI and HAI were different in the prevalence of multidrug
resistant pathogens (19% vs 5% vs 29%).
Conclusions: Current guidelines for the treatment of healthcare-associated pneumonia lead to a
high rate of adequate antibiotic therapy at the expense of overtreatment of the majority of
patients. Overall, patients with HCAI have a higher prevalence of multidrug resistant organisms
between CAI and HAI patients which probably justifies the development of specific treatment rec-
ommendations for this group of patients in order to prevent overtreatment and associated unse-
lective pressure with the increased risks of resistances development.
KEY WORDS: Healthcare-associated infection, epidemiology, microbiology, pneumonia, endo-
carditis, urinary tract infection, bloodstream infections
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INTRODUCTION
The concept of healthcare associated infections (HCAI) was proposed in 2002 as a new category
between community (CAI) and hospital-acquired infections (HAI) [1, 2]. Since then diverse defini-
tions of HCAI have been used being the definition proposed by Friedman et al [1] the most used in
clinical studies on HCAI.
Patients with HCAI can represent a proportion as high as 50% of all patients admitted from the
community setting [1, 3-5]. Nearly half of HCAI patients receive antibiotic therapy according to inter-
national guidelines for community-acquired infection [6]. In 2005 the ATS/IDSA recommended the
treatment for healthcare associated pneumonia (HCAP) similar to hospital-acquired pneumonia [7].
The lack of recognition of this group of patients among those that emerge from the community
setting, along with the absence of specific recommendations, for the major focus of infection has
led to high rates of inadequate antibiotic therapy among theme [6].
Doctors need to know the microbiology involved by focus of infection in order to plan adequate
antibiotic therapy, a well-known prognostic factor with a number needed to treat of 10 patients
to save one life [8]. 
The knowledge of the microbiological profiles of HCAI by focus of infection would also help inter-
national societies in the development of specific treatment recommendations.
The purpose of the current study is to present a systematic review of the microbiological profile
involved in HCAI by focus of infection, comparing with CAI and HAI microbiological profiles.
METHODS
Data sources and Searches
This search was performed in 8th November 2012, in accordance with the recommendations of the
Cochrane collaboration, from earliest achievable data until that day, using MEDLINE/PubMed (ref-
erences found from 1989), SCOPUS (references found from 1974) and ISI Web of Knowledge (ref-
erences found from 1968). A manual search of references from reports, earlier reviews and
retrieved studies was also performed. Abstract books and CD-ROMs from several annual scientif-
ic meetings were searched for relevant abstracts (Figure 2.2.1). No language restriction was
applied and papers written in a foreign language were translated.
The electronic search strategy covered the main subject areas: ((((“healthcare” [All Fields] OR
“health care” [All Fields] OR “health-care” [All Fields]) AND (“related” OR “associated” [All Fields])) OR
“healthcare-related” [All Fields] OR “healthcare-associated” [All Fields] OR “health care-related” [All
Fields] OR “health care-associated” [All Fields]) AND (“Infection” [MeSH Terms] OR “bacteremia”
[MeSH Terms] OR “endotoxemia” [MeSH Terms] OR “bacteraemia” [All Fields] OR “sepsis” [MeSH
Terms] OR “severe sepsis” [MeSH Terms] OR “septicemia” [MeSH Terms] OR “pyohemia” [MeSH
Terms] OR “pyemia” [MeSH Terms] OR “pyaemia” [MeSH Terms] OR “poisoning, blood” [MeSH Terms]
OR “blood poisoning” [MeSH Terms] OR “pneumonia” [MeSH Terms] OR “pneumonia lobat” [MeSH
Terms] OR “lobar, pneumonia” [MeSH Terms] OR “pneumonitis” [MeSH Terms] OR “pulmonary infla-
mation” [MeSH Terms] OR “lung inflamation” [MeSH Terms] OR “bronchopneumonia” [MeSH Terms]
OR “peritonitis”[MeSH Terms] OR “cystitis”[ MeSH Terms] OR “pyelonephritis”[ MeSH Terms] OR
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Study selection
The inclusion criteria were all observational studies (cohort, cross-sectional or case-control) on
adult patients admitted to hospital that provided microbiology results according to place of
acquisition of infection and that used the definition of HCAI from Friedman et al [1], in order to
allow comparison of results.
The following definitions of infection by setting were used:
– CAI - infection detected within 48 hours of hospital admission in patients without previ-
ous contact with healthcare service. 
– HAI - localized or systemic condition: 1) that results from adverse reaction to the presence
of an infectious agent(s) or its toxin(s) and 2) that was present 48 hours or more after hos-
pital admission and not incubating at hospital admission time [9]. 
– HCAI: an infection present at hospital admission or within 48 hours of admission in
patients that fulfilled any of the following criteria [1]:
“pyelocystitis”[ MeSH Terms]) AND “adult”[Filter]) was applied. The last search was done on 8th
November 2012.
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Figure 2.2.1 – Flow diagram of study selection
* received intravenous therapy at home, wound care or specialized nursing care
through a healthcare agency, family or friends; or had self-administered intravenous
medical therapy in the 30 days before the infection. Patients whose only home ther-
apy was oxygen use were excluded;
* attended a hospital or hemodialysis clinic or received intravenous chemotherapy in
the previous 30 days;
* were hospitalized in an acute care hospital for 2 or more days in the previous 90 days,
* resided in a nursing home or long-term care facility.
Methicillin-resistant Staphylococcus aureus, Pseudomonas sp, Acinectobacter sp, Stenotrophomonas
maltophilia and extended-spectrum beta-lactamases producers were grouped into multidrug
resistant organisms (MDR).
Data extraction and quality assessment
The results of the literature search were accessed by two reviewers (TC, MA) and non-relevant
studies were excluded based on title and abstract. For potentially relevant studies, the full text was
obtained, and two investigators (TC, MA) independently assessed study eligibility and extracted
data on study design, objectives of the included studies, microbiological profile by focus of infec-
tion and place of acquisition (HCAI, CAI and HAI) using a data extraction protocol; disagreements
were resolved through consultation with a third reviewer (LA).
Each selected study was independently evaluated by two reviewers (TC, MA) for the strength of
evidence through examination of the study design and quality of data. 
Potential threats to the internal validity of included studies were evaluated considering the fol-
lowing criteria:
– The authors define inclusion criteria, 
– The authors define an adequate selection method (for instance, all hospitalized patients
with infection),
– The selection of participants was consecutive,
– The outcome data was complete (no attrition bias) and 
– All results were reported (reporting bias).
Studies that met all of the above 5 criteria, were classified as “low risk of bias”. Studies that partial-
ly met one or more criteria were classified as “moderate risk of bias”. Studies were classified as “high
risk of bias” if one or more of these criteria was not met.
Data analysis 
Data on individual studies included are provided in table 2.2.1; table 2.2.2 shows the microbiolog-
ic profile by focus of infection (pneumonia, endocarditis, urinary and bloodstream infections). 
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A meta-analysis was not performed due to the nature of the objectives of this review and the het-
erogeneity of the studies included.
RESULTS
The search retrieved a total of 49,405 references, among which 15,311 duplicates were identified.
Of the 34,094 remaining articles, 33,828 were excluded based on title and abstract (figure 2.1.1).
Full texts were obtained for the 266 articles that remained. Of those: 106 were review articles or
opinion pieces (commentaries and letters), and 108 did not meet inclusion criteria. Of the remain-
ing 52 studies: 30 used the initial definition of Friedman et. al [1], but only 20 provided data on
microbiology and were included (figure 2.2.1). 
Of the 20 studies included in this systematic review: 10 were prospective (3 multicenter and 7 sin-
gle center) and 10 retrospective (3 multicenter and 7 single center); involving 10.967 patients. 
The description of individual studies included by focus of infection is shown in table 2.2.1, name-
ly: pneumonia (table 2.2.1.a.), endocarditis (table 2.2.1.b), urinary tract infections (table 2.2.1.c) and
bloodstream infections (table 2.2.1.d).
Infections by Source
Healthcare-associated pneumonia (HCAP) was characterized in 1744 patients of which 1022
patients had microbiological documentation (isolation rate =59%). The micro-organisms isolat-
ed were: Streptococcus pneumoniae in 389 (38%), Staphylococcus aureus in 116 (11%), Klebsiella
pneumonia in 113 (11%), Pseudomonas aeruginosa in 98 (10%), Haemophilus influenza in 55 (5%),
atypical agents in 38 (4%), E. coli in 15 (1.5%), other Streptococci in 15 (1.5%), Enterobacter spp in
14 (1.4%), Acinectobacter spp in 8 (0.8%), Moraxella catarrhalis in 8 (0.8%), Stenotrophomonas mal-
tophilia in 6 (0.6%), anaerobes in 5 (0.5%), virus in 5 (0.5%), Serratia marcescens in 5 (0.5%), Proteus
mirabilis in 4 (0.4%), Citrobacter spp. in 3 (0.3%), Morganella morganii in 2 (0.2%), fungus in 2
(0.2%), Corynebacterium spp in 2 (0.2%), and Nocardia spp in 1 (0.1%). MRSA were isolated in 72
(7%) and ESBL strains in 17 (2%). In 11.5% of the HCAP cases the authors did not specify the
responsible agent.
In community-acquired pneumonia the top three microorganisms were: Streptococcus pneumo-
nia in 1331 (59%), atypical agents in 341 (15%) and Haemophilus influenza in 164 (7%) (table 2.2.2). 
Only one study compares HCAI with CAI and HAI [10] being the top three microorganisms:
Streptococcus pneumonia (70% vs 90% vs 40%), Pseudomonas aeruginosa (12% vs 2% vs 31%) and
Staphylococcus aureus (3% vs 1% vs 10%), without mention to the proportion of MRSA (table 2.2.2). 
Considering only low risk of bias studies, there were 6 studies including 4103 patients: 1050 in the
HCAI group with an isolation rate of 70% and 3053 in the CAI group with an isolation rate of 60%,
the microbiological profile remained the same, with exception of the MDR prevalence that
decreases to 13%, probably due to higher rate of overall isolation that diluted their prevalence.
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Table 2.2.1 – List of studies included for the objective of analyze of the involved microbiologic profile globally and by foci
of infection, according to place of acquisition
a) Pneumonias
Study Umeki [21] Park [3] Shindo [22] Seki [23] Garcia-Vidal [24] Jung [25]
Design Prospective, single
center study, in 
202 patients, 
Japan, 2 years
Prospective, single
center study, in 
339 patients with
positive 
microbiology, 
Korea, 2 years
Retrospective, 
single center
study, in 371
patients, Japan, 
1 year and 
3 months
Retrospective,
single center
study, in 34
patients, 
Japan, 
4 months
Prospective, single center
study, in 2153 patients, 
Spain, 8 years and 9 months,
those with more than one
condition of HCAI, 
neutropenia, AIDS, after 
transplantation of chronic
corticosteroid treatment 
were excluded
Retrospective, 
single center
study, in 527
patients, Korea, 
1 year
Patients in each
category, n (%)
CAI
123 (61)
HCAI
79 (39)
CAI
172 (51)
HCAI
167 (49)
CAI
230 (62)
HCAI
141 (38)
CAI
20 (59)
HCAI
14 (41)
CAI
1668 (74)
HCAI
485 (26)
CAI
296 (56)
HCAI
231 (44)
Isolation rate, 
n (%)
48 (39) 48(61) 172 (100) 167 (100) 109 (47) 77 (55) 20 14 1066 (64) 322 (66) 83 (28) 79 (34)
Streptococcus
pneumoniae, 
n (%), p value *
12 (25),
p=0.270
12 (25) 55 (32),
p<0.001
22 (13) 44(40) 19 (25) 13 (65) 3 (21) 686 (64) 188 (58) 33 (40) 11 (14)
Haemophilus
influenzae, 
n (%), p value*
10 (21),
p=0.132
2 (4) 4 (2) 2 (1) 17 (16) 4 (5) 2 (10) 0 (0) 80 (8) 25 (8) 3 (4) 2 (3)
Klebsiella pneu-
moniae, n (%), 
p value*
1 (2)
p=0.003
8 (17) 26 (15),
p=0.007
45 (27) 4 (4) 10 (13) 0 (0) 1 (7) 13 (16) 23 (29)
Pseudomonas
aeruginosa, n (%)
p value*
4 (8)
p=1.000
2 (4) 23 (13),
p=0.064
35 (21) 4 (4) 8 (10) 0 (0) 3 (21) 19 (2) 7 (2) 5 (6) 10 (13)
Staphylococcus
aureus, n (%), 
p value*
4 (8),
p=0.003
12 (25) 24 (14) 29 (17) 14(18) 14 (13) 1 (8) 3 (21) 5 (0.5) 6 (2) 15 (18) 13 (16)
MRSA (of all
Staphylococcus
aureus), n (%)
p value*
4 (100) 
p=0.036
9 (75) 9 (38),
p=0.059
18(62) 2 (3) 5 (5) 0(0) 3(100) 6 (40) 9 (69)
E. coli, n (%)
p value *
1(2)
p=1.000
1(2) 2 (1) 5 (3) 1 (1) 0(0) 0(0) 0(0) 0(0) 1 (1)
Atypical agents, 
n (%), p value*
7(15)
p=0.487
2(4) 27 (16),
P<0.001
5 (3) 16 (21) 1(1) 1 (8) 0 (0) 192 (18) 21(7) 3 (4) 0 (0)
MDR, n (%)
p value*
10 (21) 12 (25) 35 (20) 59 (35) 6 (6) 17 (22) 0 (0) 6 (43) 19 (2) 7 (2) 15 (18) 30 (38)
Risk of bias High Low Low High Low Moderate
*p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled.
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Table 2.2.1 – List of studies included for the objective of analyze of the involved microbiologic profile globally and by foci
of infection, according to place of acquisition
a) Pneumonias (continuation)
Study Jeon [26] Lee i [27] Depuydt [28] Pascual [10] Park [29] Carratalà [30]
Design Retrospective, 
multicenter study,
in 210 patients
older than 60
years, Korea, 
2 years
Retrospective, 
multicenter study, 
in 303 patients,
Korea, 21 months
Retrospective, 
single center study,
287 episodes in
269 patients,
Belgium , 1 year.
Patients with 
neutropenia, 
transplantation or
transferred from
another hospital
were excluded
Retrospective, single 
center study, in 308
patients with 
bacteriemic pneumonia,
Spain, 6 years
Retrospective, single
center study, in 345
patients, Korea, 
1 year. Defines CAI
and HCAI until 72 h
after hospital 
admission. Patients
with neutropenia,
AIDS and after trans-
plantation were 
excluded
Prospective, single
center study, in
727 patients,
Spain, 4 years.
Patients with 
neutropenia, AIDS
and after 
transplantation
were excluded
Patients in each
category, n (%)
CAI
175 
(83)
HCAI
35 
(17)
CAI
207 
(68)
HCAI
96 
(32)
CAI
159 
(55)
HCAI
128 
(45)
CAI
206 
(67)
HCAI
60 
(20)
HAI
42 
(13)
CAI
163 
(47)
HCAI
182 
(53)
CAI
601 
(83)
HCAI
126 
(17)
Isolation rate, 
n (%)
63 (36) 30 (86) 84 (41) 55 (57) 14 (9) 20 
(16)
206
(100)
60 
(100)
42 
(100)
46 (28) 65 (36) 337 (56) 85 (67)
Streptococcus
pneumoniae, 
n (%), p value *
21 (33),
p=0.005
2 (7) 41 (49),
p=0.306
24 (44) 9 (64) 6 (30) 185 (90) 42 (70) 17 (40) 28 (61) 25 (38) 204(61) 35(41)
Haemophilus
influenzae, 
n (%), p value*
7 (11),
p=0.211
1 (3) 3 (4) 0 (0) 2 (4),
p=1.000
4 (6) 36 (11) 15 (18)
Klebsiella 
pneumoniae, 
n (%), p value*
13 (21),
p=0.515
8 (27) 3 (4) 5 (9) 4 (9),
p=0.406
13 (20) 1 (0.3) 0(0)
Pseudomonas
aeruginosa, 
n (%), p value*
4 (6),
p=0.006
8 (27) 1 (1) 4 (7) 4 (2) 7 (12) 13 (31) 2 (4),
p=0.119
9 (14) 3 (1) 5 (6)
Staphylococcus
aureus, n (%)
p value*
9 (11),
p=0.006
12 (40) 5 (6) 9 (16) 13 (93) 3 (15) 2 (1) 2 (3.3) 4 (9.5) 6 (13),
p=0.158
13 (20) 3 (1) 0(0)
MRSA (of all
Staphylococcus
aureus), n (%)
p value*
6(66),
p=0.012
9 (75) 2(40),
p=0.002
8(89) 0 (0) 2 (37) 1(17) 5 (38) 1 (33) 0(0)
E. coli, n (%), 
p value*
0 (0) 2 (4) 0 (0),
p=0.265
3 (5) 2 (0.6) 3 (4)
Atypical agents, 
n (%)
2 (3) 0 (0) 18 (21) 4 (7) 75 (22) 5 (6)
MDR, n (%)
p value*
10 (16) 20 (67) 3 (4) 17 (31) 4 (29) 6 (30) 4 (2) 7 (12) 13 (31) 7 (15) 21 (32) 4 (1) 5 (6)
Risk of bias Low Low High High Moderate Low
*p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled
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Table 2.2.1 – List of studies included for the objective of analyze of the involved microbiologic profile globally and by foci
of infection, according to place of acquisition
b) Endocarditis
Study Wu [12] Benito b [4]
Design Retrospective, single center study, in a tertiary care
center with a large oncology department, including
190 episodes in 192 patients, Taiwan, 5 years
Prospective, single center study, in 1622 patients, USA, 
6 months. They excluded intra-venous drug user, prosthetic
valves. 
Number of patients 
per category, n (%)
CAI
148 (74)
HCAI
30 (15)
HAI
22 (11)
CAI
1065 (11)
HCAI
254 (53)
HAI
303 (36)
p value*
Staphylococci, n (%) 75 (51) 23 (77) 17 (77) 210 (22) 141 (59) 107 (37) 0.3
MSSA (of all Staphylococci
isolation), n (%)
57 (76) 8( 35) 0 (0)
MRSA (of all Staphylococci
isolation), n (%)
14 (19) 13 (57) 17 (100) 25 (12) 76 (32) 41 (14) 0.014
Coagulase negative
Staphylococci, n (%)
4 (5) 2 (9) 0(0) 67 (7) 36 (15) 39 (14) 0.23
Streptococci, n (%) 51 (34) 4 (13) 2 (9)
Streptococcus viridans, 
n (%)
35 (24) 3 (75) 0 (0) 293 (31) 33 (14) 14 (5) 0.023
Enterococci, n (%) 5 (3) 3 (10) 1 (5) 92 (10) 42 (18) 42 (15) 0.38
Gram negative bacilli, n (%) 2 (1) 0 (0) 1 (5)
MDR, n (%) 15 (10) 13 (43) 17 (77) 25 (2) 76 (30) 41 (14) 0.014
Risk of bias Moderate Low
*p value refers to comparison of CAI with healthcare associated = non nosocomial + nosocomial and HCAI with nosocomial.
Table 2.2.1 – List of studies included for the objective of analyze of the involved microbiologic profile globally and by foci
of infection, according to place of acquisition
c) Urinary tract infection
Study Aguilar-Duran [5]
Design Prospective, single center study, in 251 patients with positive cultures, Spain, 7-8 months
Number of patients per category, n (%) CAI
88 (35)
HCAI
97 (13)
HAI
66 (26)
E. coli, n (%),
p value*
66 (75),
p =0.62
69 (71) 36 (55),
p =0.03
Klebsiella spp, n (%)
p value*
9 (10),
p =0.80
8 (8) 10 (15),
p =0.20
ESBL 1 (1) 9 (12) 6 (13)
Pseudomonas aeruginosa, n (%), p value* 1 (1),
p =0.02
9 (9) 7 (11),
p =0.79
Proteus spp, n (%), p value 5 (6),
p =0.73
4 (4) 4 (6),
p =0.71
Other gram negative rods, n (%), p value* 4 (5),
p =0.42
2 (2) 6 (9),
p = 0.06
Enterococcus spp, n (%)
p value*
1 (1),
p =0.37
4 (4) 1(2),
p =0.64
MDR 2 (3) 18 (19) 15 (23)
Risk of bias High
*p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled.
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Table 2.2.1 – List of studies included for the objective of analyze of the involved microbiologic profile globally and by foci
of infection, according to place of acquisition
d) Bloodstream infections
Study Marschall [15] Son [16] Evans [31] Rodriguez-Bano [17] Vallés [18]
Design Prospective, single 
center study, in 250
patients with gram 
negative bacteremia,
USA, 6 months
Prospective, 
multicenter study, in
1144 patients, Korea, 
12 months
Retrospective, 
multicenter study, 
in 226 patients with
spinal cord injury 
and disorder, USA, 
7 years. They analyze
episodes and not
patients
Prospective, multicenter
study, in 821 isolates,
Spain, 2-5 months. They
included different
episodes in the 
same patient and 
potential contaminants
too
Prospective, multicen-
ter, international study,
in 726 patients, 
Spain and Argentina, 
12 months
Patients per 
category, n (%)
CAI
28 
(11)
HCAI
132
(53)
HAI
90
(36)
CAI
380
(33)
HCAI
558 
(49)
HAI
206
(18)
CAI
36
(9)
HCAI
110
(27)
HAI
267
(64)
CAI
150
(18)
HCAI
195
(24)
HAI
476
(58)
CAI
343
(47)
HCAI
131
(18)
HAI
252
(35)
E. coli, n (%)
p value*
16(57)
p=0.001 
33(25) 10(11)
p=0.01
179(47) 
p<0.001
56
(27)
83 (15)
p<0.001
9(25)
p=0.25 
19(17) 24(9)
p=0.07
57 (38) 72 (37) 96 (20)
p<0.01
70
(21)
35 (27) 46 (19)
Klebsiella 
pneumoniae, 
n (%), p value*
2(7)
p= 0.3
20 (15) 23(26)
p=0.05
12 (13) 
p=0.197
34
(17)
74 (13)
p=0.254
6(17)
p=0.39
10(9) 26(10)
p=0.87
12 (8) 13 (7) 39 (8) 13 (4) 6 (5) 15(6)
Pseudomonas
aeruginosa, 
n (%),p value*
0(0)
p= 0.4
9 (7) 10(11)
p=0.3
11 (3) 
p=0.007
16 (8) 36(7)
p=0.522
2(6)
p=0.34
14(13) 29(11) 
p= 0.73
1(<1),
p<0.01 
13 (7) 26 (5) 6 (2) 6 (5) 16 (6)
Staphylococcus
aureus, n (%)
p value*
28 (7)
p=
0.009
29
(14)
85 (15) 
p=0.691
12(33)
p=0.61
33(30) 97(36)
p=0.21
10 (7) 22 (11) 67 (14) 34 (10) 18 (14) 25 (10)
MRSA (of all
Staphylococcus
aureus), n (%)
p value*
5 (18) 
p= 0.25 
9 (31) 59 (69)
p<0.001
4 (11),
p=0.5
20 (18) 82 (31),
p=0.02
0 (0) 6 (27) 24 (36) 1 (3) 5 (28) 13 (52)
Streptococcus
pneumonia, 
n (%), p value*
15 (4)
p=0.04
2 (1) 7 (1)
p=0.747
27 (18)
p<0.01
11 (6) 3 (<1)
p=0.01
73 (21)
p<0.001
6 (5) 4 (2)
ESBL, n (%)
p value*
8 (4) 13
(14)
40 (25) 6 (9) 7 (8) 21 (16)
MDR, n (%)
p value*
0(0)
p= 0.4
9 (7) 10(11)
p=0.3
29 (8) 46 (8) 162 (79) 6 (17) 34 (31) 111(42) 7 (5) 29(15) 99 (21) 7 (2) 11 (8) 29 (12)
Primary 
bacteremia, n (%)
Not mentioned CAI
22 (6)
HCAI
28 (5)
HAI
29 (14)
Not mentioned Not mentioned Not mentioned
Focus of secondary
bacteremia
CAI HCAI HAI CAI HCAI HAI CAI HCAI HAI CAI HCAI HAI
Intravascular
device
0 (0) 26 (20) 14 (16) 0 (0) 24 (12) 116 (24) 0 (0) 10 (8) 37 (15)
Urinary 16
(57)
38
(20)
13 
(14)
119
(31)
30
(14)
32
(6)
46 (31) 41(21) 73 (15) 40 (12) 23 (18) 16 (7)
Intra-abdominal 4 (14) 22 (17) 15 (17) 116 (31) 56 (27)98 (18) 33(22) 40(20) 70(14) 85(25) 29(22) 84(33)
Pneumonia 42 (11) 2(14) 79 (14) 28(19) 22(11) 55(12) 87(25) 27(21) 39(15)
Soft tissue 
infection
13 (3) 6 (3) 15 (3) 8(5) 10(5) 21(4)
Endocarditis 8(5) 9(5) 6(1)
Other 68 (18) 3 (1) 37 (7) 5(3) 4(2) 8(2) 71(21) 21(16) 28(11)
Unknown 6 (21) 27 (21) 32 (36) 22(15) 45(23) 127(27) 59(17) 21 (16) 48 (19)
Risk of bias High Low High Moderate High
*p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled
MDR = MRSA, Pseudomonas sp, Acinectobacter sp, Stenotrophomonas maltophilia, ESBL
The ATS/IDSA guidelines for the treatment of community-acquired pneumonia [11] recommend as
empirical antibiotic therapy: cefotaxime, ceftriaxone or ampicillin/sulbactam plus azithromycin or
monotherapy with a fluroquinolone. Considering only described microbes (n=904) if the first rec-
ommendation is applied to patients with HCAP, 678 (75%) would get adequate antibiotic therapy;
if the option was a beta-lactamic plus azithromycin the number would increase to 683 (76%) due
to anaerobes coverage; if it was a fluroquinolone the number getting adequate antibiotic thera-
py would increase to 692 (77%), due to Enterobacter spp coverage.
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Table 2.2.2 – Microbiological profile of healthcare-associated infection by focus of infection and comparison with com-
munity and hospital-acquired infections
PNEUMONIA ENDOCARDITIS BLOODSTREAM 
INFECTION
Number of 
studies/patients
12 studies /
5735 patients
Number of
studies/patients
2 studies /
1814 patients
Number of
studies/patients
5 studies /
3167 patients
number of 
patients 
(isolations)
HCAI
1744
(1029 -
59%)
CAI
4020
(2251 -
56%)
HAI
42
(100%)
number of patients 
per category 
(isolation rate)
HCAI
277
(100%)
CAI
1213
(100%)
HAI
325
(100%)
number of isolations 
per category 
HCAI
1126
CAI
937
HAI
1291
Microorganism, n (%) Microorganism, n (%) Microorganism, n (%)
Streptococcus
pneumoniae
389 
(38)
1331
(59)
17 
(40)
Staphylococci, n (%) 164 
(59)
285 
(24)
124
(38)
E. coli 215 
(19)
331 
(35)
259
(20)
Klebsiella 
pneumoniae
113 
(11)
65
(3)
MRSA (of all
Staphylococci
isolation)
89 
(54)
39 
(14)
58 
(47)
Staphylococcus 
aureus
102
(9)
84 
(9)
274
(21)
Staphylococcus
aureus
116 
(11)
101 
(5)
4 
(10)
Enterococci 45 
(16) 
97 
(8)
43 
(13)
MRSA (of all
Staphylococcus 
aureus isolation)
40/102
(39)
10/84
(12)
178/
274
(65)
MRSA (of all
Staphylococci 
isolation)
68 
(59)
31 
(31)
Coagulase negative
Staphylococci
38 
(14)
71 
(6)
39 
(12)
Klebsiella pneumoniae 83 
(7)
45 
(5)
177 
(14)
Pseudomonas
aeruginosa 
98 
(10)
67 
(3)
13 
(31)
Streptococcus viridans 36 
(13)
328 
(27)
14 
(4)
ESBL (of all E. coli and
Klebsiella spp isolation)
20/298
(7)
14/376
(4)
61/436
(14)
Haemophilus
influenza
55 
(5)
164 
(7)
Gram negative bacilli 0 
(0)
2 
(0.2)
1
(0.3)
Pseudomonas 
aeruginosa 
58 
(5)
20 
(2)
117 
(9)
Atypical agents 38 (4) 341
(15)
Streptococcus 
pneumonia
19 
(2)
115
(12)
14
(1)
E. coli 15 
(1)
6 
(0.2)
MDR 223
(22)
117
(5)
13 
(31)
MDR 89 
(32)
40 
(3)
58 
(18)
MDR 129 
(12)
49
(5)
411 
(32)
The ATS /IDSA guidelines for the treatment of healthcare-associated pneumonia and hospital-
acquired pneumonia [7] recommend as empirical antibiotic therapy: cefepime, ceftazidime, imipen-
em, meropenem or piperacillin-tazobactam plus ciprofloxacin, levofloxacin, amikacin, gentamicin
or tobramycin plus linezolid or vancomycin. If these recommendations were applied, 828 (92%)
would receive adequate antibiotic therapy. Patients with Acinectobater spp. (n=8) would only be
covered if the isolated rods were sensitive, ESBL (n=17) strains only if carbapenems were used and
atypical agents (n=38) if a fluroquinolone was the option. Stenotrophomonas spp. (n=6) and fungi
(n=2) would be left out regardless of the option. Using these guidelines instead of community-
acquired pneumonia recommendations would result in overtreatment of 696 patients (77%).
If piperacillin-tazobactam or aztreonam plus azithromycin were used the rate of adequate antibi-
otic therapy would increase to 88%.
There were only two studies on endocarditis [4, 12]. Benito et al [4] in a study with low risk of bias
found significant differences between CAI, HCAI and HAI in what concerns the prevalence of
MRSA (higher in HCAI, when compared with CAI and HAI) and Streptococcus viridans (lower in HAI,
when compared with the other two groups) (Table 2.2.1.b).
The study on urinary tract infection [5], classified as having a high risk of bias, showed important
differences in the microbiological profile according to different settings (Table 2.2.1.c); the per-
centage of ESBL among E. coli and Klebsiella spp. was 1% in CAI, 12% in HCAI and 13% in HAI.
Bloodstream HCAI also had a microbiology profile different from CAI and HAI (Table 2.2.1.d). The
proportion of ESBL among E. coli and Klebsiella spp isolation was 7% in HCAI, 4% in CAI and 14%
in HAI, of MRSA, among all Staphylococcus aureus isolation was 39% vs 12% vs 65% and of MDR
organisms was 12%, 5% and 32%, respectively. 
The top three pathogens in HCAI regardless of focus of infection were: Streptococcus pneumoniae in
406 (17%), Staphylococci spp in 402 (17%) and E. coli in 299 (12%). Pseudomonas aeruginosa were
present in 164 (7%), MRSA in 192 (8%) and ESBL in 41 (2%); MDR represent 459 (19%) of all isolations.
In CAI the top four were: Streptococcus pneumoniae in 1431 (32%), Staphylococci spp in 559 (12%),
E. coli in 403 (9%) and atypical agents in 341 (8%). Pseudomonas aeruginosa were present in 88
(2%), MRSA in 79 (2%) and ESBL (among E. coli and Klebsiella spp. isolations) in 20 (0.4%); MDR rep-
resent 224 (5%) of all isolations. 
In HAI the top three were: Staphylococci spp in 441 (26%), E. coli in 295 (17%) and Klebsiella spp. in
187 (11%). Pseudomonas aeruginosa were present in 137 (8%), MRSA in 223 (13%) and ESBL in 53
(3%); MDR represent 497 (29%) of all isolations. 
Regarding risk of bias of the included studies: 8 presented a low, 4 a moderate and 8 a high risk of
bias (Table 2.2.3).
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DISCUSSION
We found a unique microbiological profile of healthcare-associated infections when compared to
community-acquired and hospital-acquired infections for pneumonia, endocarditis, urinary and
bloodstream infections.
Considering that the major foci of infection that drive patients into hospital care are respiratory,
genitourinary and abdominal infections [13, 14], it is noteworthy the lack of low risk of bias studies
regarding genitourinary and intra-abdominal infections. Bloostream infections also represent an
important proportion of patients admitted into hospital care [13] but their analysis regarding
microbiology should focus on primary BSI which was not the case in the included studies [15-18]. 
Respiratory infections are consensually the most frequent infections among hospitalized patients
despite the place of acquisition. This focus had the higher number of studies included in the cur-
rent analysis, although only one among 12 studies did a comparison of HCAI with HAI [10], and it
was a high risk of bias study with a low number of patients included in each group, not allowing
any firm conclusions to be drawn.
Focusing on the comparison between HCAP and CAP, the most prevalent pathogen was common in
both groups – Streptoccus pneumoniae – but the proportion of MDR pathogens was higher in HCAP,
22% vs 5% in CAP. Nevertheless, Pseudomonas aeruginosawas present only in 10% of all HCAP with
isolation and MRSA in 7%, a proportion that does not justify empirical antibiotic coverage.
The existing recommendations for the treatment of this group of patients [7] recommend huge
spectrum empirical antibiotic coverage, including Pseudomonas spp. and MRSA. If those guide-
lines were to be used nearly 80% of the patients would be over treated a well-known factor for
the development and increasing rate of multidrug resistance [19].
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Table 2.1.4 – Studies with moderate or high risk of bias according to pre-defined criteria
Study Defines 
inclusion 
criteria
Defines 
selection
method
Consecutive
selection of
patients
Attrition 
bias
Reporting 
bias
Overall
Jung [25] yes yes yes partial partial Moderate
Rodriguez-Bano [17] yes yes Not mentioned partial partial Moderate
Park [29] yes yes yes partial partial Moderate
Wu [12] yes yes yes partial partial Moderate
Pascual [10] yes yes yes yes yes High
Depuydt [28] yes yes yes yes yes High
Seki [23] yes yes yes yes yes High
Umeki [21] yes yes yes yes yes High
Aguilar-Duran [5] yes yes yes yes yes High
Evans [31] yes yes Not mentioned yes yes High
Vallés [18] yes yes yes yes yes High
Marschall [15] yes yes yes yes yes High
On the other hand if recommendations for CAP are used in HCAP patients a significant proportion
will still get adequate antibiotic therapy (at least 75%) without creating such a large unnecessary
microbiologic pressure. This rate could be increased to 88% if the recommended antibiotic thera-
py would be piperacillin-tazobactam or aztreonam plus azithromycin.
In endocarditis, two studies were analyzed [4, 12]: the first one included few patients and had mod-
erate risk of bias; the second one [4] included a significant number of patients but the exclusion of
intra-venous drug users and patients with prosthetic valves has probably deviated the predicted
profile to one with a lower rate of Staphilococci spp. including MRSA, preventing generalization of
the findings.
Only one study on urinary tract infections was found – a single center, with low number of patients
and a high risk of bias. Clearly larger, multicenter studies, with a design towards microbiological
characterization according to place of acquisition on genitourinary infections are needed.
The five studies on bloodstream infections gathered an appreciated number of patients, with sim-
ilar proportions of patients in the three groups, but in order to discuss empiric antibiotic therapy
one needs to be aware of the microbiological profile of primary BSI. None of the studies mention
that; in fact only one study [16] described the proportion of primary BSI by place of acquisition, but
without describing the microorganisms involved in this subgroup.
Regardless of the foci the top three pathogens in HCAI are the same as in CAI, but with different
proportions of MDR organisms (12% vs 5%). Of notice is the fact that Pseudomonas, MRSA and
ESBL strains individually represent less than 10% of all isolations, though not implying empirical
coverage. 
Of regard is the need to identify individual risk factors for particular MDR organisms in each
patient in order to deliver the more appropriate antibiotic therapy, which would be different for
Pseudomonas, for MRSA or for ESBL strains.
Limitations
The research method for this systematic review was exhaustive leading to a huge number of
retrieved studies and a very long process of selection; this type of sensitive electronic search in
several databases, including relevant conference proceedings and a hand search of additional
sources ensures that no relevant study was excluded. 
The permissive criteria for inclusion in this study were essential to achieve the main goal: gather-
ing all studies on HCAI that provided a detailed microbiology profile by focus of infection. 
The majority of included studies were considered of low or moderate quality despite the simplic-
ity of the evaluation. The criteria used were: clear definition of inclusion criteria and selection
method, consecutive selection of patients, and no attrition or reporting bias. Considering that we
only found observational studies we think that those are the most adequate criteria to evaluate
risk of bias in this type of studies. 
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Summary of the main results
This review incorporates all published studies on HCAI that provided original data on microbio-
logical profile using the definition by Friedman et al. [1] Important differences in the microbiolog-
ical profile of HCAI when compared with CAI and HAI for endocarditis, respiratory, urinary and
bloodstream infections were found.
More than half of the studies were on HCAP; for this group of patients the application of the exist-
ing guidelines would lead to a high rate of adequate antibiotic therapy due to the overtreatment
of the majority of patients, creating unnecessary unselective pressure and consequently higher
probability of resistances development. If CAP guidelines were to be applied to this group of
patients three quarters would still get adequate antibiotic therapy with a significant lower risk of
resistance development. Based on the microbiology results gathered in this systematic review, the
rate of antibiotic therapy adequacy would increase to 88% if piperacillin-tazobactam or aztreon-
am plus azithromycin were used in the empirical treatment of HCAP. 
The existing studies are insufficient in providing adequate microbiological characterization of
HCAI by focus of infection, furthermore, for some foci, like abdominal, are inexistent, making
impossible for the clinician an adequate prescription of empirical antibiotic therapy and prevent-
ing the development of specific recommendations.
However based on the results founded the empirical coverage of Pseudomonas aeruginosa, MRSA
or ESBL strains is only justify in patients with specific risk factors [20].
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CONCLUSIONS AND RECOMMENDATIONS
This systematic review provides the clinician with a thorough characterization of the microbiolog-
ic profile involved in HCAI by focus of infection, in the hope that it leads to an optimal selection
of empiric antibiotic therapy and consequently an improvement in outcome. 
For HCAP, based on the results gathered we suggest empirical treatment with piperacillin-
tazobactam or aztreonam plus azithromycin if local microbiology documents a high rate of gram
negative bacilli not sensitive to non-pseudomonal 3rd generation cephalosporins, otherwise CAP
recommendations seem to be more equilibrate in terms of adequacy of treatment and unselec-
tive pressure.
For the remaining foci of infection the evidence available is clearly not sufficient to draw firm con-
clusions. Further studies focused on the major focus of infection, namely intra-abdominal, geni-
tourinary, skin and soft tissue and primary bloodstream infections directed towards detailed
microbiology characterization are urgently needed in order to allow the development of specific
treatment recommendations.
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2.3. HEALTHCARE-ASSOCIATED INFECTIONS AND INADEQUATE 
INITIAL ANTIBIOTIC THERAPY: A SYSTEMATIC REVIEW
ABSTRACT 
Introduction: Healthcare-associated infections (HCAI) have been increasingly recognized as a
separate group between community (CAI) and hospital (HAI) acquired infections. The lack of con-
sensual guidelines for the treatment of these patients has probably leaded to an increased rate of
inadequate initial antibiotic therapy a well-known prognostic factor. The purpose of the current
study is to present a systematic review on the rate of inadequate initial antibiotic therapy among
healthcare associated infections.
Methods: The search strategy focused on healthcare-associated infection. MEDLINE, SCOPUS and
ISI Web of Knowledge were searched for articles published from the earliest achievable data until
November 2012. Abstracts from scientific meetings were searched for relevant abstracts along
with a manual search of references from reports, earlier reviews and retrieved studies. All studies
that used Friedman et al. definition of HCAI and that provide data on the rate of inadequacy of ini-
tial antibiotic treatment were included. 
Findings: The search retrieved a total of 49,405 references, among which 15,311 duplicates were
identified, 33,828 were excluded based on title and abstract. Full texts were obtained for the 266
articles that remained: 106 were review articles or opinion pieces, 143 did not meet inclusion cri-
teria and 17 were included in this systematic review, involving 10.238 patients. In bloodstream
infections the rate of inadequate initial antibiotic therapy among HCAI patients varied between
24% and 36%, in pneumonia between 6% and 37%, in urinary infections between 22% and 26%
and in endocarditis it was 57%. In all included studies, patients with HCAI had a higher rate of
inadequate initial antibiotic therapy when compared to CAI patients and in 9 studies this differ-
ence was statistically significant. Overall the rate of inadequate initial antibiotic therapy found
among HCAI patients was 25%.
Conclusions: Patients with HCAI have a high rate of inadequate initial antibiotic therapy, higher
than patients with CAI, reinforcing the need for the development of specific treatment recom-
mendations for this group of patients.
KEY WORDS: Healthcare-associated infection, adequacy of antibiotic therapy, pneumonia, blood-
stream infections, endocarditis, urinary tract infection.
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INTRODUCTION
In recent years, the traditional distinction between community-acquired and hospital-acquired
infections has become less clear, with some infections having characteristics of both types [1-5].
Infections detected within 48 hours of hospital admission in patients with a close contact with the
healthcare system have been proposed to constitute a new category: healthcare-associated infec-
tions (HCAI), based on different microbiology profiles and the associated need for a different
approach regarding empiric antibiotic therapy [6-8].
The percentage of patients with HCAI can be higher than 50% among hospitalized patients from
the community setting [1, 5, 9, 10] and nearly half of this patients receive antibiotic therapy according
to international guidelines for community-acquired infection [11].
Being the microbiology profile involved in HCAI different from CAI and HAI, the lack of specific rec-
ommendations for the main focus of infection among patients with HCAI may be associated with
a significant rate of inadequate initial antibiotic therapy.
The purpose of the current study is to present a systematic review on the rate of inadequate ini-
tial antibiotic therapy among healthcare-associated infections.
METHODS
Data sources and Searches 
This search was performed in 8th November 2012, in accordance with the recommendations of the
Cochrane collaboration, from earliest achievable data until the date of the research, using MED-
LINE/PubMed (references found from 1989), SCOPUS (references found from 1974) and ISI Web of
Knowledge (references found from 1968). A manual search of references from reports, earlier
reviews and retrieved studies was also performed. Abstract books and CD-ROMs from several
annual scientific meetings were searched for relevant abstracts (Figure 2.3.1). No language restric-
tion was applied and papers written in a foreign language were translated.
The electronic search strategy covered the main subject areas: ((((“healthcare” [All Fields] OR
“health care” [All Fields] OR “health-care” [All Fields]) AND (“related” OR “associated” [All Fields])) OR
“healthcare-related” [All Fields] OR “healthcare-associated” [All Fields] OR “health care-related” [All
Fields] OR “health care-associated” [All Fields]) AND (“Infection” [MeSH Terms] OR “bacteremia”
[MeSH Terms] OR “endotoxemia” [MeSH Terms] OR “bacteraemia” [All Fields] OR “sepsis” [MeSH
Terms] OR “severe sepsis” [MeSH Terms] OR “septicemia” [MeSH Terms] OR “pyohemia” [MeSH
Terms] OR “pyemia” [MeSH Terms] OR “pyaemia” [MeSH Terms] OR “poisoning, blood” [MeSH Terms]
OR “blood poisoning” [MeSH Terms] OR “pneumonia” [MeSH Terms] OR “pneumonia lobat” [MeSH
Terms] OR “lobar, pneumonia” [MeSH Terms] OR “pneumonitis” [MeSH Terms] OR “pulmonary infla-
mation” [MeSH Terms] OR “lung inflamation” [MeSH Terms] OR “bronchopneumonia” [MeSH Terms]
OR “peritonitis”[MeSH Terms] OR “cystitis”[ MeSH Terms] OR “pyelonephritis”[ MeSH Terms] OR
“pyelocystitis”[ MeSH Terms]) AND “adult”[Filter]) was applied. 
Study selection
The inclusion criteria were all observational studies (cohort, cross-sectional or case-control) on
adult patients admitted to hospital that:
– adopted a correct definition of CAI or HAI,
– adopted the HCAI definition proposed by Friedman et al. [1],
– defined adequate empirical antibiotic treatment as antibiotic prescribed within the first
24 hours of diagnosis matching in vitro susceptibility of a pathogen deemed to be the
likely cause of infection and
– provided data on adequacy/inadequacy of initial antibiotic therapy by place of acquisition
of infection.
The following definitions of infection by setting were used:
– CAI - infection detected within 48 hours of hospital admission in patients without pre-
vious contact with healthcare service. 
– HAI - localized or systemic condition: 1) that results from adverse reaction to the pres-
ence of an infectious agent(s) or its toxin(s) and 2) that was present 48 hours or more
after hospital admission and not incubating at hospital admission time [12]. 
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Figure 2.3.1 – Flow diagram of study selection
– HCAI: an infection present at hospital admission or within 48 hours of admission in
patients that fulfilled any of the following criteria [1]:
* received intravenous therapy at home, wound care or specialized nursing care
through a healthcare agency, family or friends; or had self-administered intra-
venous medical therapy in the 30 days before the infection. Patients whose only
home therapy was oxygen use were excluded;
* attended a hospital or hemodialysis clinic or received intravenous chemotherapy
in the previous 30 days;
* were hospitalized in an acute care hospital for 2 or more days in the previous 90 days,
* resided in a nursing home or long-term care facility.
Data extraction and quality assessment
The results of the literature search were accessed and non-relevant studies were excluded based
on title and abstract. For potentially relevant studies, the full text was obtained, study eligibility
was assessed and data extracted on study design, objectives of the included studies and rate of
inadequate initial antibiotic therapy using a data extraction protocol.
Each selected study was evaluated for the strength of evidence through examination of the study
design and quality of data. 
Potential threats to the internal validity of included studies were evaluated considering the fol-
lowing criteria:
– The authors define inclusion criteria, 
– The authors define an adequate selection method (for instance, all hospitalized patients
with infection),
– The selection of participants was consecutive,
– The outcome data was complete (no attrition bias) and 
– All results were reported (reporting bias).
Studies that met all of the above 5 criteria, were classified as “low risk of bias”. Studies that partial-
ly met one or more criteria were classified as “moderate risk of bias”. Studies were classified as “high
risk of bias” if one or more of these criteria was not met.
Data analysis 
Data on individual studies included are provided in table 2.3.1; table 2.3.2 shows the rate of inad-
equate intial antibiotic therapy according to place of acquisition of infection and risk of bias of
included studies. 
50 | HEALTHCARE-ASSOCIATED INFECTIONS: CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
C
H
A
PTER 2.3
A meta-analysis was not performed due to the nature of the objectives of this review and the het-
erogeneity of the studies included.
RESULTS
The search retrieved a total of 49,405 references, among which 15,311 duplicates were identified.
Of the 34,094 remaining articles, 33,828 were excluded based on title and abstract (Figure 2.3.1).
Full texts were obtained for the 266 articles that remained. Of those: 106 were review articles or
opinion pieces (commentaries and letters), and 143 did not meet inclusion criteria. Of the 17 stud-
ies included in this systematic review: 10 prospective (4 multicenter and 6 single center) and 7 ret-
rospective (2 multicenter and 5 single center), involving 10.238 patients admitted to hospital
adult units.
The description of individual studies included in the study is shown in table 2.3.1 according to dif-
ferent focus of infection. In bloodstream infections the rate of inadequate initial antibiotic thera-
py among HCAI patients varied between 24% and 36%, in pneumonia between 6% and 37%, in
urinary infections between 22% and 26% and in endocarditis it was 57%. In all included studies,
patients with HCAI had a higher rate of inadequate initial antibiotic therapy when compared to
CAI patients and in 9 studies this difference was statistically significant. 
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Table 2.3.1 – List of studies included for the analysis of the rate of inadequate initial antibiotic therapy according to focus
and place of acquisition of infection
a) Bloodstream infections
Study Marschall [21] Son [14] Rodriguez-Bano [22] Bishara [23] Vallés [13]
Design Prospective, single 
center study, in 250
patients with gram 
negative bacteremia,
USA, 6 months
Prospective, 
multicenter study, in
1144 patients, 
Korea, 12 months
Prospective, 
multicenter study, in
821 isolates, Spain, 
2-5 months. They
included different
episodes in the same
patient and potential
contaminants too
Prospective, single 
center study, in 12 1
patients with
Staphylococcus aureus
bacteremia, Israel, 
10 years. They included 
different episodes in the
same patient
Prospective, 
multicenter, 
international study, 
in 726 patients, 
Spain and Argentina, 
12 months
Microbiological
documentation,
n (isolation rate)
250 (100) 1144 (100) 821 isolates 1261 (100) 720 isolates (99)
Patients in each
category, n (%)
CAI
28 
(11)
HCAI
132
(53)
HAI
90
(36)
CAI
380
(33)
HCAI
206
(18)
HAI
558
(49)
CAI
150
(18)
HCAI
195
(24)
HAI
476
(58)
HCAI
526
(42)
HAI
735
(58)
CAI
343
(47)
HCAI
131
(18)
HAI
252
(35)
Inadequate antibi-
otic therapy, n (%)
6
(21)
36
(27)
37 
(41)
39
(11)
46 
(24)
129
(25)
35 
(23)
54 
(28)
180
(38)
189
(36)
288 
(39)
(10) (34) (41)
p value * 0.5 0.03 <0.001 0.687 <0.01 >0.05 <0.05 <0.01
OR (95%CI), with
CAI as reference 
Not available Not available Not available Not available Crude OR = 1.8 (1.0-3.2)
Risk of bias Low high moderate Low high
* p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled
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Table 2.3.1 – List of studies included for the analysis of the rate of inadequate initial antibiotic therapy according to focus
and place of acquisition of infection
b1) Pneumonia
Study Park [9] Shindo [15] Garcia-Vidal [24] Jung [25] Park [16]
Design Prospective, single cen-
ter study, in 339 patients
with positive microbiol-
ogy, Korea, 2 years
Retrospective, single
center study, in 371
patients, Japan, 1 year
and 3 months
Prospective, single cen-
ter study, in 2153
patients, Spain, 8 years
and 9 months. Patients
having more than one
condition of HCAI, with
neutropenia, AIDS, after
transplantation and
chronic corticosteroid
treatment were 
excluded
Retrospective, single cen-
ter study, in 527 patients,
Korea, 1 year
Retrospective, single
center study, in 345
patients, Korea, 1 year.
Defines CAI and HCAI
until 72 h after hospital
admission. Patients with
neutropenia, AIDS and
after transplantation
were excluded
Microbiological
documentation, 
n (isolation rate)
339 (100) 186 (50) 1388 (62) 162 (31) 111 (32)
Per category,
patients/ microbio-
logical 
documentation, 
n (isolation rate)
CAI
172 
(51)
HCAI
167 
(49)
CAI
163/42
(26)
HCAI
118/54
(46)
CAI
1668/1066
(64)
HCAI
485/322
(66)
CAI
296/83
(28)
HCAI
231/79
(34)
CAI
163/46
(28) HCAI
182/65
(36)
Inadequate antibi-
otic therapy, n (%)
22(13) 47 (28) 10(10) 15 (21) 66(6) 22(7) 19 (4) 27 (37) 4 (9) 16 (25)
p value* <0.001 0.038 Not available 0.092 0.032
OR (95%CI) Not available
Risk of bias Low Low Low Low Low
*p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled
b2) Pneumonia
Study Carratalà [3] Jeon [17] Lee [18] Wu [26]
Design Prospective, single center
study, in 727 patients, Spain, 
4 years. Patients with neu-
tropenia, AIDS and after
transplantation were 
excluded
Retrospective, multicenter
study, in 210 patients 
older than 60 years, 
Korea, 2 years
Retrospective, multicenter
study, in 303 patients, 
Korea, 21 months
Retrospective, single center
study, in 372 patients with
Klebsiella Pneumoniae
bacteriemic pneumonia, 
Taiwan, 4 years
Microbiological 
documentation, 
n (isolation rate)
422 (58) 93 (44) 139 (46) 372 (100)
Per category, patients/
microbiological 
documentation, 
n (isolation rate)
CAI
601/337
(56)
HCAI
126/85
(67)
CAI
175/63
(36)
HCAI
35/30
(86)
CAI
207/84
(41)
HCAI
96/55
(57)
CAI
208
(100)
HCAI
164
(100)
Inadequate antibiotic
therapy, n (%)
12 (4) 7(8) 11 (6) 8 (23) 12(6) 23 (24) 4 (2) 9 (6)
p value* 0.03 0.002 0.001 0.087
OR (95%CI) Not available
Risk of bias Low Low Low Low
* p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled
Overall the rate of inadequate initial antibiotic therapy found among HCAI patients was 25%.
Independently of the focus of infection the rate of inadequate initial antibiotic therapy increased
from CAI to HCAI and from HCAI to HAI, this phenomenon is more evident if we consider only low
risk of bias studies (table 2.3.2.).
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Table 2.3.1 – List of studies included for the analysis of the rate of inadequate initial antibiotic therapy according to focus
and place of acquisition of infection
c) Other foci
Study Wu [27] Aguilar-Duran [10] Horcajada [19]
Design Retrospective, single center study, in 
a tertiary care center with a large 
oncology department, including 190
episodes in 192 patients, Taiwan, 5 years
Prospective, single center study, in 
251 patients with positive cultures, 
Spain, 7-8 months
Prospective, multicenter study, in
246 patients with bacteriemic
UTI, Spain, 5-6 months
Microbiological 
documentation, 
n (isolation rate)
200 (100) 251 (100) 246 (100)
Patients per category CAI
148 
HCAI
30
HAI
22
CAI
88
HCAI
97
HAI
66 
CAI
133
HCAI
113
Focus of infection Endocarditis Urinary Urinary
Inadequate antibiotic
therapy, n (%)
54 (40) 17 (57) NA 13 (15) 20 (22) 18 (31) (11) (26)
p value* 0.095 p= NA 0.33 0.25 p=0.003
OR (95%CI) Not available
Risk of bias High Low High
*p value refers to comparison of HCAI with CAI or HCAI with HAI for the specific item signaled
All HCAI infection Low risk of bias Moderate risk of bias High risk of bias All studies
Number of patients/
microbiological 
documentation, 
n (isolation rate)
(number of studies)
7109/4974 (70%)
(12 studies)
821 isolates 
(1 study)
2308/2310 (100%) 
(4 studies)
10238/8105 (78%) 
(17 studies)
Per category CAI
3769/2217
(59)
HCAI
2359/1776 
(75)
HAI
891/891
(24)
CAI
/150
(100)
HCAI
/195
(100)
HAI
/476
(100)
CAI
1004/1004
(100)
HCAI
480/480
(100)
HAI
832/832
(100)
CAI
4923/3371
(68)
HCAI
3034/2451
(81)
HAI
2199/2199
(100)
Inadequate antibiotic
therapy, n (%)
179 
(8)
429 
(24)
324 
(44)
35 
(23)
54 
(28)
129
(63)
141 
(33)
137 
(28)
232 
(29)
355 
(11)
620 
(25)
685 
(31)
Table 2.3.2 – Rate of inadequate initial antibiotic therapy according to place of acquisition of infection and risk of bias of
all included studies 
Regarding risk of bias of the included studies: 12 presented a low, 1 a moderate and 4 a high risk
of bias (Table 2.3.3).
DISCUSSION
This systematic review incorporates all published studies on HCAI that provided original data on
the inadequacy of initial antibiotic therapy. The majority of the included studies had a low risk of
bias, resulting in good quality of the evidence assembled. Patients with HCAI presented a higher
rate of inadequate initial antibiotic therapy when compared to those with CAI, regardless of the
focus of infection. 
With the available data one cannot provide a summary measure of the association of HCAI with
inadequate initial antibiotic therapy since only one study provides such a description of associa-
tion between both variables [13]. 
Overall there was an increasing rate of inadequate initial antibiotic therapy from CAI, to HCAI and
from HCAI to HAI, achieving statistical significance by plain comparison in the majority of the
studies, regardless the focus of infection [3, 9, 13-19]. This increment of inadequate initial antibiotic
therapy was even clearer if only low risk of bias studies were included in the analysis.
Considering that adequate antibiotic therapy, is a well-known prognostic factor with a number
needed to treat of 10 patients to save one life [20], and the high rate of inadequate initial antibiot-
ic therapy among HCAI patients we suggest that specific treatment recommendations should be
developed for this particular group of patients. 
To reinforce the existing evidence more studies are needed in this domain, focusing mainly on the
measurement of the association of HCAI with inadequate antibiotic therapy.
Limitations
The research method for this systematic review was exhaustive leading to a huge number of
retrieved studies and a very long process of selection; this type of sensitive electronic search in
several databases, including relevant conference proceedings and a hand search of additional
sources ensures that no relevant study was excluded. 
The permissive criteria for inclusion in this study were essential to achieve the main goal: gather-
ing all studies on HCAI that used Friedman et al. [1] definition and provide data on inadequacy of
initial antibiotic therapy in this group of patients. 
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Table 2.3.3 – Studies with moderate or high risk of bias according to pre-defined criteria
Study Defines 
inclusion 
criteria
Defines 
selection
method
Consecutive
selection of
patients
Attrition 
bias
Reporting 
bias
Overall
Rodriguez-Bano [22] yes yes Not applicable no Partial Moderate
Son [14] yes yes yes yes no High
Vallés [13] yes yes yes no yes High
Wu [27] yes yes yes yes yes High
Horcajada [19] yes yes yes no yes High
The majority of included studies were considered of low quality despite the simplicity of the eval-
uation. The criteria used were: clear definition of inclusion criteria and selection method, consec-
utive selection of patients, and no attrition or reporting bias. Considering that we only found
observational studies we think that those are the most adequate criteria to evaluate risk of bias in
this type of studies. 
CONCLUSIONS AND RECOMMENDATIONS
This review incorporates all published studies on HCAI that provided original data on the inade-
quacy of initial antibiotic therapy using the definition by Friedman et al. [1]. Patients with HCAI pre-
sented a high rate of inadequate initial antibiotic therapy, significantly higher when compared to
those with CAI, reinforcing the need for the development of specific treatment recommendations
for this group of patients.
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2.4. HEALTHCARE-ASSOCIATED INFECTIONS AND MORTALITY: 
A SYSTEMATIC REVIEW
ABSTRACT 
Introduction: Hospital acquired infections (HAI) are recognized as an independent prognostic
factor among patients with severe infections. The role of healthcare-associated infections (HCAI)
in mortality has not yet been systemized. The purpose of the current study is to provide a system-
atic review on the impact of HCAI on mortality.
Methods: The search strategy focused on healthcare-associated infection. MEDLINE, SCOPUS and
ISI Web of Knowledge were searched for articles published from the earliest achievable data until
November 2012. Abstracts from scientific meetings were searched for relevant abstracts along with
a manual search of references from reports, earlier reviews and retrieved studies. All studies that
used Friedman et al. definition of HCAI and that provide data on mortality rate were included. 
Findings: The search retrieved a total of 49,405 references, among which 15,311 duplicates were
identified, 33,828 were excluded based on title and abstract. Full texts were obtained for the 266
articles that remained: 106 were review articles or opinion pieces, 131 did not meet inclusion cri-
teria and 29 were included in this systematic review, involving 64.313 patients. 
In BSI, HCAI had significant higher mortality rate when compared with CAI. In pneumonia, most of
the studies only compare HCAI with CAI, and most of theme found a significantly higher mortality
rate in the first group: 16-30% vs 4-8% (p<0.05), for 30-day mortality and 18-32% vs 5-16% (p<0.05),
for hospital mortality. Healthcare-associated pneumonia was significantly associated with 1-year
mortality, adjusted OR (CI95%) = 2.0 (1.9-2.1) in one study. Healthcare-associated endocarditis was
independently associated with hospital mortality in another study, adjusted OR (CI95%) = 6.0 (2.3-
16.1). In urinary tract infections HCAI mortality varied between 5-11% in HCAI vs 1-4% in CAI.
Conclusions: This review provides evidence that healthcare-associated pneumonia and endo-
carditis represent an independent prognostic factor. More studies focusing on the measure of
association between HCAI and mortality overall and for specific focus of infection are needed.
KEY WORDS: Healthcare-associated infection, mortality, pneumonia, bloodstream infections,
endocarditis, urinary tract infection.
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INTRODUCTION
According to the 2012 World Health Organization report, infections are among the top three lead-
ing causes of death worldwide [1], with community-acquired infections playing a major role.
Additionally, several studies on severe infection and sepsis have proven an association between
hospital-acquired infection and increased mortality [2, 3].
At the end of the XXth century, the significant increase in the healthcare services provided in the
outpatient clinical setting has led to the creation of a new category of infection in 2002 - health-
care-associated infections – a new name for this increasing group of patients that come from the
community with previous close contact with the healthcare system. Their role as a prognostic fac-
tor is yet to be determined.
The purpose of the current study is to present a systematic review about the mortality rate of
healthcare-associated infections (HCAI) comparing with community (CAI) and hospital-acquired
infections (HAI).
METHODS
Data sources and Searches 
This search was performed in 8th November 2012, in accordance with the recommendations of the
Cochrane collaboration, from earliest achievable data until the research day, using
MEDLINE/PubMed (references found from 1989), SCOPUS (references found from 1974) and ISI
Web of Knowledge (references found from 1968). A manual search of references from reports, ear-
lier reviews and retrieved studies was also performed. Abstract books and CD-ROMs from several
annual scientific meetings were searched for relevant abstracts (Figure 2.4.1). No language restric-
tion was applied and papers written in a foreign language were translated.
The electronic search strategy covered the main subject areas: ((((“healthcare” [All Fields] OR
“health care” [All Fields] OR “health-care” [All Fields]) AND (“related” OR “associated” [All Fields])) OR
“healthcare-related” [All Fields] OR “healthcare-associated” [All Fields] OR “health care-related” [All
Fields] OR “health care-associated” [All Fields]) AND (“Infection” [MeSH Terms] OR “bacteremia”
[MeSH Terms] OR “endotoxemia” [MeSH Terms] OR “bacteraemia” [All Fields] OR “sepsis” [MeSH
Terms] OR “severe sepsis” [MeSH Terms] OR “septicemia” [MeSH Terms] OR “pyohemia” [MeSH
Terms] OR “pyemia” [MeSH Terms] OR “pyaemia” [MeSH Terms] OR “poisoning, blood” [MeSH Terms]
OR “blood poisoning” [MeSH Terms] OR “pneumonia” [MeSH Terms] OR “pneumonia lobat” [MeSH
Terms] OR “lobar, pneumonia” [MeSH Terms] OR “pneumonitis” [MeSH Terms] OR “pulmonary infla-
mation” [MeSH Terms] OR “lung inflamation” [MeSH Terms] OR “bronchopneumonia” [MeSH Terms]
OR “peritonitis”[MeSH Terms] OR “cystitis”[ MeSH Terms] OR “pyelonephritis”[ MeSH Terms] OR
“pyelocystitis”[ MeSH Terms]) AND “adult”[Filter]) was applied.
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Study selection
The inclusion criteria were all observational studies (cohort, cross-sectional or case-control) on
adult patients admitted to hospital that:
– adopted a correct definition of CAI or HAI,
– adopted the HCAI definition proposed by Friedman et al. [4],
– provided data on mortality rate by place of acquisition of infection.
The following definitions of infection by setting were used:
– CAI - infection detected within 48 hours of hospital admission in patients without pre-
vious contact with healthcare service. 
– HAI - localized or systemic condition: 1) that results from adverse reaction to the pres-
ence of an infectious agent(s) or its toxin(s) and 2) that was present 48 hours or more
after hospital admission and not incubating at hospital admission time [5]. 
– HCAI: an infection present at hospital admission or within 48 hours of admission in
patients that fulfilled any of the following criteria [4]:
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Figure 2.4.1 – Flow diagram of study selection
* received intravenous therapy at home, wound care or specialized nursing care
through a healthcare agency, family or friends; or had self-administered intra-
venous medical therapy in the 30 days before the infection. Patients whose only
home therapy was oxygen use were excluded;
* attended a hospital or hemodialysis clinic or received intravenous chemotherapy
in the previous 30 days;
* were hospitalized in an acute care hospital for 2 or more days in the previous 90 days,
* resided in a nursing home or long-term care facility.
Data extraction and quality assessment
The results of the literature search were accessed and non-relevant studies were excluded based
on title and abstract. For potentially relevant studies, the full text was obtained, study eligibility
was assessed and data extracted on study design, objectives of the included studies and mortal-
ity rate using a data extraction protocol.
Each selected study was evaluated for the strength of evidence through examination of the study
design and quality of data. 
Potential threats to the internal validity of included studies were evaluated considering the fol-
lowing criteria:
– The authors define inclusion criteria, 
– The authors define an adequate selection method (for instance, all hospitalized patients
with infection),
– The selection of participants was consecutive,
– The outcome data was complete (no attrition bias) and 
– All results were reported (reporting bias).
Studies that met all of the above 5 criteria, were classified as “low risk of bias”. Studies that partial-
ly met one or more criteria were classified as “moderate risk of bias”. Studies were classified as “high
risk of bias” if one or more of these criteria was not met.
Data analysis 
Data on individual studies included are provided in table 2.4.1; table 2.4.2 shows the 14-days, 
30-days, hospital and one year mortality rate, according to place of acquisition of infection.
A meta-analysis was not performed due to the nature of the objectives of this review and the het-
erogeneity of the studies included.
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RESULTS
The search retrieved a total of 49,405 references, among which 15,311 duplicates were identified.
Of the 34,094 remaining articles, 33,828 were excluded based on title and abstract (Figure 2.4.1).
Full texts were obtained for the 266 articles that remained. Of those: 106 were review articles or
opinion pieces (commentaries and letters), and 131 did not meet inclusion criteria. Of the 29 stud-
ies included in this systematic review, all were cohort studies: 16 prospective (7 multicenter and 9
single center), 12 retrospective (4 multicenter and 8 single center) and one multicenter cohort
study that does not mention if it is prospective or retrospective including a total of 64.313 patients.
In BSI there was a tendency towards increasing mortality from CAI to HCAI and HAI. HCAI had sig-
nificant higher mortality rate when compared with CAI [6, 7] and lower when compared with HAI [4]
(table 2.4.1.). 
In pneumonia most of the studies only compare healthcare-associated (HCAP) with community-
acquired pneumonia (CAP), and several found significantly higher mortality in the first group [8-15].
Three studies provided a measure of association of HCAP and mortality. Lee [11] studied the asso-
ciation of HCAP with hospital mortality and provided a crude OR (CI95% ) = 0.91 (0.38-0.83), not
retained in final multivariate model. Wu [12] study the association of HCAP with hospital mortality
and found an adjusted OR (CI95%) = 1.44 (0.68-3.05). Hsu 
[16] also founded that HCAP was an inde-
pendent risk factor for hospital mortality, adjusted OR (CI95% ) = 1.62 (1.49-1.76), and for one-year
mortality, adjusted OR (CI95%) = 1.99 (1.87-2.11) (table 2.4.1.). 
In endocarditis, two studies showed a significant higher mortality in patients with HCAI when
compared with CAI [17, 18]; one [17] provided a measure of association with an adjusted OR (CI95%) =
6.0 (2.3-16.1) (table 2.4.1.).
In urinary tract infections only one study, with high risk of bias showed significant higher mortal-
ity in patients with HCAI when compared with CAI [19] (table 2.4.1.).
Looking at crude mortality, regardless of focus of infection, HCAI patients presented higher 
14-days, 30-days, 1-year and hospital mortality than patients with CAI and similar to HAI patients
(at 14-days, 30-days and hospital discharge) (table 2.4.2)
Regarding the risk of bias of the 29 studies included: 19 presented a low, 1 moderate and 9 a high
risk of bias, according to previously defined criteria (table 2.4.3).
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b) Pneumonias
Study Park [8] Shindo [9] Jung [10] Jeon [25] Lee [11] Depuydt [26] Webster [27] Pascual [28]
Design Prospective,
single center
study, in 339
patients, 
Korea, 2 years
Retrospective, single
center study, in 371
patients, Japan, 
1 year and 3 months
Retrospective
, single center
study, in 527
patients,
Korea, 1 year
Retrospective,
multicenter
study, in 210
patients older
than 60 years,
Korea, 2 years
Retrospective,
multicenter
study, in 
303 patients,
Korea, 21
months
Retrospective,
single center
study, 287
episodes in
269 patients,
Belgium, 1
year. Patients
with neutrope-
nia, transplan-
tation or trans-
ferred from
another hospi-
tal were
excluded
Prospective, 
multicenter study,
in 28 patients 
with
Staphylococcus
aureus pneumo-
nia, excluding
pregnant or nurs-
ing women, neu-
tropenic < 1.0x109,
HIV infection and
patients with 
cystic fibrosis,
Canada, 2 years
Retrospective,
single center
study, in 308
patients with
bacteriemic
pneumonia,
Spain, 6 years
Outcome Hospital 
mortality
30-day 
mortality
Hospital 
mortality
Hospital 
mortality
Hospital 
mortality
Hospital 
mortality
Hospital 
mortality
Hospital 
mortality
Hospital 
mortality
Patients 
in each
category, 
n (%)
CAI
172
(51)
HCAI
167
(49)
CAI
230
(62)
HCAI
141
(38)
CAI
230
(62)
HCAI
141
(38)
CAI
296
(56)
HCAI
231
(44)
CAI
175
(83)
HCAI
35 
(17)
CAI
207
(68)
HCAI
96 
(32)
CAI
159
(55)
HCAI
128 
(45)
CAI
12
(43)
HCAI
16 
(57)
CAI
206
(67)
HCAI
60
(20)
HAI
42
(13)
Deceased,
n (%)
27
(16)
47 
(28)
11
(5)
22
(16)
17
(7)
30
(21)
32 
(11)
65 
(28)
20 
(11)
2 
(6)
11 
(5)
17 
(18)
10 
(6)
15 
(13)
0 
(0)
5 
(31)
(17) (19) (34)
p value* 0.006 <0.001 <0.001 <0.001 0.314 0.001 0.09 0.052 Not available
OR
(95%CI),
with CAI 
as refer-
ence 
Not available Not 
available
Not 
available
Not available Not available 0.906 
(0.377-2.179)
Not available Not available Not available
Risk of 
bias
Low Low Low Low Low High Low High
*p value refers to comparison of HCAI with CAI or HCAI with HAI 
Table 2.4.1 – List of included studies, by focus and place of acquisition of infection
a) Bloodstream infections
Study Friedman [4] Marschall [20] Evans [21] Son [6] Rodriguez-
-Bano [22]
Vallés [23] Crane [7] Rodriguez-
-Bano [24]
Design Prospective, 
multicenter
study, in 504
patients, USA, 
4-5 months
Prospective, 
single center
study, in 250
patients with
gram negative
bacteremia,
USA, 6 months
Retrospective,
multicenter
study, in 413
isolate among
patients with
spinal cord
injury and 
disorder, 
USA, 7 years. 
Prospective, 
multicenter 
study, in 
1144 patients, 
Korea, 12 months
Prospective, 
multicenter
study, in 821 
isolates, Spain, 
2-5 months
Prospective,
multicenter,
international
study, in 726
patients, 
Spain and
Argentina, 
12 months
Retrospective,
multicenter
study, in 347
patients older
than 65 years,
USA, 2 years
Multicenter
study, in 
344
episodes,
Spain, 
5 months
Outcome Hospital 
mortality
Hospital 
mortality
Hospital 
mortality
30-day 
mortality
30-day 
mortality
ICU
mortality
14-day 
mortality
14-day 
mortality
Patients 
in each
category, 
n (%)
CAI
143
(28)
HCAI
186
(37)
HAI
175
(35)
CAI
28
(11)
HCAI
132 
(53)
HAI
90
(36)
CAI
36
(9)
HCAI
110 
(27)
HAI
267
(64)
CAI
380 
(33)
HCAI
206
(18)
HAI
558
(49)
CAI
150
(18)
HCAI
195
(24)
HAI
476
(58)
CAI
130
(18)
HCAI
195
(24)
HAI
249
(48)
CAI
159
(46)
HCAI
151
(44)
HAI
37
(10)
CAI
150
(44)
HCAI
194
(56)
Deceased,
n (%)
19
(13)
37
(20)
52
(30)
2
(7)
18
(14) 
15
(17) 
(8) (11) (12) (10) (18) (23) 29
(19)
43
(22) 
116
(24) 
(29) (43) (41) 10
(6)
23
(15)
5
(14)
(15) (19)
p value* 0.15 0.0020.5 0.5 Not available 0.007 0.188 Not available Not available 0.04 ns 0.3
OR (95%CI), with CAI as reference was not available in any study
Risk of
bias
Low Low High High High High Low High
* p value refers to comparison of HCAI with CAI or HCAI with HAI 
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Table 2.4.1 – List of included studies, by focus and place of acquisition of infection
b) Pneumonias (continuation)
Study Wu [12] Park [13] Carratalà [14] Umeki [29] Garcia-Vidal [30] Rello [15] Hsu [16]
Design Retrospective,
single center
study, in 372
patients with
klebsiella 
pneumonia
pneumonia,
Taiwan, 4 years
Retrospective,
single center
study, in 345
patients, Korea, 
1 year. Defines
CAI and HCAI
until 72 h after
hospital admis-
sion. Patients
with neutrope-
nia, AIDS and
after transplan-
tation were
excluded
Prospective,
single 
center 
study, in 
727 patients,
Spain, 
4 years
Prospective,
single center
study, in 202
patients with
microbiologi-
cal docu-
mentation,
Japan, 
2 years
Prospective, single
center study, in
2153 patients,
Spain, 8 years and
9 months. Patients
having more than
one condition of
HCAI, with neu-
tropenia, AIDS,
after transplanta-
tion and chronic
corticosteroid
treatment were
excluded
Prospective, single
center study, in 228
patients with bac-
teriemic pneumo-
coccal pneumonia.
Excluded bac-
teremia from other
source than pneu-
monia, current
meningitis or endo-
carditis at admis-
sion or HIV infec-
tion. Spain, 8 years
and 6 months
Retrospective, single center study,
in 50758 patients from veterans
affair institutions, USA and Puerto
Rico, 4 years
Outcome Hospital 
mortality
30-day 
mortality
30-day 
mortality
30-day 
mortality
30-day 
mortality
30-day 
mortality
Hospital 
mortality
1-year mortality
Patients in
each 
category, 
n (%)
CAI
208
(56)
HCAI
164 
(44)
CAI
163
(47)
HCAI
182 
(53)
CAI
601
(83)
HCAI
126 
(17)
CAI
123
(61)
HCAI
79
(39)
CAI
1668
(74)
HCAI
485
(26)
CAI
184
(81)
HCAI
44
(19)
CAI
35180
(69)
HCAI
15578
(31)
CAI
35180
(69)
HCAI
15578
(31)
Deceased, 
n (%)
28
(14)
53 
(32)
12
(7)
35
(19)
26
(4)
13
(10)
4
(3)
5
(6)
90
(5)
56
(12)
14 
(8)
13 
(30)
(5) (10) (17) (34)
p value* <0.001 0.001 0.007 0.32 Not available <0.001 Not available Not available
OR (95%CI),
with CAI as
reference 
Adjusted =
1.44 
(0.68-3.05)
Not 
available
Not 
available
Not 
available
Not 
available
Not 
available
Adjusted 
OR = 1.62 
(1.49-1.76)
Adjusted 
OR = 1.99 
(1.87-2.11)
Risk of bias Low Low Low Low Low Low Moderate
*p value refers to comparison of HCAI with CAI or HCAI with HAI 
c) Endocarditis
Study Wu [17] Benito [31] Fowler [18] Bishara [32]
Design Retrospective, single 
center study, in 192
patients, Taiwan, 5 years
Prospective, single center study,
in 1622 patients, USA, 6 months.
They excluded intra-venous 
drug user, prosthetic valves. 
Prospective, multicenter
study, in 558 patients with
Staphylococcus aureus 
endocarditis international,
48 months
Prospective, single center study, in 1261
patients with Staphylococcus aureus 
endocarditis, Israel,10 years. If the patient
had more than one episode all were
included
Outcome Hospital mortality Hospital mortality Hospital mortality 30-day mortality 1-year mortality
Patients in
each 
category, 
n (%)
CAI
148 
(74)
HCAI
30 
(15)
HAI
22 
(11)
CAI
1065 
(11)
HCAI
254 
(53)
HAI
303
(36)
CAI
218
(39)
HCAI
326
(61)
HCAI
526
(42)
HAI
735
(58)
HCAI
526
(42)
HAI
735
(58)
Deceased 
n (%)
26
(18)
15
(50)
9
(41)
143 
(13)
54 
(21)
84 
(28)
62
(29)
57 
(18)
197
(38)
310 
(42)
330 
(63)
470 
(64)
p value* <0.001 0.52 Not available <0.001 >0.05 >0.05
OR (95%CI),
with CAI as
reference 
Crude = 3.9(1.7-8.6)
Adjusted = 6.0 (2.3-16.1)
Not available Not available Not available
Risk of bias Low Low High Low
*p value refers to comparison of HCAI with CAI or HCAI with HAI 
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Table 2.4.1 – List of included studies, by focus and place of acquisition of infection
c) Urinary tract infection
Study Aguilar-Duran [33] Horcajada [19]
Design Prospective, single center study, in 251 patients, 
Spain, 7-8 months
Prospective, multicenter study, in 246 episodes of 
bacteriemic UTI, Spain, 5-6 months
Outcome 30-day mortality Hospital mortality
Patients in each 
category, n (%)
CAI
88 (35)
HCAI
97 (39)
HAI
66 (26)
CAI
133 (54)
HCAI
113 (46)
Deceased, n (%) 1 (1) 5 (5) 6 (9) (4) (11)
p value* p= 0.21 p= 0.35 p=0.04
OR (95%CI), with CAI 
as reference 
Not available Not available
Risk of bias Low High
*p value refers to comparison of HCAI with CAI or HCAI with HAI 
Table 2.4.2 – 14-day, 30-day, hospital and 1-year mortality rate by place of acquisition of infection
14-day mortality
Low risk of bias Moderate risk 
of bias
High risk of bias All studies
Number of patients
(number of studies)
347 (1 study) 0 studies 344 (1 study) 691 (2 studies)
Per category,
n (%)
CAI
159 (46)
HCAI
151 (44)
HAI
37 (10)
CAI
150 (44)
HCAI
194 (56)
CAI
309 (45)
HCAI
345 (50)
HAI
37 (5)
Deceased at 
14 days, n (%)
10 (6) 23 (15) 5 (14) 45 (15) 37 (19) 45 (15) 60 (17) 5 (14)
30-day mortality
Low risk of bias Moderate risk 
of bias
High risk of bias All studies, 
Number of patients
(number of studies)
5446 (8 studies) 0 studies 1965 (2 studies) 7411 (10 studies)
Per category,
n (%)
CAI
3583 (65)
HCAI
1889 (34)
HAI
66 (1)
CAI
530 (27)
HCAI
401 (20)
HAI
1034 (53)
CAI
4113 (55)
HCAI
2290 (30)
HAI
1100 (15)
Deceased at 30-day,
n (%)
355 (10) 459 (24) 6 (9) 68 (13) 81 (20) 244 (24) 423 (10) 540 (24) 250 (23)
Hospital mortality
Low risk of bias Moderate risk 
of bias
High risk of bias All studies, 
Number of patients
(number of studies)
4718 (11 studies) 50758 (1 study) 1798 (5 studies) 57274 (17 studies)
Per category, 
n (%)
CAI
2684 (57)
HCAI
1452 (31)
HAI
590 (12)
CAI
35180 (69)
HCAI
15578 (31)
CAI
752 (42)
HCAI
737 (41)
HAI
309 (17)
CAI
38616 (67)
HCAI
17767 (31)
HAI
899 (2)
Deceased at hospital
discharge, 
n (%)
325
(12)
343
(24)
160
(27)
1759
(5)
3518
(23)
115
(15)
107
(15)
46
(15)
2199
(6)
3968
(22)
206
(23)
One-year mortality
Low risk of bias Moderate risk 
of bias
High risk of bias All studies, 
Number of patients
(number of studies)
1261 (1 study) 50758 (1 study) 0 studies 52019 (2 studies)
Per category,
n (%)
CAI
526 (42)
HCAI
735 (58)
CAI
35180 (69)
HCAI
15578 (31)
CAI
35706 (69)
HCAI
16313 (31)
Deceased at 1-year,
n (%)
330 (63) 470 (64) 2648 (17) 5359 (34) 2978 (8) 5829 (36)
DISCUSSION
Patients with HCAI presented a higher mortality rate when compared to those with CAI, and sim-
ilar to HAI, regardless of the focus of infection. 
Healthcare-associated pneumonia seems to be an independent risk for hospital and one-year
mortality, based on two studies [12], one with more than 50.000 patients included [16].
Also healthcare-associated endocarditis was independently associated with higher hospital mortality [17].
Regarding bloodstream and urinary infections we did not found any study providing measures of
association between HCAI and mortality.
This systematic review incorporates all published studies on HCAI that provided original data on
HCAI mortality. The majority of the included studies had a low risk of bias, resulting in good qual-
ity of the evidence assembled. 
As already described for HAI [2, 3], HCAI seems to be also an independent prognostic factor for mor-
tality. For particular focus of infection studies focusing mainly on the measurement of the associ-
ation of HCAI with mortality are needed.
Limitations
The research method for this systematic review was exhaustive leading to a huge number of
retrieved studies and a very long process of selection; this type of sensitive electronic search in
several databases, including relevant conference proceedings and a hand search of additional
sources ensures that no relevant study was excluded. 
The permissive criteria for inclusion in this study were essential to achieve the main goal: gather-
ing all studies on HCAI that used Friedman et al. [4] definition and provide data on inadequacy of
initial antibiotic therapy in this group of patients. 
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Table 2.4.3 – Studies with moderate or high risk of bias according to pre-defined criteria
Study Defines 
inclusion 
criteria
Defines 
selection
method
Consecutive
selection of
patients
Attrition 
bias
Reporting 
bias
Overall
Hsu [16] yes yes yes partial no Moderate
Evans [21] yes yes yes yes no High
Son [6] yes yes yes yes yes High
Rodriguez-Bano [22] yes yes yes yes yes High
Vallés [23] yes yes yes yes yes High
Rodriguez-Bano [24] yes yes yes yes yes High
Depuydt [26] yes yes yes yes yes High
Pascual [28] yes yes yes yes yes High
Fowler [18] yes yes yes yes yes High
Horcajada [19] yes yes yes yes yes High
The majority of included studies were considered of low quality despite the simplicity of the eval-
uation. The criteria used were: clear definition of inclusion criteria and selection method, consec-
utive selection of patients, and no attrition or reporting bias. Considering that we only found
observational studies we think that those are the most adequate criteria to evaluate risk of bias in
this type of studies. 
CONCLUSIONS AND RECOMMENDATIONS
This review incorporates all published studies on HCAI that provided original data on the mortal-
ity rate using Friedman et al. [4] definition and provides evidence that healthcare-associated pneu-
monia and endocarditis represent an independent prognostic factor. More studies focusing on
the measure of association between HCAI and mortality overall and for specific focus of infection
are needed. 
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CHAPTER 3
PATIENTS AND 
GENERAL METHODS
Foto by Virginia Lopes

PATIENTS AND GENERAL METHODS
A prospective cohort study was conducted, including all consecutive adult patients admitted to
intensive care unit (ICU), medical, surgical, nephrology and hematology wards, in a 600-bed uni-
versity affiliated, tertiary care hospital, over 1 year (1st June 2008 to 31st May 2009). 
Inclusion criteria was diagnosis of respiratory, intra-abdominal, urinary and bloodstream infection
according to the CDC criteria [1] in all adult patients (age ≥ 18 years) consecutively admitted into
the previously mentioned wards. Infection was classified according to place of acquisition in:
healthcare-associated (HCAI), community (CAI) or hospital-acquired (HAI). 
Every day patients’ medical prescription was reviewed for antibiotic therapy inclusion. All patients
under antibiotic therapy had a medical visit from the research doctor to check if they met the
inclusion criteria and if so they were included in the study. Only the first episode of infection in the
current hospital admission was characterized. 
The main outcomes were: 
– description of the microbiology profiles for each focus of infection according to the place
of acquisition of infection (including antibiogram results to allow identification of multi-
drug resistance pathogens); 
– adequacy of initial antibiotic therapy, 
– in-hospital all-cause mortality.
This study was approved by the institutional review board of Hospital de Santo António, Oporto Hospital
Centre, Portugal, and informed consent was waived due to the observational nature of the study.
DEFINITIONS
Place of acquisition of infection
Healthcare-associated infection (HCAI) was defined using the same criteria that Friedman et al.
used for healthcare-associated bloodstream infections [2] – infection at the time of hospital admis-
sion or within 48 hours of admission in patients that fulfilled any of the following criteria:
– received intravenous therapy at home, wound care or specialized nursing care through a
healthcare agency, family or friends; or had self-administered intravenous medical thera-
py in the 30 days before the infection. Patients whose only home therapy was oxygen use
were excluded;
– attended a hospital or haemodialysis clinic or received intravenous chemotherapy in the
previous 30 days;
– were hospitalized in an acute care hospital for 2 or more days in the previous 90 days,
– resided in a nursing home or long-term care facility.
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Community-acquired infection (CAI) was defined as the infection detected within 48 hours of
hospital admission in patients who did not fit the criteria for a healthcare-associated infection. 
Hospital acquired infection (HAI)was defined as a localized or systemic condition: 1) that results
from adverse reaction to the presence of an infectious agent(s) or its toxin(s) and 2) that was pres-
ent 48 hours or more after hospital admission and not incubating at hospital admission time [3].
Patients recently discharged from the hospital (in the previous 2 weeks) were also included in this
group. 
Focus of infection
For purposes of infection definition at various sites the CDC Definitions of Nosocomial Infections
were used [1] (annex 1). Bloodstream infections were classified as primary or secondary. Primary
bloodstream infections were defined according to the National Nosocomial Infection Surveillance
System [4] and include intravascular device-associated infections. Secondary bloodstream infec-
tion was defined as the one present when an organism isolated from a blood culture was related
to an infection at another site, as defined by the CDC [1].
Comorbidities
Immunosuppression state was defined by either administration in the 12 months prior to hospi-
tal admission of chemotherapy, radiation therapy or the equivalent to 0,2mg/Kg/day pred-
nisolone for at least 3 months or 1mg/Kg/day for a week in the previous 3 months to hospital
admission or human immunodeficiency virus (HIV) infection.
Metastatic cancer, haematological malignancy and acquired immunodeficiency syndrome – AIDS
(HIV positive patient with a previous episode of Pneumocystis jirovecii pneumonia, Kaposi sarco-
ma, lymphoma, tuberculosis or toxoplasmosis) were recorded using SAPS II definitions [5].
Cirrhosis (documented histological with portal hypertension with upper digestive bleeding or
previous episodes of encephalopathy or hepatic failure), chronic heart failure (class III or IV of the
New York Heart Association), chronic pulmonary failure (patient needing home oxygen therapy,
chronic obstructive pulmonary disease with chronic CO2 retention, pulmonary hypertension or
right heart failure due to chronic respiratory disease) were defined according to Acute Physiology
and Chronic Health Evaluation II definitions [6].
Chronic renal failure was defined as the need of chronic renal support or history of chronic renal
insufficiency with a serum creatinine level over 2mg/dl); atherosclerotic disease by either previ-
ous history of a transient ischemic attack, stroke, angina, myocardial infarction or peripheral arte-
rial disease; diabetes mellitus if they required insulin therapy or oral hypoglicemiants at the time
of infection.
General medical condition was assessed formally according to the Karnofsky index [7], which is
widely used in chronic medical conditions with a score between 0 and 100; a score lower than 70
means that the patient is unable to carry on normal activity or do active work.
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Severity of acute disease
Sepsis and sepsis-related conditions were diagnosed according to the criteria proposed by the
ACCP/SCCM [8]. For the first day of antibiotic therapy the extended sepsis criteria proposed by the
2001 international sepsis definitions conference [9] were recorded as well as the acute physiological
score, SAPS II [5] and the acute organ dysfunction score, SOFA score [10]. For the calculation of SAPS II
and total SOFA score, laboratory and clinical data not measured were assigned the value score of zero.
Pathogens
Multi-drug resistant organisms (MDR) were defined as microorganisms resistant to one or more
class of antimicrobial agents recommended as first line therapy [11]. Enteric gram-negative rods
were considered MDR (MDR-GN) if they were resistant to amoxicillin-clavulanate, piperacillin-
tazobactam, carbapenems, aztreonam, fluoroquinolones, 3rd generation cephalosporins or amino-
glycosides. Acinectobacter spp and Pseudomonas spp were considered MDR if they were resistant
to piperacillin-tazobactam, imipenem/meropenem, aztreonam, ciprofloxacin, cefepime, cef-
tazidime, aminoglycosides or colistin. For the purpose of this study, extended-spectrum beta-lac-
tamases (ESBL) production was recorded among E. coli and Klebsiella spp isolations. 
The presence of ESBL production among E. coli and Klebsiella spp strains was screened by the
automatic analyzer Vitek2 (BioMérieux). It was always confirmed by a disk diffusion test that
detects synergism between the cephalosporins/monobactam and clavulanate. If the interpreta-
tion of the results was doubtful Etest® was also performed: the combination strains of cefotaxime
and cefotaxime/clavulanate and ceftazidime and ceftazidime/clavulanate allows the detection of
ESBL whenever the ratio antibiotic/antibiotic + inhibitor are equal or above 8. 
The presence of carbapenemase production in Enterobacteriaceae was suspected whenever
MIC’s for ertapenem, imipenem and meropenem exceed 0.5, 1 and 1 µg/mL, respectively. In such
cases, a modified Hodge test was performed, and the ultimate confirmatory test was carbapene-
mase detection by molecular methods.
Outcome
The initial empirical antibiotic treatment was considered “adequate” if the antibiotic prescribed
within the first 24 hours matched in vitro susceptibility of a pathogen deemed to be the likely
cause of infection and when the dosage and route of administration were appropriate for current
medical status (focus and severity of infection); only patients with positive microbiology were
considered in this analysis.
Duration of hospital stay was defined as the number of days from admission to discharge or
death in patients with CAI or HCAI and as the number of days from antibiotic prescription to dis-
charge or death in patients with HAI.
STUDY PROTOCOL
A detailed protocol was designed containing information on the host, the infectious episode,
antibiotic therapy and outcome (annex 2). All data was collected by the research doctor, along
with database construction and part of the data analysis.
STATISTICAL ANALYSIS
Data were described with means and standard deviations for continuous variables or with medi-
ans and inter-quartile ranges if they showed a skewed distribution. Categorical variables were
described with absolute frequencies and percentages. T-tests or Mann-Whitney-U tests were used
to compare continuous variables. For categorical variables these comparisons were performed
using Pearson χ2 and Fisher’s exact tests. Statistical significance was defined as a p<0.05. 
Data were analyzed using SPSS, version 18 for Windows (Chicago, IL).
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Annex 1 – Definition of infection by focus according to CDC Definitions of Nosocomial Infections [1]
Pneumonia must meet at least one of the following criteria:
– Patient has rales or dullness to percussion on physical examination of the chest and at least one of the following:
• New onset of purulent sputum or change in character of sputum
• Organisms cultured from blood
• Isolation of an etiologic agent from a specimen obtained by transtracheal aspirate, bronchial brushing,
or biopsy
– Patient has a chest radiography examination that shows new or progressive infiltrate, consolidation, cavita-
tions, or pleural effusion and at least one of the following:
• New onset of purulent sputum or change in character of sputum
• Organisms cultured from blood
• Isolation of an etiologic agent from a specimen obtained by transtracheal aspirate, bronchial brushing,
or biopsy
• Isolation of virus from or detection of viral antigen in respiratory secretions
• Diagnostic single antibody titter (IgM) or fourfold increase in paired sera (IgG) for pathogen
• Histopathologic evidence of pneumonia
Tracheobronchial infections must meet at least one of the following criteria:
– Patient has no clinical or radiographic evidence of pneumonia and has at least two of the following signs
and symptoms with no other recognized cause: fever (>38ºC), cough, new or increased sputum production,
rhonchi, wheezing and at least one of the following
• Positive culture obtained by deep tracheal aspirate or bronchoscopy
• Positive antigen test on respiratory secretions
Other infections of the lower respiratory tract must meet at least one of the following criteria:
– Patient has organisms seen on smear or cultured from lung tissue or fluid, including pleural fluid
– Patient has lung abscess or empyema seen during a surgical operation or histopathologic examination
– Patient has an abscess cavity seen on radiographic examination of lung
Intra-abdominal infections (including gallbladder, bile ducts, liver – excluding viral hepatitis – spleen, pan-
creas, peritoneum, subphrenic or subdiaphragmatic space) must meet at least one of the following criteria:
– Patient has organisms cultured from purulent material from intraabdominal space obtained during surgical
operation or needle aspiration
– Patient has abscess or other evidence of intrabadominal infection seen during a surgical operation or
histopathologic examination
– Patient has at least two of the following signs or symptoms with no other cause. Fever (>38ºC), nausea, vom-
iting, abdominal pain, or jaundice and at least one of the following:
• Organisms cultured from drainage from surgically placed drain (e.g., closed suction drainage system,
open drain, T-tube drain)
• Organisms seen on Gram stain of drainage or tissue obtained during surgical operation or needle aspiration
• Organisms cultured from blood and radiographic evidence of infection, e.g., abnormal findings on ultra-
sound, CT scan, magnetic resonance imaging (MRI), or radiolabel scans (e.g., gallium, technetium) or on
abdominal x-ray
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Urinary infections are defined as:
– Symptomatic urinary tract infection – must meet at least one of the following criteria:
• Patient has at least one of the following signs and symptoms with no other recognize cause: fever
(>38ºC), urgency, frequency, dysuria, or suprapubic tenderness and a positive urine culture, that is ≥ 105
microorganisms per cm3 or urine with no more than two species of microorganisms.
• Patient has at least one of the following signs and symptoms with no other recognize cause: fever
(>38ºC), urgency, frequency, dysuria, or suprapubic tenderness and :
· Positive dipstick for leukocyte esterase and/or nitrate
· Pyuria (urine specimen with≥10wbc/mm3 or ≥3wbc/high power field of unspun urine)
· Organisms seen on Gram stain of unspun urine
· At least two urine cultures with repeat isolation of the same uropathogen (gram-negative bacteria or
S. saprophyticus) with ≥102 colonies/ml in nonvoided specimens
· ≤105 colonies/ml of a single uropathogen (gram-negative bacteria or S. saprophyticus) in a patient
being treated with an effective antimicrobial agent for a urinary tract infection
· Physician diagnosis of a urinary tract infection
· Physician institutes appropriate therapy for a urinary tract infection.
– Other infections of the urinary tract must meet at least one of the following criteria:
• Patient has organisms isolated from culture of fluid (other than urine) or tissue from affected site
• Patient has an abscess or other evidence of infection seen on direct examination, during surgical oper-
ation, or during a histopathologic examination
• Patients has at least two of the following signs or symptoms with no other recognize cause:
fever(>38ºC), localized pain, or localized tenderness at involved site and at least one of the following:
· Purulent drainage from affected site
· Organisms cultured from blood that are compatible with suspected site of infection
· Radiographic evidence of infection, e.g., abnormal ultrasound, CT scan, magnetic resonance imaging
(MRI), or radiolabel scan (gallium, technetium)
· Physician diagnosis of infection of the kidney, ureter, bladder, urethra, or tissues surrounding the
retroperitoneal or perinephric space
· Physician institutes appropriate therapy for an infection of the kidney, ureter, bladder, urethra, or tis-
sues surrounding the retroperitoneal or perinephric space.
Laboratory-confirmed bloodstream infections must meet at least one of the following criteria:
– Patient has a recognized pathogen cultured from one or more blood cultures and organism cultured from
blood is not related to an infection at another site
– Patient has at least one of the following signs and symptoms: fever (>38ºC), chills, or hypotension and at
least one of the following:
• Common skin contaminant (e.g., diphtheroids, Bacillus sp., Propionibacterium sp., coagulase-negative
staphylococci, or micrococci) is cultured from two or more blood cultures drawn on separate occasions
• Common skin contaminant (e.g., diphtheroids, Bacillus sp., Propionibacterium sp., coagulase-negative
staphylococci, or micrococci) is cultured from at least one blood culture from a patient with an intravas-
cular line, and the physicians institutes appropriate antimicrobial therapy
• Positive antigen test on blood (e.g., H. Influenza, S. Pneumoniae, N. Meningitidis, or group B Streptococcus)
and signs and symptoms and positive laboratory results are not related to an infection at another site
INFECÇÃO ASSOCIADA A CUIDADOS DE SAÚDE: CLASSIFICAÇÃO, EPIDEMIOLOGIA E TRATAMENTO
Enfermaria____________________   Data de Admissão Hospitalar  _____ / _____ / _____
CONTEXTO DA INFECÇÃO:
COMORBILIDADES
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Comorbilidades
Hepática = Cirrose provada por biópsia e hipertensão portal documentada, hemorragias digestivas altas atribuíveis à
hipertensão portal ou episódios prévios de falência hepática ou encefalopatia.
Renal = Doente em diálise crónica ou com uma creatinina basal maior ou igual 2mg/dL.
Cárdio-Circulatória = Classe III ou IV da NYHA.
Respiratória = Doente com oxigenioterapia de longa duração domiciliária, DPOC com hipercapnia documentada no
pré-internamento, com hipertensão pulmonar documentada ou com insuficiência cardíaca direita secundária à
doença pulmonar crónica.
Hematológica = Qualquer doença hematológica maligna ou neutropenia crónica (maior ou igual a 3 meses) ou neu-
tropenia menor ou igual a 1000 PMN/dL.
Neoplástica = Metástases provadas por cirurgia, imagiologia ou por outro método.
Annex 2 – Study protocol
Infecção adquirida na comunidade – é a infecção adquirida pelo doente antes da sua admissão no hospital, ou
diagnosticada dentro das primeiras 48 horas após a sua admissão, em doentes que não tiveram recentemente nen-
hum contacto com instituições ou pessoal de saúde e, por isso, não cumprem os critérios para infecção associada a
cuidados de saúde ou nosocomial.
Infecção associada a cuidados de saúde – é a infecção adquirida pelo doente antes da sua admissão no hospital,
ou diagnosticada nas primeiras 48 horas após a sua admissão, em doentes que cumprem um dos seguintes
critérios:
1. O doente recebeu terapêutica endovenosa no domicílio, tratamento de feridas ou de enfermagem, ou auto-
administrou terapêutica endovenosa nos 30 dias anteriores ao internamento. Estão excluídos doentes que
apenas fizeram oxigénio domiciliar. 
2. Foi observado em hospital ou centro de hemodiálise ou fez quimioterapia nos 30 dias antes da infecção. 
3. Foi internado em hospital de agudos por dois ou mais dias nos 90 dias antes da infecção. 
4. Reside num lar ou instituição asilar.
Infecção nosocomial – é a infecção adquirida pelo doente após as primeiras 48 horas da sua admissão hospitalar
(exclui doenças em incubação na admissão)
Situações médicas pré-existentes
Corticoterapia de longa duração = Equivalente a pelo menos 0,2mg/Kg/dia de prednisolona durante pelo menos 3
meses nos 12 meses precedentes. 
Corticoterapia de curta duração = Equivalente a pelo menos 1 mg/Kg/dia de prednisolona durante pelo menos 1
semana nos 3 meses precedentes.
Quimioterapia = Fez quimioterapia nos 12 meses precedentes.
Radioterapia = Fez radioterapia nos 12 meses precedentes.
Seropositivo para o VIH, sem critérios de SIDA
SIDA = Seropositivo para o HIV com Pneumonia a Pneumocystis carinii, sarcoma de Kaposi, linfoma, tuberculose ou
infecção a Toxoplasma. Critérios em conformidade com as recomendações do CDC.
PATIENTS AND GENERAL METHODS | 81
C
H
A
PT
ER
 3
Outras comorbilidades
Diabetes mellitus SIM   □ NÃO  □ Insulino-tratado SIM   □ NÃO  □
Doença aterosclerótica (história prévia de AIT, AVC, angor, EAM ou doença arterial periférica) SIM   □ NÃO  □
Instrumentação prévia
Catéter de Foley SIM   □ NÃO  □
C. Venoso Central  SIM   □ NÃO  □
Catéter arterial  SIM   □ NÃO  □
Tubo Oro-Traqueal  SIM   □ NÃO  □
Sonda oro/naso-gástical  SIM   □ NÃO  □
PEG  SIM   □ NÃO  □
Número de hospitalizações no ano anterior (> 48 horas) _______
Índice de Karnovsky    ________
INFECÇÃO
Foco
Foi isolado o microrganismo causal? SIM   □ NÃO  □
Caracterização da resistência aos antimicrobianos
Pneumonia Inflamação da pele e tecidos moles Endocardite
Traqueobronquite Infecção óssea / articular Infecção de prótese implantada
Infecção urinária Infecção do local cirúrgico Meningite
Infecção abdominal aguda Infecção associada a cateter Outra infecção
Microorganismo isolado Local de isolamento
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Caracterização da sepsis
SAPS II ________ SOFA score 1º dia de ATB ______
TRATAMENTO ANTIMICROBIANO
Houve tratamento antimicrobiano prévio SIM   □ NÃO  □
Data da infecção ___ /___ /___ 
* no dia em que a mudança ocorreu registar uma das opções: 1. ausência de resposta / agravamento clínico, 2. orientação 
microbiológica, 3. ausência de infecção, 4. efeitos secundários, 5. outra,
Duração total do tratamento antimicrobiano deste episódio de sépsis: ____ dias
Estão presentes, de novo, pelo menos dois dos seguintes sinais ou sintomas
1 Hipertermia >38ºC Hipotermia <36ºC
2 Taquipneia > 20 rpm PaCO2 < 32 mmHg
3 Taquicardia > 90 bpm
4 Leucocitose (leucóciots > 12 000µL-1) Leucopenia (leucócits < 4 000µL-1) Formas imaturas > 10%
Preenche critérios de: Sepsis Sepsis grave Choque séptico
Alteração do estado de consciência Edemas periféricos BH > 20ml/Kg /24h
Glicemia > 120mg% sem diabetes PCR > 5 mg/dl SvcO2 > 70%
PaO2/FiO2 < 300 Creatinina > 2mg/dL (176,8mmol/L) ou Diurese
< 0,5mL/kg/h em 2h
Coagulopatia (INR >1.5 ou aPTT
> 60s)
PA sistólica <90mmHg ou PA média
<65mmHg
Bilirrubina > 4mg /dL (34,2mmol/L) TRC > 2 segundos
Queda> 40mmHg PA sistólica Plaquetas < 100 000
Lactato > 1 mmol/L (18mg/dL) Íleo paralítico
Nome Dose Via de 
administração
Dia de mudança ou
suspensão (após iní-
cio de ATB)
Motivo*
Tratamento antimicrobiano de 1ª intenção
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4.1. ADDITIONAL RISK FACTORS FOR INFECTION BY MULTIDRUG-
RESISTANT PATHOGENS IN HEALTHCARE- ASSOCIATED INFECTIONS: 
A LARGE COHORT STUDY
ABSTRACT
Background: There is a lack of consensus regarding the definition of risk factors for healthcare-
associated infection (HCAI). The purpose of this study was to identify additional risk factors for
HCAI, which are not included in the current definition of HCAI, associated with infection by mul-
tidrug-resistant (MDR) pathogens, in all hospitalized infected patients from the community.
Methods: This 1-year prospective cohort study included all patients with infection admitted to a
large, tertiary care, university hospital. Risk factors not included in the HCAI definition, and inde-
pendently associated with MDR pathogen infection, namely MDR Gram-negative (MDR-GN) and
ESKAPE microorganisms (vancomycin-resistant Enterococcus faecium, methicillin-resistant
Staphylococcus aureus, extended-spectrum beta-lactamase-producing Escherichia coli and
Klebsiella species, carbapenem-hydrolyzing Klebsiella pneumonia and MDR Acinetobacter bau-
mannii, Pseudomonas aeruginosa, Enterobacter species), were identified by logistic regression
among patients admitted from the community (either with community-acquired or HCAI).
Findings: There were 1035 patients with infection, 718 from the community. Of these, 439 (61%)
had microbiologic documentation; 123 were MDR (28%). Among MDR: 104 (85%) had MDR-GN
and 41 (33%) had an ESKAPE infection.
Independent risk factors associated with MDR and MDR-GN infection were: age [adjusted odds
ratio (OR) = 1.7 and 1.5, p = 0.001 and p = 0.009, respectively], and hospitalization in the previous
year (between 4 and 12 months previously) (adjusted OR = 2.0 and 1.7, p = 0.008 and p = 0.048,
respectively). Infection by pathogens from the ESKAPE group was independently associated with
previous antibiotic therapy (adjusted OR = 7.2, p < 0.001) and a Karnofsky index <70 (adjusted OR
= 3.7, p = 0.003). Patients with infection by MDR, MDR-GN and pathogens from the ESKAPE group
had significantly higher rates of inadequate antibiotic therapy than those without (46% vs 7%,
44% vs 10%, 61% vs 15%, respectively, p < 0.001).
Conclusions: This study suggests that the inclusion of additional risk factors in the current defini-
tion of HCAI for MDR pathogen infection, namely age >60 years, Karnofsky index <70, hospitaliza-
tion in the previous year, and previous antibiotic therapy, may be clinically beneficial for early
diagnosis, which may decrease the rate of inadequate antibiotic therapy among these patients.
KEY WORDS: Healthcare-associated infections, Multidrug resistant pathogens infection,
Multidrug resistant gram negatives infection, ESKAPE microorganisms’ infection, Independent risk
factors, Inadequate antibiotic therapy
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INTRODUCTION
Traditionally, infections have been classified as community or hospital-acquired, according to their
place of acquisition, and this classification is still used to guide diagnosis and treatment of infec-
tions [1, 2]. However, an increasing number of patients reside in nursing homes, the use of aggressive
medical therapies (intravenous therapy, wound dressing) at home is more common, an increasing
number of invasive therapies (hemodialysis, chemotherapy, radiotherapy) are performed in outpa-
tient clinics, and there is a greater population of older patients, with more chronic diseases and fre-
quent utilization of medical resources. This has led to the creation of a new group among the tra-
ditional classification of infections, termed “healthcare-associated infections” (HCAI).
In 2002, Deborah Friedman and colleagues [3] proposed a definition of HCAI including the above
subgroups of patients, but despite being widely used in clinical studies [4-9], there is a lack of con-
sensus regarding risk factors, and more recent studies have included additional risk factors such
as an immunocompromised state, hospitalization in the previous year and prior antibiotic thera-
py [5,10]. Unfortunately, most of the studies performed using the HCAI classification have been
restricted to respiratory infections [4,5,8,10], bloodstream infections [3,6,11] or a single pathogenic agent
[7,9,12], creating the need to widen the study of risk factors for infection by multidrug-resistant
(MDR) pathogens to all infected patients hospitalized from the community.
The objective of this study was to identify additional risk factors associated with infection by MDR
pathogens in all infected patients admitted from the community into the hospital setting
(patients with community-acquired and HCAI, including all foci of infection and associated
pathogens), and not included in the adopted definition of HCAI [3].
METHODS
Study design and patient population
A prospective cohort study was conducted in a 600-bed tertiary care university affiliated hospital,
over a 1-year period (1 June 2008 to 31 May 2009). All consecutive adult infected patients admit-
ted to the medical, surgical, nephrology or hematology wards of the hospital, or to the intensive
care unit (ICU) were included, based on a diagnosis of infection according to the Center for
Disease Control (CDC) criteria [1]. The primary outcome of interest was infection by a MDR
pathogen. All patients completed the follow-up until hospital discharge. This study was approved
by the Institutional Review Board of Hospital de Santo António, Oporto Hospital Centre, Portugal,
and informed consent was waived owing to the observational nature of the study.
Definitions
Community-acquired infection (CAI) was defined as an infection detected within 48 h of hospital
admission in patients who did not fit the criteria for a HCAI.
HCAI was defined using the same criteria of Friedman et al. [3]-an infection present at the time of hos-
pital admission or within 48 h of admission in patients that fulfilled any of the following criteria:
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– received intravenous therapy at home; wound care or specialized nursing care through a
healthcare agency, family or friends; or self-administered intravenous medical therapy in
the 30-day period before the onset of the infection;
– attended a hospital or hemodialysis clinic, or received intravenous chemotherapy in the
previous 30 days;
– hospitalized in an acute care hospital for 2 or more days in the previous 90 days;
– resided in a nursing home or long-term care facility.
Hospital-acquired infection (HAI) was defined as a localized or systemic condition that resulted from
an adverse reaction to the presence of an infectious agent(s) or its toxin(s), and that occurred 48 h or
more after hospital admission and was not incubating at the time of admission [1]. Infections in patients
recently discharged from hospital within the previous 2-week period were also included in this group.
The CDC definitions were used to define infections at different anatomic sites [1]. The definition of
MDR organisms used was adopted from the CDC recommendations for the management of MDR
organisms in healthcare settings that defines MDR organisms as bacteria that are resistant to one
or more classes of antimicrobial agents recommended as first line therapy [13]. Thus, enteric Gram-
negative rods were considered MDR (MDR-GN) if they were resistant to amoxicillin-clavulanate,
piperacillin-tazobactam, carbapenems, aztreonam, fluoroquinolones, or third-generation
cephalosporins or aminoglycosides. Acinetobacter spp. and Pseudomonas spp. were considered
MDR if they were resistant to piperacillin-tazobactam, imipenem/meropenem, aztreonam,
ciprofloxacin, cefepime, ceftazidime, aminoglycosides or colistin.
We grouped vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus
aureus (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and
Klebsiella species, carbapenem-hydrolyzing Klebsiella pneumonia and MDR Acinetobacter bauman-
nii, Pseudomonas aeruginosa and Enterobacter species into a group denominated ESKAPE, accord-
ing to a previous publication of the Infectious Diseases Society of America [14].
The presence of ESBL production among E. coli and Klebsiella spp. strains was screened by the
automatic analyzer Vitek2 (bioMérieux, France). It was confirmed by a disk diffusion test that
detects synergism between the cephalosporins/monobactam and clavulanate. If the interpreta-
tion of the results was doubtful, we also performed the Etest® (AB Biodisk, Solna, Sweden); a com-
bination of cefotaxime and cefotaxime/clavulanate and ceftazidime and ceftazidime/clavulanate
indicated ESBL production whenever the ESBL ratio with antibiotic:antibiotic+inhibitor was ≥8.
The presence of carbapenemase production in Enterobacteriaceaewas suspected whenever min-
imum inhibitory concentrations for ertapenem, imipenem and meropenem exceeded 0.5, 1 and 1
μg/mL, respectively. In such cases, a modified Hodge test was performed, and the ultimate confir-
matory test was carbapenemase detection by molecular methods.
The risk factors studied for association with infection by MDR pathogens (including MDR-GN and
the ESKAPE group) included age, sex, previous antibiotic therapy (in the last month prior to the cur-
rent infection), previous hospitalization (in the last 12 months prior to the current infection, but not
in the last 3 months), patient comorbidities and general medical condition. The comorbidities stud-
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ied included immunosuppression (administration of radiation therapy in the 12 months prior to
hospital admission, administration of 0.2 mg/kg/day of prednisolone for at least 3 months prior to
hospital admission, administration of 1 mg/kg/day of prednisolone for 1 week in the 3 months prior
to hospital admission or infection with human immunodeficiency virus), chronic liver disease [15],
chronic heart failure [15], chronic respiratory disease [15], hematological disease [16], cancer (metastatic
disease not under chemotherapy in the previous 12 months), diabetes mellitus requiring insulin
therapy or oral hypoglycemic agents before the infection and/or atherosclerosis (defined as a previ-
ous history of a transient ischemic attack, stroke, angina, myocardial infarction or peripheral arterial
disease). The patient’s general medical condition was assessed by the Karnofsky index [17]. A score
lower than 70 implies that the patient is unable to perform normal activities or do active work.
Adequacy of initial antibiotic therapy, hospital length of stay, Simplified Acute Physiology Score
(SAPS II) and hospital mortality were also compared between groups of patients with and with-
out infection by MDR pathogens (MDR-GN and ESKAPE). The initial empirical antibiotic treatment
was considered “adequate” if the response to the initial antibiotic prescribed within 24 h of diag-
nosis matched in vitro susceptibility of the pathogen deemed to be the likely cause of the infec-
tion, and when the dosage and route of administration were appropriate for the patient’s current
medical status (focus and severity of infection); only patients with positive microbiology were
considered in this analysis. SAPS II [16] was recorded on the first day of antibiotic therapy.
Statistical analysis
Continuous variables are described as mean and standard deviation (SD), or as median and inter-
quartile range if they showed a skewed distribution. Categorical variables are described with
absolute frequencies and percentages. Comparison of demographic and clinical characteristics of
infected patients from the community (either with CAI or HCAI) and patients with HAI was made
using the Student t-test (for continuous variables with normal distribution), the Mann–Whitney U
test (for continuous variables with skewed distribution) and the Pearson χ2 test (for categorical
variables).
Comparison of inadequate antibiotic therapy, hospital length of stay, SAPS II and hospital mortal-
ity between the group of patients infected with MDR pathogens and those not infected, along
with comparison of the group infected by MDR-GN with those not infected, and the group infect-
ed by ESKAPE pathogens and those not infected, was made with the same tests according to the
type of variables compared (continuous with normal distribution, continuous with skewed distri-
bution or categorical).
All variables potentially associated with MDR pathogen infection (including MDR-GN and ESKAPE
pathogens) were studied among all infected patients admitted from the community, those with
CAI and HCAI, and included: age, sex, previous antibiotic therapy, hospitalization in the previous
year, immunosuppression, chronic hepatic disease, chronic heart failure, chronic respiratory dis-
ease, chronic hematologic disease, cancer, diabetes, atherosclerosis and decreased functional
capacity (Karnofsky index <70). Those with a clear association in the univariate analysis (p < 0.1)
were included in the multivariable analysis. The results of the multivariable models are expressed
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as odds ratio (OR) with 95% confidence interval and p-values. The calibration was tested using the
Hosmer-Lemeshow goodness-of-fit test. The significance level was defined as p < 0.05. Data were
analyzed using SPSS version 18 for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
During the study period a total of 3733 patients were assessed and 1035 (28%) met the inclusion
criteria of having infection according to the CDC definitions of infection. The mean ± SD age of
the patients included was 65 ± 20 years, and the mean SAPS II was 29 ± 13; 49% of patients were
male, and the overall hospital mortality rate was 13% (Table 4.1.1). Of these, 718 were admitted to
hospital from the community with infection: 493 (48%) with a CAI and 225 (22%) with a HCAI.
These populations were significantly different from patients with HAI, with a lower proportion of
immunosuppressed patients (19% vs 27%, p = 0.007), a lower proportion of hospitalizations in the
previous year (33% vs 55%, p < 0.001) and less likelihood of antibiotic therapy in the last month
(19% vs 73%, p < 0.001). Hospital mortality was significantly lower in patients from the communi-
ty (CAI or HCAI) than in those with HAI (11% vs 19%, p < 0.001) (Table 4.1.1). Of the 718 patients
with CAI or HCAI, 439 (61%) had microbiologic documentation; of these, 123 were MDR (28%), 104
(85%) with MDR-GN and 41 (33%) with ESKAPE organisms.
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Table 4.1.1 – Demographic and clinical characteristics of patients, according to place of acquisition of infection
Patients’ characteristics TOTAL
(n = 1035)
CAI and HCAI
(n = 718)
HAI
(n = 317)
p-value
Male sex, n (%) 506 (49) 344 (48) 162 (51) 0.343*
Age, mean (SD) 65 (20) 65 (20) 64 (19) 0.405&
SAPSII, mean (SD) 29 (13) 29 (12) 30 (13) 0.962&
Severity of infection, n (%) 0.922*
Localized infection without SIRS 281 (27) 195 (27) 86 (27)
Sepsis 364 (35) 251 (35) 113 (36)
Severe sepsis 296 (29) 209 (29) 87 (27)
Septic shock 94 (9) 63 (9) 31 (10)
Previous comorbidities, n (%) 671 (65) 460 (64) 211 (67) 0.438*
Chronic hepatic disease, n (%) 22 (2) 18 (3) 4 (1) 0.822$
Chronic renal disease, n (%) 149 (14) 94 (13) 55 (17) 0.072*
Chronic heart failure, n (%) 74 (7) 46 (6) 28 (9) 0.163*
Chronic respiratory disease, n (%) 66 (6) 52 (7) 14 (4) 0.086*
Hematologic disease, n (%) 60 (6) 35 (5) 25 (8) 0.056*
Cancer, n (%) 45 (4) 26 (4) 19 (6) 0.084*
Diabetes, n (%) 204 (20) 144 (20) 60 (19) 0.674*
Atherosclerotic disease, n (%) 242 (23) 168 (23) 74 (23) 0.985*
Immunosuppression, n (%) 221 (21) 137 (19) 84 (27) 0.007*
Karnofsky index<70, n (%) 319 (31) 227 (32) 92 (29) 0.405*
Hospitalization in the previous year, n (%) 413 (40) 239 (33) 174 (55) <0.001*
Previous antibiotic therapy, n (%) 367 (36) 137 (19) 230 (73) <0.001*
Hospital mortality, n (%) 138 (13) 79 (11) 59 (19) 0.001*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital-acquired infection, IQR – Inter-quartile range, SD – Standard deviation,
SOFA – Sepsis-related Organ Failure Assessment, SIRS – Systemic inflammatory response syndrome
*Pearson Qui-square Test; &Independent samples t-test; $ Fisher exact test.
From the univariate analysis, age, previous antibiotic therapy, hospitalization in the previous year
(from 4 months to 1 year), chronic heart failure, chronic respiratory disease, atherosclerosis and a
Karnofsky index <70 were selected for multivariate analysis of independent risk factors associat-
ed with infection by MDR pathogens, including infection by MDR-GN (Table 4.1.2). For the ESKAPE
group, previous antibiotic therapy, hospitalization in the previous year, and a Karnofsky index <70
were the variables selected for the multivariate model (Table 4.1.2).
Regarding infection by MDR pathogens, the final model retained age (adjusted OR per category
= 1.7, p = 0.001) and hospitalization in the previous year (from 4 months to 1 year) (adjusted OR =
2.0, p = 0.008) (Table 4.1.3) as independent risk factors. The final model for MDR-GN infection also
retained age (adjusted OR per category = 1.5, p = 0.009) and hospitalization in the previous year
(from 4 months to 1 year) (adjusted OR = 1.7, p = 0.048) (Table 4.1.3). For ESKAPE pathogen infec-
tion, the final model retained previous antibiotic therapy (adjusted OR = 7.2, p < 0.001) and
Karnofsky index <70 (adjusted OR = 3.7, p = 0.003) (Table 4.1.3).
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Table 4.1.2 – Risk factors for MDR, MDR gram-negatives and ESKAPE group pathogens infection
Association of demographic and clinical variables with infection by MDR, MDR gram negatives and ESKAPE pathogens among patients admitted from the communi-
ty (with community-acquired or healthcare-associated infections), using logistic regression
Variables Total,
n (%)
n=718
Microbiolo -
gical docu-
mentation,
n (%)
n=439
MDR,
n (%)
n=123
Crude
OR
p-value MDR-GN,
n (%)
n=104
Crude
OR
p-value ESKAPE
pathogens,
n (%)
n=41
Crude
OR
p-value
Age 1.6* <0.001 1.5* 0.009 1.3* 0.170
≤60 years 271 (38) 166 (38) 33 (27) 30 (28) 13 (32)
61-80 years 250 (35) 157 (36) 44 (36) 37 (36) 13 (32)
>80 years 197 (27) 116 (26) 46 (37) 37 (36) 15 (36)
Male sex 344 (48) 203 (46) 56 (46) 1.1 0.656 45 (43) 0.9 0.542 21 (51) 1.2 0.503
Previous antibiotic
therapy
137 (19) 94 (21) 38 (31) 1.9 0.009 30 (29) 1.7 0.033 20 (49) 4.2 <0.001
Hospitalization in 
the previous year 
(4 months - 1 year)
146 (20) 102 (23) 37 (30) 2.1 0.006 29 (28) 1.8 0.031 14 (34) 3.3 0.003
Immunosupression
(not meeting criteria
of HCAI)
113 (16) 81 (19) 25 (20) 1.1 0.685 24 (23) 1.5 0.116 10 (24) 1.5 0.306
Chronic hepatic 
disease
18 (3) 14(3) 4 (3) 0.9 0.818 3 (3) 0.9 0.829 2 (5) 1.7 0.522
Chronic heart failure 46 (6) 27 (6) 13 (11) 2.5 0.026 11 (11) 2.3 0.038 2 (5) 0.8 0.723
Chronic respiratory
disease
52 (7) 30 (7) 13 (11) 2.2 0.056 11 (11) 1.9 0.093 4 (10) 1.6 0.439
Chronic haema -
tologic disease
35 (5) 29 (7) 8 (7) 1.0 0.945 5 (5) 0.7 0.444 5 (12) 2.2 0.139
Cancer (not meeting
criteria of HCAI)
10 (1) 6 (1) 2 (2) 1.5 0.666 2 (2) 1.6 0.578 0 (0)
Diabetes 144 (20) 96 (22) 32 (26) 1.3 0.291 27 (26) 1.4 0.239 11 (27) 1.4 0.421
Atherosclerosis 168 (23) 105 (24) 40 (33) 1.8 0.017 32 (31) 1.6 0.069 13 (32) 1.5 0.222
Karnofsky index<70 227 (32) 149 (34) 57 (46) 1.8 0.006 44 (42) 1.6 0.046 22 (54) 2.5 0.006
*increase in the odds per category of age; MDR – multi-drug resistant; MDR-GN – multi-drug resistant gram negatives; OR – odds ratio; ESKAPE - Enterococcus faecium
Vancomycin-resistant, MRSA, ESBL producing E. coli and Klebsiella species, Klebsiella pneumonia Carbapenamase-hydrolyzing and MDR Acinectobacter baumannii,
Pseudomonas aeruginosa and Enterobacter species
Patients with infection by a pathogen belonging to one of the three MDR groups had a signifi-
cantly higher rate of inadequate antibiotic therapy: 16% in the study population, 46% in the group
of patients with infection by MDR pathogen, 44% in the group with infection by MDR-GN, and
61% in the group with an ESKAPE group infection (p < 0.001). Despite that, median hospital length
of stay was similar in all groups, as were SAPS II and hospital mortality rate (Table 4.1.4).
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Table 4.1.3 – Independent variables associated with infection by MDR, MDR gram-negatives and pathogens from the
ESKAPE group
Selection of variables significantly and independently associated with infection by a MDR pathogen, MDR gram negative or a pathogen from the ESKAPE group,
among the group of patients admitted from the community (with community or healthcare-associated infection), using multiple logistic regression
Variables MDR,
n (%)
n = 123
Adjusted
OR
CI95% p-value MDR Gram
negatives,
n (%)
n = 104
Adjusted
OR
CI95% p-value ESKAPE
pathogens,
n (%)
n= 41
Adjusted
OR
CI95% p-value
Age 1.7 1.3-2.3 0.001 1.5 1.1-2.1 0.009
≤60 years 33 (27) 30 (28) 13 (32)
61-80 years 44 (36) 37 (36) 13 (32)
>80 years 46 (37) 37 (36) 15 (36)
Previous antibiotic
therapy
38 (31) 30 (29) 20 (49) 7.2 3.1-17.0<0.001
Hospitalization in
the previous year 
(4 months - 1 year)
37 (30) 2.0 1.2-3.4 0.008 29 (28) 1.7 1.0-3.0 0.048 14 (34)
Karnofsky index
<70
57 (46) 44 (42) 22 (54) 3.7 1.6-8.6 0.003
*increase in the odds per category of age; MDR – multi-drug resistant; OR – odds ratio; CI – confidence interval; ESKAPE - Enterococcus faecium Vancomycin-resistant,
MRSA, ESBL producing E. coli and Klebsiella species, Klebsiella pneumonia Carbapenamase-hydrolyzing and MDR Acinectobacter baumannii, Pseudomonas aeruginosa
and Enterobacter species
Table 4.1.4 – Impact of infection by MDR pathogens, including MDR gram-negatives and pathogens from the ESKAPE
group, in antibiotic therapy and hospital outcome
Comparison of inadequate antibiotic therapy, hospital length of stay, SAPS II and hospital mortality between the group of patients infected with MDR pathogens and those
not infected, along with comparison of the group infected by MDR-GN with those not infected, and the group infected by ESKAPE pathogens and those not infected
Variables MDR, Non-MDR, Non-
MDR 
vs MDR,
MDR-GN Non-MDR-
GN,
Non-MDR-
GN vs 
MDR-GN,
ESKAPE
pathogens,
Non-
ESKAPE
pathogens,
Non-ESKAPE
vs ESKAPE,
n (%) n (%) p value n (%) n (%) p value n (%) n (%) p value
Inadequate ATB therapy 57 (46) 19 (7) <0.001* 46 (44) 30 (10) <0.001* 25 (61) 51 (15) <0.001*
Hospital LOS, median
(IQR)
10 (7–17) 10 (7–16) 0.944# 10 (7–15) 10 (7–17) 0.487# 11 (8–15) 10 (7–17) 0.280#
SAPS II, mean (SD) 32 (13) 30 (13) 0.171& 31 (13) 30 (13) 0.428& 32 (17) 30 (12) 0.373&
Hospital mortality 19 (15) 31 (12) 0.280* 13 (13) 37 (13) 0.928* 9 (22) 41 (12) 0.062*
ATB – antibiotherapy, CAI – community-acquired infection, LOS – length of stay, IQR – inter-quartil range, MDR – multi-drug resistant, MDR GN – multi-drug resistant
gram negatives, ESKAPE - Enterococcus faecium Vancomycin-resistant, MRSA, ESBL producing E. coli and Klebsiella species, Klebsiella pneumonia Carbapenamase-
hydrolyzing and MDR Acinectobacter baumannii, Pseudomonas aeruginosa and Enterobacter species
*Pearson Qui-square Test; # Mann–Whitney test, &Students t-test
DISCUSSION
In this study, age >60 years, hospitalization in the previous year (in the last 4 to 12 months), previ-
ous antibiotic therapy (last month) and Karnofsky index <70 were found to be significantly and
independently associated with infection by MDR pathogens. These risk factors were not consid-
ered in the definition of risk factors of HCAI proposed by Friedman et al. Patients with infection by
MDR microorganisms had a significantly higher rate of inadequate initial antibiotic therapy, but
did not have a longer hospital length of stay or higher hospital mortality rate. This is probably one
of the first studies containing a thorough description of independent and significant risk factors
associated with infection by pathogens of the ESKAPE group as well as their impact regarding
inadequate antibiotic therapy, hospital length of stay and hospital mortality.
In order to define the new group of infections across community and hospital settings, a defini-
tion of all risk factors for MDR pathogen infections is required. The definition proposed by
Friedman et al. [3] is one of the most used in clinical studies regarding HCAI, but it was developed
for bloodstream infections. Further studies followed, using similar definitions, but again only for a
single focus of infection or single pathogens. Our study identified additional risk factors for MDR
pathogen infection.
Micek et al. [10] performed a retrospective cohort study of hospitalized patients with pneumonia,
and identified immunocompromised state and hospitalization in the previous 12 months as risk
factors for HCAI. They found a higher proportion of MDR organisms in the HCAI group, with a sig-
nificant association with inappropriate antibiotic therapy and hospital mortality rate. One limita-
tion discussed by the authors was the fact that they did not evaluate severity-of-illness scores. In
the current study severity scores were considered and they were similar in all groups, with no sig-
nificant differences in hospital mortality rate between groups. Park et al. [5] also performed a ret-
rospective cohort study on HCAI-pneumonia, using the Friedman et al. definition and prior antibi-
otic therapy in the 30 days before the pneumonia episode, and found a higher proportion of MDR
pathogens when compared with community-acquired pneumonia, and a significant association
with inappropriate initial antibiotic therapy. Brito and Niederman [18] performed a review of all arti-
cles published since the American Thoracic Society guidelines were published [2], and concluded
that patients at risk of pneumonia by MDR pathogens were those who had severe illness, were
hospitalized in the past 90 days, had antibiotic therapy in the past 6 months, had poor functional
status as defined by activities of daily living score, and were immunosuppressed, similar to the risk
factors described here.
Wright et al. [19] performed a retrospective cohort study to determine risk factors for MDR
pathogens among patients in the Emergency Department with urinary tract infections, and
described the following independent risk factors: age ≥65 years, diabetes, prior use of antibiotics,
and urinary catheterization. Chen et al. [20] studied patients from the community with bacteremia
but with prior hospitalization from periods of 3–90, 91–180 to up to 181–360 days, and conclud-
ed that the presence of antimicrobial-resistant bacteria in the past 360 days was an independent
risk factor for antimicrobial-resistant bacteremia, reaffirming that hospitalization in the previous
year represented a risk factor for MDR pathogen infection. Pop-Vicas et al. [21], in a 6-year study of
patients with positive cultures for MDR organisms, noted an increasing prevalence of MDR-GN at
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admission to a tertiary-care hospital (positive cultures within the first 48 h after hospital admis-
sion). Factors independently associated with isolation of the resistant organisms were age ≥65
years, prior antibiotic therapy for ≥14 days and prior residence in a long-term-care facility.
The current study has the major advantage of being prospective, with clear and consensual defi-
nition of infection [1]. It included all major foci of infection that drove patients into hospital care
and not only pneumonia, bacteremia or urinary infection as in other previous studies. It clearly
identified the place of acquisition and the appropriateness of initial antibiotic therapy. Data
regarding severity of illness and the impact of infection by MDR organisms in the appropriateness
of initial antibiotic therapy, hospital length of stay and mortality rate were also investigated. Data
collection was performed by a single trained doctor, and all protocols were completed with no
missing data thus minimizing information bias. All patients completed follow-up until hospital
discharge. Most importantly, risk factors described in this study have been previously mentioned
in studies restricted to single focus of infection or pathogen, by other authors from different parts
of the world, suggesting important external applicability of these conclusions.
The study also has certain limitations that should be acknowledged. The research was performed
in a single institution and the number of patients from the community was relatively small. There
is accumulating evidence that HCAI seems to be a group encompassing CAI and HAI, but specific
definition of risk factors are lacking. The diversity of definitions used has led to diverse findings
not comparable between studies, and therefore not consequential in specific treatment recom-
mendations development.
Implementation of standardized approaches for the treatment of HCAI is desirable, since failure to
recognize this group of infected patients appears to be associated with administration of inap-
propriate antibiotic therapy in hospitalized patients with serious infection, and may be related to
poor prognosis.
CONCLUSIONS
The results of this study suggest that the inclusion of additional risk factors for MDR pathogen
infection in HCAI definition, namely age >60 years, Karnofsky index <70, hospitalization in the pre-
vious year, and previous antibiotic therapy, may be clinically beneficial because of early diagnosis
and a decrease in the rate of inadequate antibiotic therapy in these patients. Further research
involving a large number of patients from different institutions and geographic areas is warrant-
ed to confirm these findings.
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4.2. DIFFERENCES IN MICROBIOLOGICAL PROFILE BETWEEN 
COMMUNITY-ACQUIRED, HEALTHCARE-ASSOCIATED AND 
HOSPITAL-ACQUIRED INFECTIONS 
ABSTRACT
Background: Microbiological profiles were analysed and compared for intra-abdominal (IAI), uri-
nary (UTI), respiratory and bloodstream infections (BSI) according to place of acquisition: commu-
nity-acquired (CAI), with a separate analysis of healthcare-associated (HCAI), and hospital-
acquired (HAI) infections. 
Methods: Prospective cohort study performed at a university affiliated tertiary care hospital over
1 year. Inclusion criteria were meeting the Centers for Disease Control (CDC) definition of intra-
abdominal, urinary, respiratory and bloodstream infections. 
Results: A total of 1035 patients were included in the study. More than 25% of intra-abdominal
infections were polymicrobial; multi-drug resistant gram-negatives were 38% in CAI, 50% in HCAI
and 57% in HAI. E. coli was the most prevalent among urinary infections: 69% in CAI, 56% in HCAI
and 26% in HAI; ESBL producers’ pathogens were 10% in HCAI and 3% in CAI and HAI. In respira-
tory infections Streptococcus pneumoniae was the most prevalent in CAI (54%) and MRSA in HCAI
(24%) and HAI (24%). A significant association was found between MRSA respiratory infection and
hospitalization in the previous year (adjusted OR = 6.3), previous instrumentation (adjusted OR =
4.3) and previous antibiotic therapy (adjusted OR = 5.7); no cases were documented among
patients without risk factors. Hospital mortality rate was 10% in CAI, 14% in HCAI and 19% in HAI.
Conclusions: This study shows that HCAI has a different microbiologic profile than those from
community or hospital acquired for the four main focus of infection. Knowledge of this fact is
important because the existing guidelines for CAI are not entirely applicable for this group of
patients.
KEY WORDS: healthcare-associated infection; intra-abdominal infection; urinary infection; respira-
tory infection bloodstream infection.
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INTRODUCTION
Over the last decade the massive increase in outpatient clinical care has led to a new context for
the emergence of healthcare-associated infections (HCAI). This is a new name for the new group
of infections from patients in the community that have a previous history of exposure to the
healthcare system and that do not fit the nosocomial infection criteria [1]. 
In 2002, Deborah Friedman [1] proposed a new classification for CAI-bloodstream infections (BSI)
in patients with recent hospital admission or exposure to significant medical care - HCAI-BSI -
after a cohort study of 504 patients with BSI where she noticed significant differences in the
microbiological profiles between HCAI, CAI and hospital aquired infection - BSI (HAI-BSI).
This new concept of HCAI is spreading throughout the scientific world and evidence has emerged
suggesting that this might represent a new group of infections with microbiological and outcome
characteristics that are different from CAI and HAI [2-5].
The studies performed previously have focused primarily on single focus of infection: pneumonia
[3, 4, 6], BSI [2, 5, 7] or Urinary Tract Infection (UTI) [8]. To the best of our knowledge, no study has been
published concerning Intra-abdominal Infection (IAI), although these are among the three most
common infections that result in hospitalization [9].
The objective of this study is to analyse differences in the microbiological profiles and outcomes of
the major focus of infection that drive patients into hospital care: IAI, UTI, respiratory and BSI - HCAI,
CAI and HAI. Additionally independent risk factors for respiratory infection by MRSA will be described.
METHODS
Study design and patient population
This prospective cohort study included all consecutive adult patients admitted to the intensive
care unit (ICU), medical, surgical, nephrology and haematology wards of a 600-bed university affil-
iated, tertiary care hospital from 1st June 2008 until 31st May 2009. 
The inclusion criterion was diagnosis of the infection according to the CDC criteria [10], in an adult
patient (age ≥ 18 years) admitted onto one of the previously mentioned wards. Infections were
classified as CAI, HCAI or HAI, according to the place of acquisition. Only the first episode of infec-
tion in the current hospital admission was characterized for each patient. 
The primary outcome was detailed microbiological characterization of the microbiological profile
of IAI, UTI, respiratory infections and BSI, according to the place of acquisition, including analysis
of the prevalence of multi-drug resistant (MDR) pathogens. Secondary outcomes were differences
in hospital length of stay (LOS) and mortality for different focus of infection according to the place
of acquisition.
This study was approved by the Institutional Review Board of Hospital de Santo António, Oporto
Hospital Centre, Portugal, and informed consent was waived due to the observational nature of
the study.
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Definitions
CAI was defined as an infection detected within 48 hours of hospital admission in patients who
did not fit the criteria for a HCAI. 
HAIwas defined as a localized or systemic condition that resulted from an adverse reaction to the
presence of an infectious agent(s) or its toxin(s), and that occurred 48 hours or more after hospi-
tal admission and was not incubating at the time of admission [11]. Infections in patients recently
discharged from the hospital within the previous 2-week period were also included in this group. 
HCAI was defined using the same criteria that Deborah Friedman used for HCAI-BSI [1]. The infec-
tion must have been present at the time of hospital admission or within 48 hours of admission in
patients that fulfilled any of the following criteria:
– Received intravenous therapy at home, wound care or specialized nursing care through a
healthcare agency, family or friends; or, self-administered intravenous medical therapy in
the 30 day period before the onset of the infection. Patients whose only home therapy was
oxygen use were excluded.
– Attended a hospital or haemodialysis clinic, or received intravenous chemotherapy in the
previous 30 days.
– Were hospitalized in an acute care hospital for 2 or more days in the previous 90 days.
– Resided in a nursing home or long-term care facility.
The CDC definitions were used to define infections at different anatomic sites [10]. BSI were classi-
fied as primary or secondary. Primary BSI were defined according to the National Nosocomial
Infection Surveillance System [12], and include intravascular device-associated infections. A second-
ary BSI was defined as the presence of an organism isolated from a blood culture that was relat-
ed to an infection at another site [10].
MDR organisms were those resistant to one or more classes of antimicrobial agents that are recom-
mended as first line therapy [13]. Enteric gram-negative rods were considered MDR if they were resist-
ant to amoxicillin-clavulanate, piperacillin-tazobactam, carbapenems, aztreonam, fluoroquinolones,
3rd generation cephalosporins, aminoglycosides or trimethoprim-sulfamethoxazole. Acinectobacter
spp and Pseudomonas spp were considered MDR if they were resistant to piperacillin-tazobactam,
imipenem/meropenem, aztreonam, ciprofloxacin, cefepime, ceftazidime, aminoglycosides or col-
istin. The presence of ESBL production among E. coli and Klebsiella spp strains was screened by the
automatic analyser Vitek2 (BioMérieux). It was always confirmed by a disk diffusion test that detects
synergism between the cephalosporins/monobactam and clavulanate. If the interpretation of the
results was doubtful we also performed Etest®: the combination strains of cefotaxime and cefo-
taxime/clavulanate and ceftazidime and ceftazidime/clavulanate allows the detection of ESBL
whenever the ratio antibiotic/antibiotic + inhibitor is equal or above 8. 
The comorbidities of patients in the study included immunosuppression (administration of
chemotherapy in the 12 months prior to hospital admission, either radiation therapy or adminis-
tration of 0.2 mg/kg/day prednisolone for at least 3 months prior to hospital admission, adminis-
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tration of 1mg/kg/day of prednisolone for 1 week in the 3 months prior to hospital admission or
infection with human immunodeficiency virus), chronic liver disease [14], chronic heart failure [14],
chronic respiratory disease [14], chronic renal failure (defined as the need for chronic renal support
or a history of chronic renal insufficiency with a serum creatinine level over 2 mg/dl), haematolog-
ical disease [15], cancer [15], diabetes mellitus requiring insulin therapy or oral hypoglycaemic agents
before the infection and/or atherosclerosis (defined as a previous history of a transient ischemic
attack, stroke, angina, myocardial infarction or peripheral arterial disease).
General medical condition was assessed by the Karnofsky index [16]. A score of lower than 70
implies that the patient is unable to perform normal activities or do active work.
Sepsis and sepsis-related conditions were diagnosed according to the criteria proposed by the
ACCP/SCCM [17]. For the first day of antibiotic therapy, the acute physiological score, SAPS II [15], and
the acute organ dysfunction score, SOFA [18], were recorded.
The initial empirical antibiotic treatment was considered “adequate” if the antibiotic prescribed
within the first 24 hours matched in vitro susceptibility of a pathogen deemed to be the likely
cause of infection and when the dosage and route of administration were appropriate for current
medical status (focus and severity of infection); only patients with positive microbiology were
considered in this analysis.
Statistical analysis
Data were described with medians and inter-quartile ranges. Comparisons were performed using
Pearson χ2 or Fisher’s exact test for categorical variables and the Mann-Whitney-U-test for contin-
uous variables. 
Independent risk factors associated with infection by MRSA were assessed in respiratory infections,
through a logistic regression model, with gender, age, Karnovsky index < 70, severity of infection,
SAPS II, total SOFA score, hospitalization in the previous year, previous instrumentation, previous
antibiotic therapy, atherosclerosis, diabetes, cancer, haematologic disease, chronic respiratory dis-
ease, chronic heart failure, chronic renal failure, chronic hepatic disease and imunossupression as
independent variables. Factors found to be significant at the p<0,05 level in the univariate analysis
or that were considered clinical important were included in the initial model, and forward stepwise
variable elimination was then performed to develop the final model. Model calibration was
assessed using the Hosmer-Lemeshow goodness-of-fit test. Statistical significance was defined as
p<0.05. Data were analyzed using SPSS version 18 for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
During the study period a total of 3733 patients were admitted into the wards and assessed: 1035
(28%) met the inclusion criteria of having infection according to the CDC definitions of infection.
Of all patients, 48% (n= 493) were diagnosed with CAI, 22% (n= 225) with HCAI and 30% (n= 317)
with HAI. 
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Among the patients with HCAI: 6 (3%) received intravenous therapy, wound care or specialized
nursing care at home, 95 (42%) attended a hospital or a haemodialysis clinic or received intra-
venous chemotherapy in the previous 30 days, 98 (44%) were admitted to an acute care hospital
for 2 or more days in the previous 90 days and 42 (19%) resided in a long-term care facility or in a
nursing home; 16 (7%) had more than one.
Patients with HCAI were older (74 years) than patients with CAI (67 years, p=0.009) or HAI (67
years, p=0.004), had higher prevalence of previous comorbidities (84% vs 55% vs 67%, p<0.001),
namely chronic renal disease (28% vs 6% vs 17%, p<0.005), immunossupression (32% vs 13% vs
27%, p<0.005) and more frequently needed help in daily activities (measured by a Karnofsky
index of less than 70) (20% vs 23% vs 33%, p<0.05) (Table 4.2.1).
In HCAI the main focus of infection was urinary (45%); in CAI, respiratory (50%) and in HAI, intra-
abdominal and respiratory (25% and 21% respectively). Overall microbiology documentation of
infection was 68%: 56% in CAI, 73% in HCAI and 83% in HAI, (p<0.05) (table 4.2.2).
No significant differences were found between the 3 groups (CAI, HCAI or HAI) regarding type of
microorganism, namely gram-negatives, gram positives or fungi (table 4.2.3), but there was an increase
in polymicrobial infection from CAI (8%), to HCAI (15%) and HAI (20%), as well as of MDR organisms:
32%, 62% and 74% (p<0.05). The prevalence of ESBL producer micro-organisms was significantly high-
er in HCAI (8%), when compared with the other two groups (2% in CAI, 3% in HAI, p<0.005). 
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Table 4.2.1 – Patient characteristics, according to place of acquisition of infection 
Patients’ characteristics TOTAL
(n = 1035)
CAI
(n = 493)
HCAI
(n = 225)
HAI
(n = 317)
HCAI vs. CAI
p value
HCAI vs. HAI
p value
Male sex, n (%) 506 (49) 236 (48) 108 (48) 162 (51) 0.974* 0.476* 
Age, median (IQR) 68 (52-81) 67 (49-81) 74 (56-83) 67 (53-80) 0.009† 0.004†
SAPSII, median (IQR) 29 (22-34) 28 (20-34) 30 (24-35) 28 (22-34) 0.039† 0.119†
Total SOFA score, median (IQR) 1 (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 0.561† 0.678†
Severity of infection, n (%) 0.117* 0.243*
Infection 281 (27) 126 (26) 69 (31) 86 (27)
Sepsis 364 (35) 178 (36) 73 (32) 113 (36)
Severe sepsis 296 (29) 139 (28) 70 (31) 87 (27)
Septic shock 94 (9) 50 (10) 13 (6) 31 (10)
Previous comorbidities, n (%) 671 (65) 270 (55) 190 (84) 211 (67) <0.001* <0.001* 
Chronic hepatic disease, n (%) 22 (2) 11 (2) 7 (3) 4 (1) 0.454‡ 0.214‡
Chronic renal disease, n (%) 149 (14) 31 (6) 63 (28) 55 (17) <0.001* 0.003* 
Chronic heart failure, n (%) 74 (7) 25 (5) 21 (9) 28 (9) 0.031* 0.841* 
Chronic respiratory disease, n (%) 66 (6) 34 (7) 18 (8) 14 (4) 0.597* 0.081* 
Hematologic disease, n (%) 60 (6) 9 (2) 26 (12) 25 (8) <0.001* 0.149* 
Cancer, n (%) 45 (4) 10 (2) 16 (7) 19 (6) 0.001* 0.602* 
Diabetes, n (%) 204 (20) 91 (19) 53 (24) 60 (19) 0.114* 0.191* 
Atherosclerotic disease, n (%) 242 (23) 101 (21) 67 (30) 74 (23) 0.006* 0.093* 
Immunosuppression, n (%) 198 (19) 66 (13) 71 (32) 84 (27) <0.001* 0.019* 
Karfosky index<70, (%) 319 (31) 115 (23) 112 (50) 106 (33) <0.001* <0.001* 
Previous antibiotic therapy, n (%)367 (36) 51 (10) 86 (38) 230 (73) <0.001* <0.001* 
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, IQR – Inter-quartile range.
*Pearson Qui-square Test; † Independent samples median test; ‡ Fisher exact test.
The overall microbiological profile considering the 12 most frequent microorganisms according
to place of acquisition of infection was also significantly different with: E. coli (39%), Streptococcus
pneumoniae (23%) and Haemophilus influenza (7%) as the most frequent among CAI; E. coli (42%),
MSSA (13%) and Klesiella pneumoniae (7%) in HCAI and E. coli (20%), Pseudomonas aeruginosa
(15%) and MRSA (13%) in HAI (table 4.2.3).
In patients with CAI, HCAI or HAI-IAI, the most prevalent pathogen was E. coli, followed by
Salmonella in CAI, MSSA in HCAI and Clostridium difficile in HAI. There was a high prevalence (>25%)
of polymicrobial infections independently of the place of acquisition of infection (table 4.2.4). 
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Table 4.2.2 – Distribution of focus of infection, according to place of acquisition of infection 
Focus of infection TOTAL
(n = 1035)
n (%)
CAI
(n = 493)
n (%)
HCAI
(n = 225)
n (%)
HAI
(n = 317)
n (%)
HCAI vs. CAI
p value
HCAI vs. HAI
p value
Respiratory 419 (40) 244 (50) 70 (31) 105 (33) <0.001* 0.622*
Urinary 344 (33) 140 (28) 102 (45) 102 (32) <0.001* 0.002*
Intra-abdominal 213 (21) 104 (21) 31 (14) 78 (25) 0.020* 0.002*
Primary bloodstream infection 57 (6) 4 (1) 21 (9) 32 (10) <0.001† 0.719†
Other 2 (0) 1 (0) 1 (1) 0 (0) <0.001† 1.000†
Microbiological confirmation 703 (68) 274 (56) 165 (73) 264 (83) <0.001* 0.005*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection.
*Pearson Qui-square Test; † Fisher exact test.
Table 4.2.3 – Microbiological profiles of monomicrobial infections, according to place of acquisition of infection
Positive microbiology TOTAL
(n = 703) 
n (%)
CAI
(n = 274) 
n (%)
HCAI
(n = 165) 
n (%)
HAI
(n = 264) 
n (%)
HCAI vs CAI
p value
HCAI vs HAI
p value
Type of microorganism 0.975† 0.849†
Gram negative 384 (55) 163 (60) 90 (55) 131 (50) 
Gram positive 204 (29) 83 (30) 47 (28) 74 (28) 
Fungi 15 (2) 5 (2) 3 (2) 7 (3) 
Polymicrobial 100 (14) 23 (8) 25 (15) 52 (20) 
Pathogen <0.001† <0.001†
E. coli 197 (32) 96 (39) 59 (42) 42 (20) 
S. pneumoniae 65 (11) 58 (23) 6 (4) 1 (1) 
Pseudomonas aeruginosa 43 (7) 6 (2) 5 (4) 32 (15) 
MRSA 39 (6) 2 (1) 8 (6) 29 (13) 
MSSA 39 (6) 7 (3) 18 (13) 14 (6) 
Klebsiella pneumoniae 36 (6) 11 (4) 10 (7) 15 (7) 
Proteus mirabilis 22 (3) 9 (4) 4 (3) 9 (4) 
Haemophilus influenzae 18 (3) 16 (7) 1 (1) 1 (1) 
Enterococcus faecalis 16 (2) 6 (2) 2 (1) 8 (4) 
Enterobacter cloacae 13 (2) 3 (1) 1 (1) 9 (4) 
Acinectobacter baumannii 13 (2) 1 (0) 2 (1) 10 (5) 
Enterococcus faecium 13 (2) 0 (0) 4 (3) 9 (4) 
Others 89 (15) 36 (15) 20 (14) 33 (16)
TOTAL monomicrobial 603 (100) 251 (100)         140 (100) 212 (100)
MDR 324 (54%) 80 (32%) 87 (62%) 157 (74%) <0.001* 0.019*
ESBL 21 (3%) 4 (2%) 11 (8%) 6 (3%) 0.005† 0.023*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, MRSA – Methicillin resistant Staphylococcus aureus,
MSSA – Methicillin sensitive Staphylococcus aureus.  ESBL - Extended-spectrum beta-lactamases producer. MDR – Multi-drug resistant
*Pearson Qui-square Test, † Fisher exact test.
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Table 4.2.4 – Comparison of the microbiological profiles, according to place of acquisition and focus of infection 
CAI (n = 251)
n (%)
HCAI (n = 140)
n (%)
HAI (n = 212)
n (%)
HCAI vs. CAI
p value 
HCAI vs. HAI
p value 
Intra-abdominal infection, 124 patients with microbiologic documentation
45 (100) 23 (100) 56 (100)
E. coli, 15 (33) E. coli, 4 (17) E. coli, 10 (18) 0.015† 0.008†
Salmonella, 3 (7) MSSA, 3 (13) Clostridium difficile, 5 (9)
Klebsiella pneumoniae, 2 (4) Bacillus cereus, 2 (9) Candida albicans, 4 (7)
MRSA, 4 (7)
Others, 11 (25) Others, 8 (35) Others, 10 (18)
Polymicrobial, 14 (31) Polymicrobial, 6 (26) Polymicrobial, 23 (41) 0.418* 0.280*
MDR, gram negative, 9 (38) MDR, gram negative,3 (50) MDR, gram negative, 8 (57) 0.660† 1.000†
ESBL producers, 1 (2) ESBL producers, 1 (4) ESBL producers, 2 (4) 1.000† 1.000†
Urinary infection, 306 patients with microbiologic documentation
117 (100) 92 (100) 97 (100)
E. coli, 81 (69) E. coli, 51 (56) E. coli, 25 (26) <0.115† <0.001†
Proteus mirabilis, 9 (8) Klebsiella pneum., 8 (9) Pseudomonas aeruginosa,
12 (12)
Enterococcus faecalis, 6 (5) Proteus mirabilis, 4 (4) Enterococcus faecalis, 8 (8)
Others, 16 (14) Others, 14 (15) Others, 31 (32)
Polymicrobial, 5 (4) Polymicrobial, 15 (16) Polymicrobial, 21 (22) 0.002* 0.270*
MDR, gram negative, 49 (47) MDR, gram negative,49 (70) MDR, gram negative, 43 (69) 0.003* 1.000*
ESBL producers, 3 (3) ESBL producers, 9 (10) ESBL producers, 3 (3) 0.032† 0.134†
Respiratory infection, 215 patients with microbiologic documentation
107 (100) 29 (100) 79 (100)
S. pneumoniae, 58 (54) MRSA, 7 (24) MRSA, 19 (24) <0.001† 0.042†
Haemophilus influenza, 14 (13) S. pneumoniae, 5 (17) Pseudomonas aeruginosa, 
14 (18)
MSSA, 5 (5) Pseudomonas aeruginosa, 
4 (14)
MSSA, 8 (10)
Acinectobacter baumannii, 
8 (10)
Others, 26 (24) Others, 9 (31) Others, 24 (30)
Polymicrobial, 4 (4) Polymicrobial, 4 (14) Polymicrobial, 6 (8) 0.077† 1.000†
MDR, 11 (10) MDR,12 (41) MDR, 45 (57) 0.001* 0.453*
Bloodstream infections (primary and secondary), 153 patients with microbiologic documentation
57 (100) 50 (100) 46 (100)
E. coli, 22 (39) E. coli, 16 (32) MRSA, 8 (17) <0.001† 0.001†
S. pneumoniae, 17 (30) MSSA, 13 (26) E. coli, 4 (9)
Enterococcus faecium, 4 (9)
MSSA, 4 (9)
Pseudomonas aeruginosa, 4 (9)
Staphylococcus epidermidis, 4 (9)
Others, 18 (31) Others, 19 (38) Others, 14 (30)
Polymicrobial, 0 (0) Polymicrobial, 2 (4) Polymicrobial, 4 (9) 0.422†
MDR, 17 (30) MDR, 24 (50) MDR, 36 (86) 0.073* 0.341*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, MRSA – Methicillin resistant Staphylococcus aureus,
MSSA – Methicillin sensitive Staphylococcus aureus, MDR – multidrug resistant microorganism.  
*Chi-square test; †Fisher exact test.
Off the 31 patients with IAI (14% of all HCAI): 23 (74%) had microbiological confirmation, being 17
(74%) monomicrobial and off those 6 (35%) were caused by gram-negative bacilli. Among the
gram-negative bacilli the resistance rates were 33% to ciprofloxacin, 33% to amoxicillin-clavu-
lanate, 17% to gentamicin and 17% to 3rd generation cephalosporins. No resistance to piperacillin-
tazobactam, trimethroprim-sulfamethoxazole, amikacin or carbapenem was observed.
In patients with UTI the most prevalent pathogen was also E. coli, followed by Proteus mirabilis in
CAI, Klebsiella pneumoniae in HCAI and Pseudomonas aeruginosa in HAI. There was an increasing
prevalence of polymicrobial infections from CAI (4%), to HCAI (16%, p=0.002) and HAI (22%,
p=0.270). The proportion of MDR-gram-negatives was also higher in HCAI (70%) and HAI (69%,
p=1.000) than in CAI (47%, p = 0.003). In HCAI there was a higher prevalence of ESBL producers
(10%) than in CAI (3%, p=0.032) or HAI (3%, p=0.134) (table 4.2.4). 
There were 102 patients with UTI (45% of all HCAI); off those 92 (90%) had microbiological confir-
mation being 77 (84%) monomicrobial. In monomicrobial HCAI-UTI, 70 (91%) were caused by
gram-negative bacilli. Among the group of gram-negative bacilli, resistance rates were: 50% to
trimethroprim-sulfamethoxazole, 49% to ciprofloxacin, 24% to amoxicillin-clavulanate, 13% to
gentamicin, 3% to 3rd generation cephalosporins, 1% to piperacillin-tazobactam and 1% to car-
bapenem. No resistance to amikacin was observed. 
In patients with respiratory infection the most prevalent pathogens were Streptococcus pneumo-
niae and Haemophilus influenza in CAI and MRSA and Pseudomonas aeruginosa in HCAI and HAI.
Patients with HCAI had a higher rate of polymicrobial infections (14%) than those with CAI (4%)
or HAI (8%) (table 4.2.4).
A significant association of MRSA respiratory infection (n=26) and hospitalization in the previous
year [adjusted OR = 6.3; CI95% (2.3-17.0)], previous instrumentation [adjusted OR = 4.3; CI95% (1.5-
12.8)] and previous antibiotic therapy [adjusted OR = 5.7; CI95% (1.7-18.8)] was found. No cases of
MRSA respiratory infection were documented in patients without those risk factors.
In patients with BSI the most prevalent pathogens were E. coli and Streptococcus pneumoniae in
CAI, E. coli and MSSA in HCAI and MRSA, E. coli, Enterococcus faecium, MSSA, Pseudomonas aerugi-
nosa and Staphylococcus epidermidis in HAI. There was an increasing prevalence of polymicrobial
infection from 0% in CAI, to 4% in HCAI and 9% in HAI (table 4.2.4).
There were 21 (9%) primary HCAI-BSI, all monomicrobial, with MSSA accounting for 62%,
Enterococcus faecium for 10% and Citrobacter freundii for another 10% of all cases. Gram-negative
bacilli were present in 4 patients (19%). MRSA was the responsible pathogen in only 1 case. No
fungal or polymicrobial infections were found among this group. 
Out of the CAI group, only 4 patients had primary BSI. All infections were monomicrobial with dif-
ferent pathogens.
In HAI there were 32 episodes (10%) of primary BSI. MRSA was the predominant agent (19%), fol-
lowed by Pseudomonas aeruginosa (12%), MSSA (12%) and Staphylococcus epidermidis (12%).
Polymicrobial infections were present in 2 patients (6%), and fungal infection in 1.
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Patients with HCAI respiratory infection had an increased rate of inadequate antibiotic therapy
(52%) by comparison with CAI (5%) and HAI (30%); they also had a significantly higher mortality
rate (20%) than those with CAI (9%, p=0.011) (table 4.2.5).
No significant differences in crude hospital mortality were observed in the remaining focus of
infection (table 4.2.5).
Hospital LOS was higher in HAI when compared to CAI or HAI (table 4.2.5).
DISCUSSION
This study confirms that healthcare-associated infections have distinct microbiological profiles
when compared with CAI and HAI, considering the overall profiles and the rates of resistance. 
Previous studies have been restricted to respiratory, urinary and BSI [2-8, 19]. Our study broadens the
clinical application of the new classification of HCAI to include intra-abdominal infections. The
need for studies in this area is clearly stated in the 2007 HCAI summit [20] where experts declare
that “no studies specifically related to healthcare-associated infections were identified” and that
“future studies will need to be conduct to examine whether healthcare-associated IAI should be
delineated as a separate category of IAI before specific recommendations can be made”. They are
fundamental for understanding the microbiological profile involved in each focus of infection,
according to place of acquisition, in order to develop up-to-date recommendations for adequate
initial empirical antibiotic treatment, a well-known prognostic factor [3, 21]. 
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Table 4.2.5 – Hospital length of stay and crude hospital mortality rate for infections, according to focus of infection and
place of acquisition 
Intra-abdominal infections Total CAI HCAI HAI HCAI vs. CAI
p value
HCAI vs. HAI
p value
Inadequate antibiotic therapy, n (%) 24 (19) 6 (13) 3 (13) 15 (27) 1.000† 0.245†
Hospital LOS (days), median (IQR) 14 (7-25) 8 (5-20) 13 (8-24) 22 (13-33) 0.022‡ 0.154‡
Hospital mortality, n (%) 29 (14) 9 (9) 3 (10) 17 (22) 1.000† 0.177†
Urinary infections
Inadequate antibiotic therapy, n (%) 69 (23) 25 (21) 26 (28) 18 (19) 0.249* 0.115*
Hospital LOS (days), median (IQR) 11 (7-17) 9 (6-13) 9 (6-13) 19 (11-37) 0.923‡ <0.001‡
Hospital mortality, n (%) 35 (10) 14 (10) 12 (12) 9 (9) 0.662* 0.489*
Respiratory infections
Inadequate antibiotic therapy, n (%) 44 (21) 5 (5) 15 (52) 24 (30) <0.001* 0.041*
Hospital LOS (days), median (IQR) 11 (8-22) 10 (8-18) 10 (7-13) 21 (24-39) 0.054‡ <0.001‡
Hospital mortality, n (%) 63 (15) 22 (9) 14 (20) 27 (26) 0.011* 0.382*
Bloodstream infections
Inadequate antibiotic therapy, n (%) 26 (17) 6 (11) 7 (14) 13 (28) 0.583* 0.086*
Hospital LOS (days), median (IQR) 15 (9-28) 12 (8-23) 10 (8-16) 30 (22-48) 0.229‡ <0.001‡
Hospital mortality, n (%) 25 (16) 9 (16) 5 (10) 11 (24) 0.395* 0.068*
All patients included in the study
Inadequate antibiotic therapy, n (%) 148 (21) 37 (14) 45 (27) 66 (25) <0.001* 0.601*
Hospital LOS (days), median (IQR) 11 (7-22) 10 (7-17) 10 (7-14) 23 (12-39) 0.876‡ <0.001‡
Hospital mortality, n (%) 138(13) 47 (10) 32 (14) 59 (19) 0.063* 0.173*
LOS – length of stay, IQR – inter-quartile range, *chi-squire test, † Fisher exact test, ‡Mann-Whitney-U-Test.
In IAI - HCAI, polymicrobial infections played an important role as well as MDR gram-negatives.
The IDSA guidelines for diagnosis and management of complicated intra-abdominal infection [22]
recommend an antipseudomonal cephalosporin, carbapenem or β-lactam/β-lactamase inhibitor
plus metronidazol, for IAI - HCAI. Based in our results these recommendations would be appropri-
ate for our group of patients. 
In UTI-HCAI, we found a high rate of MDR gram-negative bacilli (70%). The HCAI Summit Critical
Appraisal [20] suggested that serious HCAI due to suspected gram-negative bacteria, independent-
ly of the site of infection, should be treated empirically with dual coverage that includes amino-
glycosides. That broad approach may not be needed in our group of patients with UTI and IAI, due
to the lower rate of resistance to piperacillin-tazobactam observed. The rate of ESBL producers is
still low (10%), thus not justifying empirical coverage among our patients.
Our data on respiratory infections provides further evidence for the application of ATS and IDSA
recommendations [20, 23], with empirical coverage of Pseudomonas aeruginosa. However regarding
MRSA coverage, although it was the second more prevalent pathogen in HCAI and HAI respirato-
ry infections, it was found only in patients with identified risk factors: previous instrumentation,
hospital admissions in the previous year or previous antibiotic therapy. No MRSA respiratory infec-
tions were diagnosed in patients without any of those risk factors. So empirical coverage of MRSA
is only justified in patients with HCAI and previous risk factors for infection by this pathogen.
Regarding BSI clinicians must considerer whether the likely bacteremia reflects a primary process
or results secondarily from an infection elsewhere. This distinction is not always made in epidemi-
ological studies [1, 2, 24, 25], but it is fundamental for initial antibiotic treatment planning. 
We selected the definition of HCAI that is most frequently found in the literature [1, 5, 6]. This allowed
us to compare our results to those of other studies, but this concept is clearly an evolving topic.
The prospective design of this study, with consensual definitions in the protocol, the inclusion of
different wards of the hospital including intensive care and of the four major focus of infection
with a thorough comparison of those with HCAI with those with CAI and HAI, allowed a more clear
microbiology characterization.
This study had a thorough data collection made by a single trained doctor allowing full comple-
tion of all protocols with no missing data per item, along with a complete follow up of all patients
until hospital discharge, minimizing any information bias. 
Despite being a single-centre study, the microbiological profile we describe for respiratory HCAI
is very similar to the one described in the USA [3, 19] . The microbiological profile found in BSI was
similar to the descriptions in Canadian [5], Spanish [7] and USA [2] studies suggesting that our results
might be generalized for other settings. 
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CONCLUSIONS
Our results confirm that HCAI have a unique microbiological profile and higher rates of resistance,
when compared with CAI and HAI, for the four main focus of infection. Failure to recognize this
may lead to adverse outcomes as a result of an increased risk of treatment failure.
Physicians need to be aware of this new classification of infections for patients from the commu-
nity that have previous exposure to the healthcare system for which the existing guidelines may
not apply.
Further research involving a large number of patients from different institutions and geographic
areas is warranted to confirm our findings and evaluate the need to develop specific guidelines
for this new group of patients.
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4.3. THE IMPACT OF HEALTHCARE-ASSOCIATED INFECTIONS ON 
MORTALITY: FAILURE IN CLINICAL RECOGNITION IS RELATED WITH
INADEQUATE ANTIBIOTIC THERAPY
ABSTRACT
Background: To understand if clinicians can tell apart patients with healthcare-associated infec-
tions (HCAI) from those with community-acquired infections (CAI) and to determine the impact
of HCAI in the adequacy of initial antibiotic therapy and hospital mortality. 
Methods: One-year prospective cohort study including all consecutive infected patients admit-
ted to a large university affiliated tertiary care hospital. 
Findings: A total of 1035 patients were included in this study. There were 718 patients admitted
from the community: 225 (31%) with HCAI and 493 (69%) with CAI. Total microbiologic documen-
tation rate of infection was 68% (n=703): 56% in CAI, 73% in HCAI and 83% in hospital-acquired
infections (HAI). Antibiotic therapy was inadequate in 27% of patients with HCAI vs. 14% of
patients with CAI (p<0.001). Among patients with HCAI, 47% received antibiotic therapy in accor-
dance with international recommendations for treatment of CAI. Antibiotic therapy was inade-
quate in 36% of patients with HCAI whose treatment followed international recommendations for
CAI vs. 19% in the group of HCAI patients whose treatment did not follow these guidelines
(p=0.014). Variables independently associated with inadequate antibiotic therapy were:
decreased functional capacity (adjusted OR = 2.24), HCAI (adjusted OR = 2.09) and HAI (adjusted
OR = 2.24). Variables independently associated with higher hospital mortality were: age (adjusted
OR = 1.05, per year), severe sepsis (adjusted OR = 1.92), septic shock (adjusted OR = 8.13) and inad-
equate antibiotic therapy (adjusted OR = 1.99). 
Conclusions:HCAI was associated with an increased rate of inadequate antibiotic therapy but not
with a significant increase in hospital mortality. Clinicians need to be aware of healthcare-associ-
ated infections among the group of infected patients arriving from the community since the
existing guidelines regarding antibiotic therapy do not apply to this group and they will other-
wise receive inadequate antibiotic therapy which will have a negative impact on hospital out-
come. 
KEY WORDS: healthcare-associated infection; inadequate antibiotic therapy; hospital mortality
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INTRODUCTION
According to the 2012 World Health Organization report, infections are among the top three lead-
ing causes of death worldwide [1], with community-acquired infections playing a major role.
At the end of the XXth century, there was a significant increase in the healthcare service provided
in the outpatient setting. As a consequence, the debate about the need to add a third category
named “healthcare-associated infections” [2-4] to the existing dichotomic classification of commu-
nity- and hospital-acquired infections, arose.
The classification of healthcare-associated infection proposed by Deborah Friedman and col-
leagues in 2002 [2], is one of the most widely used in clinical studies. According to theme, it is an
infection present at the time of hospital admission or within 48 hours of admission, in patients
who fulfill any of the following criteria:
– Received intravenous therapy at home, wound care or specialized nursing care through a
healthcare agency, family or friends; or, self-administered intravenous medical therapy in
the 30 day period before the onset of the infection. Patients whose only home therapy was
oxygen use are excluded.
– Attended a hospital or haemodialysis clinic, or received intravenous chemotherapy in the
previous 30 days.
– Were hospitalized in an acute care hospital for 2 or more days in the previous 90 days.
– Resided in a nursing home or long-term care facility.
Since then, several studies have shown that the microbiologic profiles of healthcare-associated
infections differ from those of community-acquired infections [2-4], and that this needs to be taken
into account when prescribing first intention antibiotic therapy. If healthcare-associated infection
is not recognized as a separate group among infected patients from the community, it might lead
to inadequate first intention antibiotic therapy and worsen the prognosis.
The objectives of this study are: to understand if doctors differentiate between patients with
healthcare-associated infections and those with community-acquired infections and to deter-
mine the impact of healthcare-associated infection in the adequacy of initial antibiotic therapy
and hospital mortality. 
METHODS
Ethics statement
This study was approved by the Institutional Review Board of Hospital de Santo António, Oporto
Hospital Centre, Portugal, and informed consent was waived due to the observational nature of
the study.
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Study design and patient population
A prospective cohort study was conducted in a 600-bed tertiary care university affiliated hospital
over the period of 1 year (1st June 2008 to 31th May 2009). All adult infected patients who were
admitted to the medical, surgical, nephrology or hematology wards of the hospital or to the inten-
sive care unit (ICU), whose infection fulfilled the CDC criteria [5], were included. Infections were
classified as community-acquired (CAI), healthcare-associated (HCAI) or hospital-acquired (HAI),
according to the place of acquisition. 
Definitions
Community-acquired infections (CAI) were defined as infections detected within 48 hours of
hospital admission in patients who did not fit the criteria for a HCAI.
Healthcare-associated infections (HCAI) were defined by the same criteria that Deborah
Friedman and colleagues used for HCAI bloodstream infections [2], regardless of the involved focus
of infection. This choice was based on the fact that this definition is widely used in similar studies
and is not limited to bloodstream infections, but can also be applied to respiratory and specific
pathogen infections [6-11].
Hospital-acquired infections (HAI) were defined as a localized or systemic condition that result-
ed from an adverse reaction to the presence of an infectious agent(s) or its toxin(s), that occurred
within 48 hours or more after hospital admission and that was not incubating at the time of
admission [12]. Infections in patients discharged from the hospital within the previous 2-week peri-
od were also included in this group.
The comorbidities of patients in the study included immunosuppression (administration of
chemotherapy in the 12 months prior to hospital admission, either radiation therapy or adminis-
tration of 0.2 mg/kg/day prednisolone for at least 3 months prior to hospital admission, adminis-
tration of 1mg/kg/day of prednisolone for 1 week in the 3 months prior to hospital admission or
infection with human immunodeficiency virus), chronic liver diseases [13], chronic heart failure [13],
chronic respiratory diseases [13], haematological diseases [14], cancer [14], diabetes mellitus requiring
insulin therapy or oral hypoglycaemic agents before the infection and/or atherosclerosis (defined
as a previous history of a transient ischemic attack, stroke, angina, myocardial infarction or periph-
eral arterial disease).
The general medical condition was assessed by the Karnofsky index [15]. A score of less than 70
implies that the patient is unable to perform normal activities or do active work.
“Hospitalization in the previous year” excluded patients already included in the group of patients
with HCAI; that is, those with hospital admissions in the previous 3 months.
Sepsis and sepsis-related conditions were diagnosed according to the criteria proposed by the
ACCP/SCCM [16].
The initial empirical antibiotic treatment was considered “adequate” if the antibiotic prescribed
within the first 24 hours matched in vitro susceptibility of a pathogen deemed to be the likely
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cause of infection and when the dosage and route of administration were appropriate for current
medical status (focus and severity of infection); only patients in which the pathogen was microbi-
ologically identified were considered in this analysis.
To evaluate if doctors treated healthcare-associated infections as community-acquired infections,
accordance of initial antibiotic therapy to the Infectious Diseases Society of America (IDSA) inter-
national recommendations for the treatment of community-acquired respiratory, urinary and
intra-abdominal infections was assessed [17-19].
Statistical analysis
Continuous variables are described as means and standard deviations (SD). Categorical variables
are described with absolute frequencies and percentages. Student T-tests or Mann-Whitney tests
were used to compare continuous values. For categorical variables these comparisons were per-
formed using Pearson χ2 test.
Variables associated with inadequate antibiotic therapy and hospital mortality were studied
using logistic regression. Those with a clear association in the univariate analysis (p-value < 0.1)
were selected for the multivariable analysis. The results of the multivariable models are expressed
as odds ratio (OR) with 95% confidence interval (CI95%) and p-values. The calibration was tested
using the Hosmer-Lemeshow goodness-of-fit test. The significance level was defined as p < 0.05.
Data was analyzed using SPSS, version 18 for Windows (Chicago, IL).
RESULTS
During the study period, a total of 3733 patients were admitted to the selected wards (103 beds);
1035 (28%) met the inclusion criteria of infections according to the CDC definitions of infection.
Of all patients included, 493 (48%) were diagnosed with CAI, 225 (22%) with HCAI and 317 (30%)
with HAI.
Patients with HCAI were older, with a higher prevalence of previous comorbidities and inability to
perform normal activities or do active work (Karnofsky index < 70) than patients in the other two
groups (p<0.05). They also had higher rate of admissions to hospital in the period between 3 and
12 months prior to the current episode, as well as previous antibiotic administration and inade-
quate antibiotic therapy, when compared to patients with CAI (p<0.001) (Table 4.3.1).
Total rate of microbiological documentation of infection was 68% (n=703): 73% (n=165) among
patients with HCAI, 56% (n=274) among those with CAI and 83% (n=264) in the group with HAI.
The empirical antibiotic therapy was changed in 92 patients (13%) among those with microbio-
logical documentation of infection (n = 703). The main reason for changing antibiotic therapy was
adjustment to microbiology findings: 81% (n = 26) in HCAI vs 83% (n = 20) in CAI vs 89% (n = 32)
in HAI. Other reasons for changing antibiotic therapy were a lack of clinical response in 11%
(n=10), side effects in 3% (n=3) and others in 1% (n=1).
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In HCAI, 27% had received inadequate antibiotic therapy vs. 14% in CAI (p<0.001). Among patients
with microbiologic documented HCAI, 47% (77) received antibiotic therapy according to interna-
tional recommendations for CAI. Antibiotic therapy was inadequate in 36% of HCAI patients
whose treatment followed the international recommendations for CAI vs. 19% in the group of
HCAI patients whose treatment did not follow CAI treatment guidelines (p=0.014).
The rate of inadequate antibiotic therapy among the four categories of HCAI was: 
– 33% in the group of patients that received intravenous therapy at home, wound care or
specialized nursing care through a healthcare agency, family or friends; or, self-adminis-
tered intravenous medical therapy in the 30 day period before the onset of the infection;
– 21% in the group of patients that attended a hospital or hemodialysis clinic, or received
intravenous chemotherapy in the previous 30 days;
– 30% in the group that were hospitalized in an acute care hospital for 2 or more days in the
previous 90 days and
– 36% in those that resided in a nursing home or long-term care facility.
Variables significantly and independently associated with inadequate antibiotic therapy were
Karnofsky index<70 [adjusted OR = 2.24 (CI95% = 1.47-4.41)], HCAI [adjusted OR = 2.09 (CI95% = 1.15-
3.80)] and HAI [adjusted OR = 2.24 (CI95% = 1.41-3.55)] (Tables 4.3.2).
Variables significantly and independently associated with higher hospital mortality were age
[adjusted OR = 1.05 (CI95% = 1.03-1.07), per year], severe sepsis [adjusted OR = 1.92 (CI95% = 1.01-
3.63)], septic shock [adjusted OR = 8.13 (CI95% = 3.84-17.23)] and inadequate antibiotic therapy
[adjusted OR = 1.99 (CI95% = 1.20-3.30)] (Table 4.3.3). 
The Hosmer and Lemeshow test did not show evidence of lack of fit in both models (p>0.1).
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Table 4.3.1 – Demographic and clinical characteristics of patients; comparing patients with healthcare-associated infec-
tions with patients with community or hospital-acquired infections
Patients’ characteristics TOTAL
(n = 1035)
HCAI
(n = 225)
CAI
(n = 493)
HAI
(n = 317)
HCAI vs. CAI
p value
HCAI vs. HAI
p value
Age, mean (SD) 65 (20) 68 (19) 64 (20) 64 (19) 0.015# 0.022#
Male sex, n (%) 506 (49) 108 (48) 236 (48) 162 (51) 0.974* 0.476* 
Severity of infection, n (%) 0.117* 0.243*
Infection 281 (27) 69 (31) 126 (26) 86 (27)
Sepsis 364 (35) 73 (32) 178 (36) 113 (36)
Severe sepsis 296 (29) 70 (31) 139 (28) 87 (27)
Septic shock 94 (9) 13 (6) 50 (10) 31 (10)
Previous comorbidities, n (%) 671 (65) 190 (84) 270 (55) 211 (67) <0.001* <0.001* 
Karnofsky index<70, (%) 319 (31) 112 (50) 115 (23) 106 (33) <0.001* <0.001* 
Hospitalization in the previous
year (excluding the last 3
months, n (%)
413 (40) 55 (43) 91 (19) 174 (55) <0.001* 0.027*
Previous antibiotic therapy, 
n (%)
367 (36) 86 (38) 51 (10) 230 (73) <0.001* <0.001* 
Inadequate antibiotic therapy, 
n (%)
148 (21) 45 (27) 37 (14) 66 (25) <0.001* 0.601*
Hospital mortality, n (%) 138 (13) 32 (14) 47 (10) 59 (19) 0.063* 0.178*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, SD – Standard deviation.  *Pearson Qui-square Test; #
T-student test.
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Table 4.3.2 – Variables associated with inadequate antibiotic therapy using logistic regression 
Variables Total
n = 703
Inadequate antibiotic 
therapy n = 148
Crude OR CI95% p- value
*Increase in OR per year; OR – Odds ratio; CI95% - 95% confidence interval
Chronic respiratory disease, n (%)
No 661 (94) 41 (95) 1.00
Yes 42 (6) 7 (5) 0.748 0.32-1.70 0.474
Chronic haematologic disease, n (%)
No 652 (93) 135 (91) 1.00
Yes 51 (7) 13 (9) 1.31 0.70-2.53 0.421
Cancer, n (%)
No 670 (95) 136 (92) 1.00
Yes 33 (5) 12 (8) 2.24 1.08-4.67 0.031
Diabetes, n (%)
No 558 (79) 119 (80) 1.00
Yes 145 (21) 29 (20) 0.92 0.59-1.45 0.727
Atherosclerosis, n (%)
No 539 (77) 101 (68) 1.00
Yes 162 (23) 47 (32) 1.74 1.17-2.60 0.007
Karnovsky index<70, n (%)
No 479 (68) 80 (54) 1.00
Yes 224 (32) 68 (46) 2.17 1.50-3.16 <0.001
Type of infection
Community-acquired, n (%) 274 (39) 37 (25) 1.00
Healthcare-associated, n (%) 165 (23) 45 (30) 2.40 1.48-3.91 <0.001
Hospital-acquired, n (%) 264 (38) 66 (45) 2.14 1.37-3.33 0.001
Focus of infection
Respiratory, n (%) 215 (31) 44 (30) 1.00
Urinary, n (%) 306 (43) 69 (47) 1.13 0.74-1.73 0.570
Intra-abdominal, n (%) 124 (18) 24 (169) 0.93 0.55-1.63 0.806
Other, n (%) 58 (8) 11 (7) 0.91 0.44-1.90 0.801
Severity of infection
Infection, n (%) 191 (27) 41 (28) 1.00
Sepsis, n (%) 238 (34) 53 (36) 1.05 0.66-1.66 0.842
Severe sepsis, n (%) 209 (30) 43 (29) 0.95 0.59-1.53 0.827
Septic shock, n (%) 65 (9) 11 (7) 0.75 0.36-1.55 0.433
Age, mean (SD) 65 (19) 69 (17) 1.02* 1.001-1.03 0.063
Sex, n (%)
Female 363 (52) 75 (51) 1.00
Male 340 (48) 73 (49) 1.05 0.73-1.51 0.793
Previous antibiotic therapy, n (%)
No 414 (59) 74 (50) 1.00
Yes 289 (41) 74 (50) 1.58 1.10-2.28 0.014
Hospitalization in the previous year 
(excluding the last 3 months), n (%)
No 389 (62) 64 (50) 1.00
Yes 241 (38) 64 (50) 1.83 1.24-2.72 0.001
Comorbidities, n (%)
No 222 (32) 38 (26) 1.00
Yes 481 (68) 110 (74) 1.44 0.95-2.16 0.083
Immunosupression, n (%)
No 529 (75) 115 (78) 1.00
Yes 174 (25) 33 (22) 0.84 0.55-1.30 0.437
Chronic hepatic disease, n (%)
No 686 (98) 143 (97) 1.00
Yes 17 (2) 5 (3) 1.58 0.55-4.56 0.396
Chronic heart failure, n (%)
No 653 (93) 134 (90) 1.00
Yes 50 (7) 14 (10) 1.51 0.79-2.87 0.214
DISCUSSION
The results of this study show that doctors treat a high proportion (47%) of patients with health-
care-associated infections according to community-acquired infections treatment recommenda-
tions, implying that they do not differentiate this sub-group of patients among those with com-
munity-acquired infections.
Patients with healthcare-associated infections who were treated according to the international
recommendations for community-acquired infections had a higher rate of inadequate antibiotic
therapy than those in whom CAI treatment recommendations were not followed. Healthcare-
associated infections were independently associated with inadequate antibiotic therapy.
Inadequate antibiotic therapy was an independent risk factor for increased hospital mortality.
Decision making regarding antibiotic treatment is unique, no treatment equals its efficacy. In the
meta-analysis on the efficacy of adequate antibiotic therapy for sepsis, by Paul et al [20], the pooled
OR for all-cause mortality was 1.6, corresponding to a number needed to treat (NNT) of 10 to save
one life, higher than aspirin in acute myocardial infarction (NNT= 41), reinforcing the need to get
initial antibiotic therapy adequate in severe infection.
The adequate treatment of healthcare-associated infections is primarily dependent on the correct
classification in patients that come from the community as CAI or HCAI. Previous studies [2-4] have
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Table 4.3.3 – Variables associated with hospital mortality using logistic regression 
Variables Hospital 
mortality
Crude OR CI95% p- value Adjusted OR CI95%
Age, mean (SD) 76 (14) 1.04* 1.03-1.06 <0.001 1.05* 1.03-1.07
Sex, n (%) 0.036
Female 59 (43) 1.00
Male 79 (57) 1.47 1.03-2.12
Previously healthy, n %) <0.001
Yes 30 (22) 1.00
No 108 (78) 2.14 1.39-3.27
Type of infection
Community-acquired, n (%) 47 (34) 1.00
Healthcare-associated, n (%) 32 (23) 1.57 0.97-2.54 0.064
Hospital-acquired, n (%) 59 (43) 2.17 1.44-3.28 <0.001
Focus of infection
Respiratory, n (%) 63 (4615) 1.00
Urinary, n (%) 35 (2510) 0.64 0.41-0.99 0.047
Intra-abdominal, n (%) 29 (2114) 0.89 0.55-1.43 0.632
Other, n (%) 11 (819) 0.18 0.64-2.63 <0.001
Severity of infection
Infection, n (%) 20 (157) 1.00
Sepsis, n (%) 30 (228) 1.17 0.65-2.11 0.597 0.980 0.50-1.92
Severe sepsis, n (%) 46 (3316) 2.40 1.38-4.17 0.002 1.919 1.014-3.632
Septic shock, n (%) 42 (3045) 10.54 5.73-19.40 <0.001 8.133 3.839-17.231
Inadequate antibiotic 
therapy,  n (%)
32 (32) 2.01 1.26-3.21 0.003 1.991 1.204-3.295
*Increase in OR per year; OR – Odds ratio; CI95% - 95% confidence interval
shown that patients with HCAI have different microbiological profiles than those with CAI, name-
ly a higher rate of multi-drug resistant pathogens [21], suggesting that the existing guidelines for
CAI might not be applicable. Clinicians need to be aware of this difference in order to adapt empir-
ic antibiotic therapy for HCAI patients.
There are a large number of epidemiological studies on healthcare-associated infections [3, 4, 6, 7, 9, 21-
23] but the existing evidence needs to be systematized, in order to make information more prof-
itable. Respiratory infections are the ones most widely addressed and the American Thoracic
Society has already published specific recommendations for healthcare-associated pneumonia
[24]; nevertheless, the wide-spectrum antibiotic therapy proposed for these patients has turned
into a much debated subject where there is no consensus among clinicians. Additional studies are
needed in this area, with thorough microbiologic characterization from different settings, before
specific recommendations regarding empirical treatment for different focus of HCAI can be made.
HCAI was not found to be an independent risk factor for hospital mortality although the associa-
tion of HCAI and higher mortality was described in the studies by Kollef et al [3] and Shorr et al [4].
However, none of them perform a multiple logistic regression to allow the statement of HCAI as
an independent risk factor, as it was done in the present study. 
There are several studies describing the negative impact of initial inadequate antibiotic therapy
on mortality [25-32]. The results of the present study are in accordance with previous findings, from
different centres and geographical areas, increasing the probability of wide external applicability
of the main results.
Major strengths of this study are its prospective design with thorough data collection, the use of
clear definitions in the protocol, data collection by a single trained doctor and full completion of
all protocols with no missing data per item minimizing any information bias. Additionally, all
patients completed the follow-up until hospital discharge.
There are also some limitations that should be pointed out. The research was performed in a sin-
gle institution and the number of patients with HCAI was relatively low. Only 68% of the patients
had microbiologic documentation of infection and were evaluated for the adequacy of empirical
antibiotic therapy; this may limit the logistic regression analysis in terms of its ability to detect all
independent variables associated with inadequate antibiotic therapy and outcome. Nevertheless,
the variables found were clinically significant and relevant, easily recognizable, and could function
as additional aids to avoid inadequate therapy.
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CONCLUSIONS
HCAI were associated with an increased rate of inadequate antibiotic therapy, but not with a sig-
nificant increase in hospital mortality. 
Clinicians need to be aware of healthcare-associated infections among the group of infected
patients arriving from the community, as the existing guidelines regarding antibiotic therapy do
not apply to them. This is essential in order to prevent the associated inadequate antibiotic ther-
apy and its negative impact on hospital outcome.
The development of specific guidelines for this group of infected patients should be considered.
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4.4. PREDISPOSITION, INSULT/INFECTION, RESPONSE AND ORGAN
DYSFUNCTION (PIRO): A PILOT CLINICAL STAGING SYSTEM FOR 
HOSPITAL MORTALITY IN PATIENTS WITH INFECTION
ABSTRACT
Background:To develop a clinical staging system based on the PIRO concept (Predisposition, type
of Insult/Infection, Response and Organ dysfunction) for hospitalized patients with infection.
Methods: One year prospective cohort study of all hospitalized patients with infection (n=1035),
admitted into a large tertiary care, university hospital. Variables associated with hospital mortali-
ty were selected using logistic regressions. Based on the regression coefficients, a score for each
PIRO component was developed and a classification tree was used to stratify patients into four
stages of increased risk of hospital mortality. The final clinical staging system was then validated
using an independent cohort (n=186).
Results: Factors significantly associated with hospital mortality were 
· for Predisposition: age, sex, previous antibiotic therapy, chronic hepatic disease, chronic hema-
tologic disease, cancer, atherosclerosis and a Karnofsky index<70;
· for Insult/Infection: type of infection 
· for Response: abnormal temperature, tachypnea, hyperglycemia and severity of infection and 
· for Organ dysfunction: hypotension and SOFA score≥1. 
The area under the ROC curve (CI95%) for the combined PIRO model as a predictor for mortality was
0.85 (0.82-0.88). Based on the scores for each of the PIRO components and on the cut-offs estimat-
ed from the classification tree, patients were stratified into four stages of increased mortality rates:
stage I: ≤5%, stage II: 6-20%, stage III: 21-50% and stage IV: >50%. Finally, this new clinical staging
system was studied in a validation cohort, which provided similar results (0%, 9%, 31% and 67%,
in each stage, respectively).
Conclusions: Based on the PIRO concept, a new clinical staging system was developed for hospi-
talized patients with infection, allowing stratification into four stages of increased mortality, using
the different scores obtained in Predisposition, Response, Infection and Organ dysfunction. The
proposed system will likely help to define inclusion criteria in clinical trials as well as tailoring indi-
vidual management plans for patients with infection.
KEY WORDS: infection, prognosis, hospital outcome, PIRO scoring system, PIRO clinical staging
system.
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INTRODUCTION
According to the 2012 World Health Organization report, infections are among the top three lead-
ing causes of death worldwide [1]. Developing new therapies for sepsis has been particularly chal-
lenging and the successive failures have been attributed to the inclusion of a very heterogeneous
group of patients. 
In 2001, the American College of Chest Physicians and the Society of Critical Care Medicine con-
vened a consensus panel, where John Marshall et al. [2] suggested an approach of sepsis similar to
the TNM (tumor, nodes and metastases) staging system [3], used for cancer patients both as a prog-
nostic tool and for individualizing therapy. This led to the PIRO concept, which attempts to char-
acterize sepsis across four components: P for ‘Predisposition (P), I for ‘Insult/Infection (I), R for
‘Response (R) and O for ‘Organ dysfunction (O) [2, 4].
This challenging concept took some time before being adopted by the scientific community and
was only recently tested in the clinical field. Different approaches have been published, a model
development [5, 6] and a scoring system [7-9] solely for patients in the intensive care unit (ICU) set-
ting; a score for patients with suspected infection admitted from the Emergency department [10]
and finally a study that developed a staging system [11] but solely for patients with severe sepsis
and not considering all the originally proposed variables.
The need for a clinical staging system applicable to all hospitalized patients with confirmed infec-
tion remained. This would help stratifying patients at risk, assess criteria for specific therapies, pre-
dict outcomes and assist in rational enrolment into clinical studies.
The objective of this study was to develop a clinical staging system based on the PIRO concept
through a prospective cohort study in a diverse population of patients with infection on hospital
admission or throughout their hospital stay. The derived clinical staging system is validated in an
independent cohort.
PATIENTS AND METHODS
A prospective cohort study was conducted in a 600-bed tertiary care university affiliated hospital
over a 1-year period (1st June 2008 to 31th May 2009). All adult (age≥18 years) infected patients
consecutively admitted to the medical, surgical, nephrology or hematology wards of the hospital,
or to ICU were included in the first 24 hours of the diagnosis of infection according to the CDC cri-
teria [12].
The data collected included all variables defined in the extended sepsis criteria [2] which were
grouped according to each PIRO component as follows. 
1. Predisposing factors (‘P’) analyzed included: age, sex, season of admission, previous antibi-
otic therapy (any antibiotic administration with therapeutic intention in the previous
month), hospitalization in the previous year, previous instrumentation, Karnofsky index [13] (a
value lower than 70 means inability to carry out normal activity or do active work) and pre-
morbid conditions. Chronic morbidities recorded were: immunosuppression (administration
124 | HEALTHCARE-ASSOCIATED INFECTIONS: CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
C
H
A
PTER 4.4
of chemotherapy, radiation therapy during 12 months prior to hospital admission or the
equivalent of 0.2mg/Kg/day prednisolone for at least 3 months or 1mg/Kg/day for a week
during 3 months prior to hospital admission or human immunodeficiency virus infection),
chronic hepatic disease [14], chronic heart failure [14], chronic respiratory disease [14], hemato-
logic disease [15], cancer [15], chronic renal failure (if there was need for chronic renal support
or a history of chronic renal insufficiency with a serum creatinine level over 2mg/dl), diabetes
mellitus (if insulin therapy or oral anti-diabetic drugs were required before the infection)
and/or atherosclerosis (if there was a previous history of transient ischemic attack, stroke,
angina, myocardial infarction or peripheral arterial disease).
2. Insult/Infection (‘I’) was characterized by: type of infection, categorized as either communi-
ty-acquired (CAI), if the infection was detected within 48 hours of hospital admission in
patients who did not fulfill the criteria for a healthcare-associated infection; healthcare asso-
ciated (HCAI - using the same criteria that Deborah Friedman used for healthcare associated
bloodstream infections regardless of the involved focus of infection) [16] or hospital-acquired
(HAI) [12]; focus of infection (categorized as respiratory [12], urinary [12], intra-abdominal [12], or
others); microbiology documentation of infection; presence of bacteremia (primary or sec-
ondary) [17] and pathogen identification, classified by category (Gram negative, Gram posi-
tive, fungus or poly-microbial).
3. Host Response variables (‘R’) included: abnormal temperature (fever or hypothermia),
tachypnea, tachycardia, abnormal white blood cells count (leukocytosis, leucopenia), altered
consciousness, hyperglycemia in the absence of diabetes, peripheral edema, high serum C-
reactive protein and severity of infection as defined in the 2001 SCCM/ESICM/ACCP/ATS/SIS
International Sepsis Definitions Conference (infection, sepsis, severe sepsis or septic shock at
presentation [2]).
4. Organ dysfunction (‘O’) was assessed by the following variables: hypoxemia, hypotension, high
serum lactate, renal dysfunction, high bilirubin, low platelet count, ileus, coagulopathy and total
SOFA score [18].
A second cohort was established to validate the proposed clinical staging system. Data for the val-
idation cohort were retrospectively collected and included all patients admitted to the same
wards between 1st December 2011 and 31st January 2012 as the derivation cohort, using the same
inclusion criteria.
The primary outcome of interest was in-hospital mortality. All patients had complete follow-up
until hospital discharge in both cohorts.
This study was approved by the institutional review board (which includes the Ethics for Health
Committee) of Hospital de Santo António, Oporto Hospital Centre, Portugal, and informed con-
sent from the participants was waived due to its purely observational nature.
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Statistical analysis
Continuous variables were described as means and standard deviations (SD) or as medians and
inter-quartile ranges (IQR) if they showed a skewed distribution. Categorical variables were
described with absolute frequencies and percentages. Student T-tests or Mann-Whitney tests
were used to compare continuous values between survivors and non-survivors. For categorical
variables, these comparisons were performed using Pearson χ2 test. 
To build the prediction models for P, I, R and O, variables with marginal association with mortality
in the univariate analysis (p value < 0.2) were screened for the multivariate analysis. Four separate
logistic regression models - one for each component “P”, “I”, “R” and “O” – were built using stepwise
selection on the variables screened in the previous phase. Once the models were fitted, four
scores for each patient were computed, representing the probability of death predicted by each
model. The four scores were combined into a logistic regression referred to as "combined PIRO".
The results of the multivariable models are expressed as odds ratio (OR) with 95% confidence
interval (CI95%) and p-values. The accuracy of the models was assessed by the area under receiver
operating characteristics curve (AU-ROC) and calibration was tested using the Hosmer-Lemeshow
goodness-of-fit test.
In order to simplify the computation of the scores for each component, the regression coefficients
were multiplied by two and rounded to the nearest integer. This simplified scoring system was
then used to compare the scores obtained directly from the derivation models with the non-
rounded coefficients. The AU-ROCs of the simplified version were identical to the derivation ones.
After obtaining the new scores for each PIRO component, a classification tree was used to define
cut-offs for component score and identify profiles of risk of death across the four PIRO compo-
nents. Each node split decision in the tree was chosen from the possible cut-offs for all compo-
nents, maximizing the within-node homogeneity according to Gini's coefficient [19] impurity meas-
ure, which is known to be closely related to both, the AU-ROC and the Mann-Whitney-U test [20].
A cross table with all possible profiles resulting from the combination of Predisposition, Infection,
Response and Organ dysfunction against hospital outcome was built and analyzed to yield the
final algorithm. In order to simplify the presentation of results, the profiles were further clustered
into four clinical stages according to the risk of death. 
The significance level for all tests was defined as p<0.05. Data were analyzed using SPSS, version
18 for Windows (Chicago, IL).
RESULTS
During the study period, a total of 3733 patients were assessed and 1035 (28%) met the inclusion
criteria for having infection according to the CDC definitions of infection and hence were includ-
ed in the study. Mean (SD) age was 65 (20) years and mean SAPS II was 29 (13), overall hospital
mortality rate was 13% (table 4.4.1). The median hospital length of stay in the derivation cohort
was 11 (7-22) days. A microbiological confirmation of infection was available in 68% of patients
(56% for CAI, 73% for HCAI and 83% for HAI).The validation cohort included 186 patients that were
significantly older, with a mean age of 69 (17) years and a mean SAPS II of 35 (15) (table 4.4.1).
126 | HEALTHCARE-ASSOCIATED INFECTIONS: CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
C
H
A
PTER 4.4
RESULTS | 127
C
H
A
PT
ER
 4
.4
Table 4.4.1 – Demographic and clinical characteristics of patients in the derivation and validation cohorts
Variables Derivation cohort 
(n=1035)
Validation cohort
(n=186)
p- value
Age in years, mean (SD) 65 (20) 69 (17) 0.002*
Male sex, n (%) 506 (49) 109 (59) 0.015#
ICU patients, n (%) 149 (14) 40 (22) 0.016#
SAPS II, mean (SD) 29 (13) 35 (15) <0.003*
Total SOFA, median (IQR) 1 (0-3) 2 (1-4) <0.001&
Hospital mortality, n (%) 138 (13) 34 (18) 0.085#
SD – standard deviation, IQR – interquartile range. SOFA – Sepsis-related Organ Failure Assessment *Independent samples t-test, #Pearson Cui-square Test; 
& Independent samples median test.
Table 4.4.2 – Association of variables of each of the four components of PIRO with hospital mortality using logistic
regression 
Predisposition Total, 
n (%)
Non-survivors, 
n (%)
Crude OR p- value
Age <0.001
≤60 years, n (%) 388 (38) 18 (5) 1.0
61-80 years, n (%) 387 (37) 63 (16) 4.0
>80 years, n (%) 260 (25) 57 (22) 5.8
Male sex, n (%) 506 (49) 79 (16) 1.5 0.036
Season
Spring, n (%) 260 (25) 25 (10) 1.0
Summer, n (%) 248 (24) 32 (13) 1.4 0.242
Autumn, n (%) 277 (27) 42 (15) 1.7 0.056
Winter, n (%) 249 (24) 39 (16) 1.7 0.041
Previous antibiotic therapy, n (%) 367 (36) 67 (18) 1.9 0.001
Hospitalization in the previous year, n (%) 413 (40) 65 (16) 1.4 0.064
Previous instrumentation, n (%) 373 (36) 67 (18) 1.8 0.001
Comorbidities, n (%) 671 (65) 108 (16) 2.1 <0.001
Immunosupression, n (%) 221 (21) 24 (11) 0.7 0.224
Chronic hepatic disease, n (%) 22 (2) 8 (36) 3.9 0.003
Chronic renal disease, n (%) 69 (7) 3 (4) 0.3 0.023
Chronic heart failure, n (%) 74 (7) 12 (16) 1.3 0.450
Chronic respiratory disease, n (%) 66 (6) 10 (15) 1.2 0.654
Chronic haematologic disease, n (%) 60 (6) 17 (28) 2.8 0.001
Cancer, n (%) 45 (4) 18 (40) 4.8 <0.001
Diabetes, n (%) 204 (20) 15 (7) 0.5 0.006
Atherosclerosis, n (%) 242 (23) 54 (22) 2.4 <0.001
Karnovsky index<70, n (%) 319 (31) 81 (25) 3.9 <0.001
SOFA - Sepsis-related Organ Failure Assessment, OR – Odds ratio
In table 4.4.2, a detailed description of patients’ characteristics and their association with hospital
mortality, according to the four components of PIRO, is shown. In table 4.4.3, variables independently
associated with hospital mortality according to each component of the PIRO concept are described.
Variables retained in the final model for predisposing factors (“P”) included age, gender, previous
antibiotic therapy, chronic hepatic disease, chronic hematologic disease, cancer, atherosclerosis and a
Karnofsky index <70. For those characterizing infection, (“I”), only the type of infection was retained.
Response (“R”) variables included abnormal temperature, tachypnea, hyperglycemia, and the severi-
ty of infection. Organ dysfunction (“O”) was characterized by hypotension and a SOFA score ≥1.
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Table 4.4.2 (continued) – Association of variables of each of the four components of PIRO with hospital mortality
using logistic regression 
Total, 
n (%)
Non-survivors, 
n (%)
Crude OR p- value
Infection
Type of infection 0.001
Community-acquired, n (%) 493 (48) 47 (10) 1.0
Healthcare-associated, n (%) 225 (22) 32 (14) 1.6
Hospital-acquired, n (%) 316 (30) 59 (19) 2.2
Focus of infection 0.140
Respiratory, n (%) 419 (40) 63 (15) 1.0
Urinary, n (%) 344 (33) 35 (10) 0.6
Intra-abdominal, n (%) 213 (21) 29 (14) 0.9
Other, n (%) 59 (6) 11 (19) 1.3
Primary bacteraemia, n (%) 57 (6) 10 (17) 1.4 0.338
Secondary bacteraemia, n (%) 96 (9) 15 (16) 1.3 0.489
Microbiology isolation, n (%) 703 (68) 99 (14) 1.2 0.303
Positive blood cultures, n (%) 154 (15) 25 (16) 1.3 0.252
Type of microorganism, n (%) 0.406
Gram negative, n (%) 384 (55) 48 (12) 1.0
Gram positive, n (%) 204 (29) 34 (17) 1.4
Fungi, n (%) 15 (2) 1 (7) 0.5
Polymicrobial, n (%) 100 (14) 16 (16) 1.3 0.410
Response
Temperature 0.006
No alteration, n (%) 461 (45) 57 (12) 1.0
Fever, n (%) 336 (33) 35 (10) 0.8
Hypothermia, n (%) 238 (22) 46 (19) 1.7
Tachypneia, n (%) 457 (44) 83 (18) 2.1 <0.001
Tachycardia, n (%) 620 (60) 96 (15) 1.6 0.013
Reactive C protein>5mg/dl, n (%) 923 (89) 126 (14) 1.3 0.389
White blood cells 0.360
No alteration, n (%) 425 (41) 56 (13) 1.0
Leucocytosis, n (%) 560 (54) 72 (13) 1.0
Leucopenia, n (%) 50 (5) 10 (20) 1.7
Altered conscious, n (%) 43 (4) 14 (33) 3.4 <0.001
Hyperglycemia, n (%) 159 (15) 38 (24) 2.4 <0.001
Severity of infection <0.001
Infection, n (%) 281 (27) 20 (7) 1.0
Sepsis, n (%) 364 (35) 30 (8) 1.2
Severe sepsis, n (%) 296 (29) 46 (15) 2.4
Septic shock, n (%) 94 (9) 42 (45) 10.5
Organ dysfunction
Hypoxemia , n (%) 267 (26) 57 (21) 2.3 <0.001
Hypotension, n (%) 175 (17) 63 (36) 5.9 <0.001
Lactacidemia>1mmol/L, n (%) 134 (13) 44 (33) 4.2 <0.001
Creatinine>2mg/dl or diuresis<0,5ml/Kg/h, n (%) 136 (13) 32 (23) 2.3 <0.001
Bilirubin>4mg/dl, n (%) 20 (2) 5 (25) 2.2 0.131
Platelets<100.000, n (%) 96 (9) 26 (27) 2.7 <0.001
Ileus, n (%) 5 (1) 3 (60) 9.9 0.012
Coagulopathy (INR>1.5 or aPTT>60s), n (%) 8 (1) 4 (3) 6.7 0.008
SOFA>0, n (%) 691 (67) 118 (17) 3.3 <0.001
SOFA - Sepsis-related Organ Failure Assessment, OR – Odds ratio
The AU-ROC(CI95%) of predicted probabilities for hospital mortality for each PIRO component and
the combined PIRO model, in the derivation and in the validation cohorts, are shown in table 4.4.4.
The combined PIRO model had an AU-ROC of 0.85 (0.82-0.88) in the derivation cohort and 0.84
(0.76-0.91) in the validation cohort. The Hosmer and Lemeshow test did not show evidence for
lack of fit in all four components or in the combined model, be it in the derivation or in the vali-
dation cohorts (p>0.1). Comparing this new PIRO model with SAPS II, it shows a higher discrimi-
nation power, with an AU-ROC of 0.85 vs 0.81. The performance was also different according to dif-
ferent settings: the PIRO score performed better in the ward with an AU-ROC of 0.84 vs 0.78 of the
SAPS II while in the ICU setting both had a similar performance, AU-ROC = 0.83 (table 4.4.4).
Using the rounded regression coefficients for each variable, a weighted clinical classification rule
was generated to yield the PIRO scores for each component (table 4.4.5). Figure 4.4.1 shows the
“Classification tree used to define cut-offs for each score and identify clusters of risk of death in
the derivation cohort”, allowing patients’ stratification in risk stages for each variable.
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Table 4.4.3 – Selection of variables independently associated with hospital mortality using logistic regression, within each
of the four components of PIRO.
Variables Total, 
n (%)
Non-survivors,
n (%)
Regression
coefficients
Adjusted OR CI95% p- value
Predisposition
Age 
≤60 years, n (%) 388 (38) 18 (5) 1.0
61-80 years, n (%) 387 (37) 63 (16) 0.7 2.0 1.5-2.7 <0.001
>80 years, n (%) 260 (25) 57 (22) 1.4 4.0 2.2-7.3 <0.001
Male sex, n (%) 506 (49) 79 (16) 0.6 1.8 1.2-2.6 0.005
Previous antibiotic therapy, n (%) 367 (36) 67 (18) 0.7 1.9 1.3-2.9 0.001
Chronic hepatic disease, n (%) 22 (2) 8 (36) 1.9 7.0 2.5-19.0 <0.001
Chronic haematologic disease, n (%) 60 (6) 17 (28) 1.5 4.3 2.2-8.5 <0.001
Cancer, n (%) 45 (4) 18 (40) 1.7 5.6 2.8-11.1 <0.001
Atherosclerosis, n (%) 242 (23) 54 (22) 0.5 1.6 1.0-2.4 0.050
Karnovsky index<70, n (%) 319 (31) 81 (25) 0.9 2.4 1.6-3.8 <0.001
Infection
Community-acquired, n (%) 493 (48) 47 (10) 1.0
Healthcare-associated, n (%) 225 (22) 32 (14) 0.5 1.6 1.0-2.5 0.064
Hospital-acquired, n (%) 316 (30) 59 (19) 0.8 2.2 1.4-3.3 <0.001
Response
Temperature
No alteration, n (%) 461 (45) 57 (12) 1.0
Fever, n (%) 336 (33) 35 (10) -0.4 0.7 0.4-1.1
Hypothermia, n (%) 238 (22) 46 (19) 0.3 1.4 0.9-2.1
Tachypneia, n (%) 457 (44) 83 (18) 0.4 1.5 1.0-2.3 0.049
Hyperglycemia, n (%) 159 (15) 38 (24) 0.6 1.7 1.1-2.8 0.016
Severity of infection
Infection or sepsis, n (%) 645 (62) 50 (8) 1.0
Severe sepsis, n (%) 296 (29) 46 (15) 0.7 1.9 1.2-3.0 0.005
Septic shock, n (%) 94 (9) 42 (45) 2.0 7.4 4.4-12.6 <0.001
Organ dysfunction
Hypotension, n (%) 175 (17) 63 (36) 1.6 4.6 3.1-7.1 <0.001
SOFA>0 691 (67) 118 (17) 0.7 2.0 1.2-3.4 0.009
SOFA – Sepsis-related Organ Failure Assessment, OR – odds ratio, CI – confidence interval
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Table 4.4.4 – Area under the receiver operating characteristics curve (95% Confidence Interval) of predicted probabilities
by hospital mortality of each PIRO component, the combined PIRO model and SAPS II, in the derivation and in the valida-
tion cohorts
Predisposition Insult Response Organ PIRO SAPS II
Study population (n=1035) 0.79 (0.75-0.83) 0.59 (0.54-0.64) 0.72 (0.67-0.77) 0.71 (0.66-0.75) 0.85 (0.82-0.88) 0.81 (0.77-0.84)
Ward (n=886) 0.84 (0.80-0.88) 0.61 (0.55-0.67) 0.66 (0.60-0.72) 0.66 (0.60-0.72) 0.84 (0.80-0.88) 0.78 (0.74-0.83)
ICU (n=149) 0.77 (0.69-0.86) 0.50 (0.40-0.60) 0.79 (0.71-0.88) 0.70 (0.61-0.79) 0.83 (0.75-0.91) 0.83 (0.76-0.91)
Validation cohort (n=186) 0.75 (0.67-0.83) 0.60 (0.49-0.70) 0.73 (0.64-0.83) 0.77 (0.69-0.85) 0.84 (0.76-0.91) 0.85 (0.78-0.92)
Table 4.4.5 – Scores attributed to the selected variables regarding each of the four components of PIRO.
P score Points I score Points R score Points O score Points
Age Type of infection Altered temperature Hypotension 3
≤60 years 0 CAI 0 No 0 SOFA>0 1
61-80 1 HCAI 1 Fever -1
>80 3 HAI 2 Hypothermia 1
Male 1 Hyperglycemia 1
Previous ATB 1 Tachypneia 1
Chronic hepatic
disease
4
Severity of
infection
Chronic haemato-
logic disease
3
Infection or 
sepsis
0
Cancer 3 Severe sepsis 1
Atherosclerosis 1 Septic shock 4
Karnovsky<70 2
TOTAL 
possible points 18 2 7 4
P  score – Predisposition score, I score – Insult/Infection score, R score – Host Response score, O score – Organ dysfunction score, ATB – antibiotic therapy, 
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, SOFA – Sepsis-related Organ Failure Assessment
Figure 4.4.1 – Classification tree used to define cut-offs for component score and identify profiles of risk of death in
the derivation cohort across the four PIRO components. 
Each node split decision in the tree was chosen from the possible cut-offs for all components, maximizing the within-node homogeneity.
Predisposition had three stages: P1 (0-2 points), P2 (3-4 points) and P3 (≥5 points). Infection had
two stages: I1 (0-1 points) and I2 (2 points). Response had two stages: R1(0-3 points) and R2 (≥4
points). Organ dysfunction had two stages: O1(0 points) and O2 (≥1 points). 
Increasing stages were associated with an increase in hospital mortality rate, both in the deriva-
tion and in the validation cohorts (table 4.4.6). The expected mortality was then computed for all
possible PIRO combinations defining patients’ risk profiles (table 4.4.7). Using this table, the pro-
files were clustered into four stages of increased risk for hospital mortality (Table 4.4.8).
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Table 4.4.6 – Risk of hospital mortality according to the total score of each PIRO component.
Predisposition Insult Response Organ
Risk of mortality 
classification
P1
Low
P2
Medium
P3
High
I1
Low
I2
High
R1
Low
R2
High
O1
Low
O2
High
Score (total sum of points) 0-2 3-4 ≥5 0-1 ≥2 0-3 ≥4 0 ≥1
Derivation Cohort 
Hospital mortality
(n=138)
3% 11% 30% 11% 19% 11% 47% 5% 17%
Percentage of total
patients (n=1035)
45% 25% 30% 69% 31% 93% 7% 33% 67%
Validation Cohort 
Hospital mortality
(n=34)
3% 16% 33% 16% 26% 12% 52% 0% 24%
Percentage of total
patients (n=186)
36% 24% 40% 73% 27% 84% 16% 24% 76%
Table 4.4.7 – Mortality rate and clinical stage according to patients PIRO characteristics, in the derivation cohort. 
Only states with more than 5 patients were included in the table.
PIRO STATES Clinical stage Mortality
n (%)
Total
n
P1 I1 R1 O1 I 0 (0) 129
P1 I1 R1 O2 I 4 (2) 185
P1 I2 R1 O1 I 1 (2) 52
P2 I1 R1 O1 I 1 (2) 44
P2 I2 R1 O1 I 1 (4) 26
P1 I1 R2 O2 II 5 (19) 26
P1 I2 R1 O2 II 5 (7) 69
P2 I1 R1 O2 II 10 (9) 113
P2 I2 R1 O2 II 5 (9) 57
P3 I1 R1 O1 II 9 (16) 56
P3 I2 R1 O1 II 6 (18) 33
P3 I1 R1 O2 III 33 (24) 140
P3 I2 R1 O2 III 28 (49) 57
P2 I1 R2 O2 IV 5 (63) 8
P2 I2 R2 O2 IV 7 (78) 9
P3 I1 R2 O2 IV 12 (71) 17
P3 I2 R2 O2 IV 6 (75) 8
Total I 7 (2) 436
Total II 40 (11) 354
Total III 61 (31) 197
Total IV 30 (71) 42
TOTAL 138 (13) 1029
Stage I (defined as [P1-2 I1-2 R1 O1] or [P1 I1 R1 O2]) included 436 patients with low or medium predis-
position, low response score (without septic shock), and either no organ dysfunction, regardless
of place of acquisition, or with organ dysfunction but without hospital-acquired infection. Patients
in stage I had a hospital mortality rate of 2% (CI95%, 0.4–3%).
Stage II ([P1 I1 R2 O2], [P1 I2 R1 O2], , [P2 I1-2 R1 O2] or [P3 I1-2 R1 O1]) included 354 patients with a low pre-
disposition, without hospital-acquired infection, but with a high response score and organ dys-
function or low predisposition, with hospital-acquired infection, low response (without septic
shock) but with organ dysfunction. This stage also included patients with medium predisposition
score with low response (no septic shock) and organ dysfunction or high predisposition with low
response and no organ dysfunction. This group of patients had a hospital mortality rate of 11%
(CI95%, 8-15%).
The 197 patients in stage III, ([P3 I1-2 R1 O2]) were patients with high predisposition, low response
and with organ dysfunction. These patients had a hospital mortality rate of 31% (CI95%, 25-37%). 
Stage IV ([P2-3 I1-2 R2 O2]) included 42 patients with a medium or high predisposition score, a high
response and also organ dysfunction, regardless of place of acquisition of infection. Their hospital
mortality rate was 71% (CI95%, 58-85%).
In the validation cohort, the mortality rate was 0% in stage I (0 / 52), 9% in stage II (5 / 54), 31% in
stage III (15 / 49) and 67% in stage IV (6 / 9) (table 4.4.9).
In figure 4.4.2 different stages of PIRO obtained according to the different combinations of
Predisposition (P1, P2, P3), Insult (I1, I2), Response (R1, R2) and Organ dysfunction scores (O1, O2) are
shown. 
132 | HEALTHCARE-ASSOCIATED INFECTIONS: CLASSIFICATION, EPIDEMIOLOGY AND TREATMENT
C
H
A
PTER 4.4
Table 4.4.8 – Clinical staging system for hospital mortality in patients with infection according to the total score in each
PIRO component in the derivation cohort (n=1035). 
Only states with more than 5 patients were included in the different stages
Stage I (n=436) Stage II (n=354) Stage III (n=197) Stage IV (n=42)
Predicted hospital mortality 
rate 0%-5%
Predicted hospital mortality
rate 6%-20%
Predicted hospital mortality
rate 21%-50%
Predicted hospital mortality
rate 51%-100%
P1-2 I1-2 R1 O1 P1 I2 R1 O2 P3 I1-2 R1 O2 P2-3 I1-2 R2 O2
P1 I1 R1 O2 P1 I1 R2 O2 
P2 I1-2 R1 O2
P3 I1-2 R1 O1
Observed hospital 
mortality rate = 2%
(CI95% = 0.4-3%)
Observed hospital 
mortality rate =11%
(CI95% = 8-15%)
Observed hospital 
mortality rate = 31%
(CI95% = 25-37%)
Observed hospital 
mortality rate = 71%
(CI95% = 58-85%)
CI – confidence interval 
DISCUSSION
This study proposes a clinical staging system for patients with infection based on the PIRO con-
cept. It was developed and validated in a large cohort of unselected hospitalized patients with
infection because most patients with infection are outside the ICU setting (86% in our study),
widening the clinical application of the original concept proposed. 
Comparing this new PIRO score with other prognostic scores, namely SAPS II, it performed supe-
riorly (0.85 vs 0.81) with a higher discrimination power, especially in the large sub-group of
patients allocated into the ward (0.84 vs 0.78).
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Table 4.4.9 – Mortality rate and clinical stage according to patients PIRO states, in the validation cohort. 
Only states with more than 5 patients were included in the table.
PIRO STATES Clinical stage Mortality
n (%)
Total
n
P1I1R1O1 I 0 (0) 20
P1I1R1O2 I 0 (0) 25
P2I1R1O1 I 0 (0) 7
P1I1R2O2 II 1 (14) 7
P1I2R1O2 II 0 (0) 8
P2I1R1O2 II 3 (17) 18
P2I2R1O2 II 1 (8) 13
P3I1R1O1 II 0 (0) 8
P3I1R1O2 III 8 (22) 36
P3I2R1O2 III 7 (54) 13
P3I1R2O2 IV 6 (67) 9
Total I 0 (0) 52
Total II 5 (9) 54
Total III 15 (31) 49
Total IV 6 (67) 9
Total 26 (16) 164
Figure 4.4.2 – Different stages of PIRO obtained according to the different combinations of Predisposition (P1, P2, P3),
Insult (I1, I2), Response (R1, R2) and Organ dysfunction scores (O1, O2). 
The numbers represent the mortality rate for each state, e.g., the state P1I1R2O2 had a mortality of 19% in the derivation cohort and 14% in the derivation cohort.
Only states with more than 5 patients were considered. The dashes (-) indicate that there was not enough patients in the respective state to evaluate mortality.
Another study [21] has also compared the performance of another PIRO score [11] with APACHE II [14]
and MEDS [22] scores in patients admitted into the emergency department with criteria for early
goal directed therapy and the severe sepsis resuscitation bundle (that is patients with severe sep-
sis) and found that for this group of patients, the discrimination power of PIRO and APACHE II (AU-
ROC = 0.71) was better than MEDS (AU-ROC = 0.63). The PIRO score proposed by us, presents an
even higher discrimination power (AU-ROC = 0.85); however, it should be noted that different
populations are included in both studies, but this staging system preformed equally well in more
severe populations as it will be discussed later. Four clinical stages of increased risk of hospital
mortality were reached, based on “P” characteristics: age, gender, previous antibiotic therapy,
chronic hepatic disease, chronic hematologic disease, cancer, atherosclerosis and a Karnofsky
index<70; “I”: type of infection; “R”: abnormal temperature, tachypnea, hyperglycemia, and the
severity of infection and “O”: hypotension and a SOFA score≥1. 
The validation cohort comprised more severe patients, which can perhaps be explained by sea-
sonal variation, as it included patients admitted in the winter, a period coincident to higher occu-
pation rates of hospital beds with more unscheduled admissions. The higher severity of the
patients included in the validation cohort is probably the explanation for the higher mortality rate
observed. Nonetheless, even in this cohort of more severe patients, the clinical staging system
performed equally well, which is a good indication of the generalizability of the model.
Many interventions tested in clinical trials of critically ill patients with severe sepsis have failed to
show benefit. One of the potential reasons for this was an inadequate, non-specific selection of
patients enrolled in those trials relying mostly on the original systemic inflammatory response syn-
drome (SIRS) criteria, with equal weight being given to all variables. A clinical staging system
derived from a prognostic model, attributing different weights to each co-variable of the four PIRO
components, is more likely to better stratify patients and refine inclusion criteria in such trials. 
Previous studies have been limited to selected populations or hospital settings [5, 7-11]. Lisboa et al [7]
developed a score derived from the PIRO concept to predict ICU mortality in patients with ventila-
tor-associated pneumonia. Rello et al [8], performed a similar study focused only on community
acquired pneumonia requiring ICU admission. The present study enriches previous findings by
including the three most frequent focus of infection which leads to patients requiring hospital care.
Howell et al [10] developed a scoring system on patients admitted to the emergency department
with suspected infection. However, they did not follow subsequent information from the hospital
course, so patients ultimately found to have a non-infectious diagnosis may have been included.
The only inclusion criteria in the present study was the presence of clinical infection, assessed by
the CDC definitions [12] which can be done immediately at bed side, thus not delaying patient
stratification and its adequate application in the current study was reinforced by the high micro-
biological documentation rate, minimizing selection bias. 
Moreno et al [9] developed a score in ICU patients, from a subset of patients from the SAPS III data-
base, using a modified definition of PIRO (PIR). They excluded patients who died during the first 48h,
which might exclude patients with high response and organ dysfunction scores (like septic shock),
thus underweighting these components in their model. Besides including all patients regardless of
the severity of infection, the present study evolves further into a clinical staging system.
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Rubulotta et al [11] also performed a secondary analysis of two cohorts of ICU patients (PROWESS
and PROGRESS databases) and defined a basic phenotypic characterization of patients admitted
with severe sepsis. However, in their retrospective study it was not possible to analyze all variables
originally proposed [2]. Being prospective and following a rigorous methodology, including a large
cohort of unselected hospitalized patients with infection, the present study has reached a pilot
clinical staging system that might include all clinical relevant variables.
Classification trees were used to optimize the discrimination ability of the model rather than
determine cut-offs heuristically after a logistic regression. Finally an independent validation
cohort was used to assess the robustness of the data and over fitting of the derived model.
Although proponents of the PIRO staging system suggested including biomarkers and/or vari-
ables reflecting genetic predisposition, these tools are not yet widely or routinely available. Thus,
analyses were derived from covariates currently available at bedside, which might help immedi-
ate patient management. Data on microbiology documentation and antibiotics appropriateness
were also not included, although they could represent major prognostic factors, they are not read-
ily available for early stratification, which is the main goal of the proposed staging system. 
The differences in mortality rates between the cohorts can be explained by random variability due
to the small sample size of the validation cohort. However, this is a single-center study with a limit-
ed number of patients, both in the derivation and in the validation cohorts; nonetheless, it might
represent a major step forward in the clinical application of the PIRO concept, expanding its appli-
cability to all hospitalized patients with infection. Further validation in different settings is needed.
In conclusion, it enriches the findings of previous studies by reaching a clinical staging system
through its prospective designed with consideration of all proposed variables [2], including
patients at various levels of care inside the hospital, with different focus of infection and severity
of disease, widening its application to the vast majority of infected patients, with a robust behav-
ior both in the derivation (AU-ROC = 0.85) and in the validation cohort (AU-ROC = 0.84).
At this point, we propose its use mainly after further validation, for early stratification and inclusion in
clinical trials. We hope that in the very near future, it can also be useful to tailor individual therapy.
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CONCLUSIONS
This study proposes a clinical staging system according to the PIRO concept, with stratification of
patients according to their risk of death, derived from different scores obtained in Predisposition
considering: age, sex, previous antibiotic therapy, chronic hepatic disease, chronic hematologic
disease, cancer, atherosclerosis and a Karnofsky index<70; type of infection in Insult/Infection;
abnormal temperature, tachypnea, hyperglycemia and severity of infection in Response and
hypotension and SOFA score≥1 in Organ dysfunction. It allowed the building of four stages with
increased risk of mortality: from stage I [i.e., P1I1R1O1] associated with a low (≤5%) risk of death, to
stage IV [i.e., P3I2R2O2], where the risk of mortality is highest (>50%). 
Staging infected patients according to the four components of the PIRO system may be a practi-
cal and relevant tool in sepsis research. In particular, this new clinical staging system for hospital
mortality in patients with infection may prove to become a useful triage tool to design individu-
alized management strategies as well as for refining inclusion criteria in clinical trials.
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CHAPTER 5
GENERAL DISCUSSION 
AND CONCLUSIONS
Foto by Virginia Lopes

5. GENERAL DISCUSSION AND CONCLUSIONS
5.1. GENERAL DISCUSSION
The definition of healthcare-associated infections (HCAI) proposed by Friedman et al. [1] is the
most widely used in clinical studies. Despite that, it is a definition far from consensus and several
additional criteria have been proposed to be included, considering that they might represent
additional risk factors for infection by multi-drug resistant (MDR) organisms. We found that age
>60 years, hospitalization in the previous year (in the last 4 to12 months), previous antibiotic ther-
apy (last month) and Karnofsky index <70 were significantly and independently associated with
infection by MDR pathogens, criteria not considered in the initial definition [1]. 
This is probably one of the first studies containing a thorough description of independent and
significant risk factors associated with infection by pathogens of the ESKAPE group, namely pre-
vious antibiotic therapy and need for help in daily activities (measured by a Karnofsky index<70),
along with their significant higher rate of inadequate antibiotic therapy, without a significant
impact in hospital length of stay or mortality. 
As with the patients infected by microorganisms from the ESKAPE group, also those with infection
by any MDR microorganism had a significantly higher rate of inadequate initial antibiotic therapy,
but did not have a longer hospital length of stay or higher hospital mortality rate. 
The data described in chapter 4.2 confirms that HCAI have distinct microbiological profiles when
compared with community-acquired (CAI) and hospital-acquired infections (HAI), for the major
focus of infection: intra-abdominal, urinary, respiratory and primary bloodstream infections,
including different rates of resistance. 
Patients with HCAI represented 31% of all patients admitted from the community setting and near-
ly half were treated according to community-acquired infections treatment recommendations [2-4],
suggesting that doctors do not differentiate this sub-group of patients among those with CAI. The
group of patients with HCAI who were treated according to the international recommendations
for CAI had a higher rate of inadequate antibiotic therapy than those in whom CAI treatment rec-
ommendations were not followed. 
Healthcare-associated infections were independently associated with inadequate antibiotic ther-
apy but not with hospital mortality. Inadequate antibiotic therapy was an independent risk factor
for increased hospital mortality.
Finally, we propose a clinical staging system for patients with infection based on the PIRO con-
cept, where HCAI plays a major role in Infection category. It was developed and validated in a large
cohort of unselected hospitalized patients with infection because most patients with infection
are outside the ICU setting (86% in our study), widening its clinical application to the majority of
in-hospital patients. 
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A consensus definition of HCAI is needed in order to proceed to a thorough characterization of
microbiology and then move forward to the development of specific treatment recommenda-
tions, in an attempt to decrease the associated higher rate of inadequate initial antibiotic therapy,
a well-known prognostic factor.
The initial HCAI definition [1] included treatments delivered at home or in an outpatient clinic and
these criteria have been widely adopted in other studies. The receipt of intravenous therapy [5-17],
wound care or specialized nursing care [8, 12-14, 17-19], and hemodialysis [5, 6, 8, 9, 11-26], as well as atten-
dance to a hospital or clinic [17, 18, 21, 24] are important factors as this group of patients have
documented higher rates of colonization and infection with MDR microorganisms [27-29]. Other
studies have included the criteria of other previous invasive procedures [6, 7, 17], like urological pro-
cedures [17]. There is no reason to believe that this last group of patients is different from the pre-
vious ones in regards to the risks of infection by MDR organisms. 
The variations to the criteria included in the initial definition [1] go from studies that include hos-
pitalization in the previous 30 days as a criteria for HCAI [6, 20, 26, 30] while others excluded patients
discharged from the hospital within the last 14 days from this group of infections [15, 23]. Regarding
previous hospitalization, we believe that this criterion must be retained in any definition of HCAI.
The presence of MDR organisms (gram positives or gram negatives) has been documented
between 6 months to one year after hospital discharge [31-33]. This risk of long lasting colonization
of both the respiratory and gastrointestinal tract with pathogens not present in the community
following hospitalization has led some authors to alter this criteria to hospitalization in the previ-
ous 6 months [18, 22, 24] or even one year [25]. However, the classification of infections that develop
among patients recently discharged from the hospital (in the previous 14 days) is somewhat con-
tentious. Some authors consider these infections occurring within 14 days of hospital discharge
nosocomial infections [27, 29, 34], while others consider infections among those hospitalized in the
last month as HCAIs. Therefore among different studies, depending on the definition of the crite-
ria of prior hospitalization, an infection occurring in the 2 weeks after hospitalization could poten-
tially be defined as HCAI or HAI [15, 20]. In our study hospitalization in the previous year was inde-
pendently associated with infection by a MDR organism.
Another criterion in the initial definition [1] is receiving chemotherapy in the last 30 days. This is a
criteria frequently used among alternative definitions [5-7, 9, 11, 13, 15, 17, 18, 23, 24] along with having active
or metastatic cancer [20, 21] that suggest receipt of some kind of anti-cancer therapy. These are a
special group of patients due to underlying immunosuppression. Immunosuppression, including
HIV infection and treatment with immunosuppressive agents is a criteria considered by several
authors [9, 11, 19, 20, 22, 25], but specifically excluded by others [23, 24]. The inclusion of these groups of
patients in the definition of HCAI is possibly one of the most controversial issues. In our popula-
tion immunosuppression was not significantly associated with infection by a multi-drug resistant
pathogen but we have excluded patients that were already under chemotherapy because it was
part of the definition adopted for the study. Nevertheless the variety of pathogens involved in this
group of patients varies largely according to the underlying cause, for example it is completely dif-
ferent in an advance HIV [35] or in a febrile neutropenic patient [36], demanding significantly differ-
ent treatments, a significant barrier for their inclusion in the same group.
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Patients admitted from nursing homes with infection have been extensively studied and may
constitute more than 50% of all cases of healthcare-associated pneumonia [28]. This criterion has
been considered by almost all studies; however caution is needed with this approach. Patients
with non-severe nursing home-acquired pneumonia (NHAP) have a pathogen distribution similar
to those expected in CAP [37]. Among, patients with severe NHAP, with organ dysfunction, resistant
pathogens have been seen [8, 37, 38]. Poor functional status and increased age have been linked to
an increased risk of infection with a MDR pathogen among NHAP patients [39, 40], and are linked to
the level of care provided in these facilities. Nursing homes with hospital-like wards carry the
same infection risk by resistant pathogens as hospitals, and should best be considered as the anal-
ogous to HAIs. Clinicians should consider factors such as functional status and level of care
required in selecting treatments for patients who reside in nursing homes. Like in previous stud-
ies restricted to NHAP, we have also found that increasing age and poor functional status were
independently associated with infection by MDR organisms, regardless of the focus of infection or
HCAI category.
Patients with recent treatment with broad spectrum antibiotics [19] were found to have a higher
proportion of multidrug resistant (MDR) pathogens in the population with HCAI pneumonia
when compared with CAI, a finding similar to the current study. 
Even with the adopted definition [1], this cohort of patients with HCAI had distinct microbiological
profiles when compared with those with CAI and HAI, considering not only the overall microbiol-
ogy profile but the rates of resistance for each focus of infection. This study adds to previous ones
the inclusion in the same cohort of patients all major foci of infection that result into hospital care:
intra-abdominal, urinary, respiratory and bloodstream infections; which represents nearly 90% of
all infections [41, 42]. 
Additionally this is the first study to describe and compare the microbiological profile of intra-
abdominal HCAI with CAI and HAI, where polymicrobial infections played an important role as
well as MDR-GN. The Infectious Diseases Society of America guidelines recommended for the
management of complicated intra-abdominal infection [3] an antipseudomonal cephalosporin,
carbapenem or b-lactam/b-lactamase inhibitor plus metronidazol. Based in our results these rec-
ommendations would be appropriate for our group of patients. 
In urinary HCAI, we found a high rate of MDR-GN bacilli (70%). The HAI Summit Critical Appraisal
[43] suggested that serious HCAI due to suspected gram-negative bacteria, independently of the
site of infection, should be treated empirically with dual coverage that includes aminoglycosides.
That broad spectrum approach may not be needed in our group of patients with urinary and
intra-abdominal infections, due to the lower rate of resistance to piperacillin-tazobactam
observed. The rate of ESBL producers is still low (10%), thus not justifying empirical coverage
among all our patients. A previous study on UTI [44] did not found significant differences in the
microbiological profile comparing HCAI with CAI and HAI, but did not analyse antibiotic resist-
ance as we did. 
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Although there are numerous studies on HCAI pneumonia, the vast majority just compares HCAI
with CAI, leaving aside the major question: should American Thoracic Society (ATS) and Infectious
Diseases Society of America recommendations [45] be applied to all these patients? Our data on
respiratory infections suggests that empirical coverage of Pseudomonas aeruginosa would be
adequate; however, regarding MRSA coverage, although it was the second more prevalent
pathogen in HCAI and HAI respiratory infections, it was only found in patients with risk factors,
namely: previous instrumentation, hospital admissions in the previous year or previous antibiotic
therapy. No MRSA respiratory infection was diagnosed in patients without any of those risk fac-
tors. In our population with respiratory HCAI, empirical coverage of MRSA is only justified in
patients with risk factors for it. Previously only one study used this definition to study CAI, HCAI
and HAI simultaneously [46], and it did not provide a detailed microbiological characterization,
namely the prevalence of MRSA among those infections.
Regarding bloodstream infections clinicians must considerer whether the likely bacteremia
reflects a primary process or results secondarily from an infection elsewhere. This distinction is not
always made in epidemiological studies [1, 47-49], but it is fundamental for initial antibiotic treatment
planning. 
Patients with HCAI had a higher rate of inadequate antibiotic therapy than those with CAI.
Decision making regarding antibiotic treatment is unique, few treatments equals its efficacy. In a
meta-analysis [50] on the efficacy of adequate empiric antibiotic therapy for sepsis, the pooled OR
for all-cause mortality was 1.6, corresponding to a number needed to treat (NNT) of 10 to save one
life, higher than aspirin in acute myocardial infarction (NNT = 41), reinforcing the relevance to get
initial antibiotic therapy adequate in severe infection, which is only possible if doctors are famil-
iarized with this classification.
The adequate treatment of healthcare-associated infections is primarily dependent on the correct
classification in patients that come from the community as CAI or HCAI. Previous studies [1, 48, 51]
have shown that patients with HCAI have different microbiological profiles than those with CAI,
namely a higher rate of multi-drug resistant pathogens, suggesting that the existing guidelines
for CAI might not be applicable. Clinicians need to be aware of this difference in order to adapt
empiric antibiotic therapy for HCAI patients.
There are a large number of epidemiological studies on healthcare-associated infections [38, 48, 49, 51-
55] but the existing evidence needs to be systematized, in order to make information more prof-
itable. Respiratory infections are the ones most widely addressed and the American Thoracic
Society has already published specific recommendations for healthcare-associated pneumonia
[45]; nevertheless, the wide-spectrum antibiotic therapy proposed for these patients has turned
into a much debated subject where there is no consensus among clinicians. Additional studies are
needed in this area, with thorough microbiologic characterization from different settings, before
specific recommendations regarding empirical treatment for different focus of HCAI can be made.
HCAI was not found to be an independent risk factor for hospital mortality although the associa-
tion of HCAI and higher mortality was described in the studies by Kollef et al. [51] and Shorr et al. [48].
However, none of them provides a measure of association between the two variables. 
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There are several studies describing the negative impact of initial inadequate antibiotic therapy
on mortality [56-63]. The results of the present study are in accordance with previous findings, from
different centres and geographical areas, increasing the probability of wide external applicability
of the main results.
The final purpose of this study was to answer the challenge posed by the authors of the PIRO con-
cept: the development of a clinical staging system based on the Predisposition of the patient, the
type of Insult/Infection characteristics, the host Response and the Organ dysfunction, aiming to
determine the role played by HCAI in it.
Most patients with severe infection are outside the ICU setting (86% in this cohort), so the clinical
staging system for patients with severe infection should be developed in different hospital set-
tings and this was the adequate population for the development and validation of such a staging
system, widening its clinical application and inserting HCAI in it which has never been done
before.
Four clinical stages of increasing risk of hospital mortality were reached, based on “Predisposition”,
namely: age, gender, previous antibiotic therapy, chronic hepatic disease, chronic hematologic dis-
ease, cancer, atherosclerosis and a Karnofsky index<70; on type of “Infection”: CAI, HCAI or HAI; on
host “Response”: abnormal temperature, tachypnea, hyperglycemia, and the severity of infection
and on “Organ dysfunction”: hypotension and a SOFA score≥1. Previous studies have been limited
to selected populations or hospital settings: ventilator-associated pneumonia [64], community
acquired pneumonia [65], ICU setting [64-66]. The present study enriches findings of those studies by
including the most frequent focus of infection that drives patients into hospital care and different
hospital settings (ICU and ward).
Previous authors have focused in a model development [67, 68] or a scoring system [64-66] for ICU
patients and another for patients in the Emergency Department with suspected infection [69] but
only one reached a staging system [70] for patients with severe sepsis, done on a previous existent
database not designed for that purpose and so not allowing the inclusion of all originally pro-
posed variables [71]. 
Although it is a single center study with a limited number of patients both in the derivation and in
the validation cohorts it enriches the findings of previous ones by reaching a clinical staging sys-
tem, through its prospective designed, with consideration of all variables originally proposed [71],
including patients at various levels of care inside the hospital, with different focus of infection and
severity of disease, widening its application to the vast majority of infected patients, with a robust
behavior in the derivation (AU-ROC = 0.85) and in the validation cohort (AU-ROC = 0.84).
Healthcare-associated infection played a major role in the infection component of PIRO.
Many interventions tested in clinical trials of critically ill patients with severe sepsis have failed to
show benefit. One of the potential reasons for this was an inadequate, non-specific selection of
patients enrolled in those trials relying mostly on the original systemic inflammatory response syn-
drome (SIRS) criteria, with equal weight being given to all variables. A clinical staging system
derived from a prognostic model, attributing different weights to each co-variable of the four PIRO
components, is more likely to better stratify patients and refine inclusion criteria in such trials. 
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Classification trees were used to optimize the discrimination ability of the model rather than
determine cut-offs heuristically after a logistic regression. Finally an independent validation
cohort was used to assess the robustness of the data and over fitting of the derived model.
Although proponents of the PIRO staging system suggested including biomarkers and/or vari-
ables reflecting genetic predisposition, these tools are not yet widely or routinely available. Thus,
analyses were derived from covariates currently available at bedside, which might help immedi-
ate patient management. Data on microbiology documentation and antibiotics appropriateness
were also not included, although they could represent major prognostic factors, they are not read-
ily available for early stratification, which is the main goal of the proposed staging system. 
The prospective design of this study, with clear definitions in the protocol, the inclusion of differ-
ent wards of the hospital including intensive care and of the four major focus of infection with a
thorough comparison of those with HCAI with those with CAI and HAI, allowed a more clear
microbiology characterization.
This study had a thorough data collection made by a single trained doctor allowing full comple-
tion of all protocols with no missing data per item, along with a complete follow up of all patients
until hospital discharge, minimizing any information bias. 
Despite being a single-centre study, the microbiological profile we describe for respiratory HCAI
is very similar to the one described in the USA [51, 54]. The microbiological profile found in BSI was
similar to the descriptions in Canadian [53], Spanish [49] and USA [48] studies suggesting that our
results might be generalized for other settings. 
There are also some limitations that should be pointed. Being a single center study, the number
of patients in each category is relatively small. Overall, only 68% of the patients had microbiolog-
ic documentation of infection and were evaluated for the adequacy of empirical antibiotic thera-
py; this may limit the logistic regression analysis in terms of its ability to detect all independent
variables associated with inadequate antibiotic therapy and outcome. Nevertheless the variables
founded were clinically significant and relevant, easily recognizable, and could be applied as addi-
tional aids to avoid inadequate antibiotic therapy.
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5.2. CONCLUSIONS AND SUGGESTIONS FOR FURTHER RESEARCH
The results of the current study on healthcare-associated infection: classification, epidemiolo-
gy and treatment, allowed the following conclusions for this population:
1. Healthcare-associated infections represented an important proportion of patients admit-
ted to hospital with severe infection from the community setting. 
2. The adopted definition of HCAI [1] for this study is the one more widely used in clinical
studies but individual criteria and the final composition are far from consensus and
require ongoing discussion.
3. HCAI appears to have different microbiological profiles globally and by different foci of
infection, with different proportions of resistant pathogens. Further studies using a con-
sensual definition are needed that make an accurate comparison of HCAI with CAI and
HAI for the major focus of infection in different hospital settings. Involving a large number
of patients from different institutions and geographic areas is warrant to fully character-
ize microbiology of HCAI and move towards the development of specific treatment rec-
ommendations.
4. The lack of a consensual definition of HCAI difficultes its recognition with an associated
higher inadequate initial antibiotic therapy. There is a need to sensitize doctors for this
growing group of patients arriving from the community setting but with a close contact
with the healthcare system.
5. HCAI infection was not an independent risk factor for hospital mortality.
6. A clinical staging system was proposed based on patients’ Predisposition, type of
Infection, host Response and Organ dysfunction (the PIRO concept) allowing stratification
of patients according to their risk of death, from stage I [i.e., P1 I1 R1 O1] associated with a
low (≤5%) risk of death, to stage IV [i.e., P3 I2 R1 O2], where the risk of mortality is highest
(>50%). Healthcare-associated infections played a significant role in type of Infection, with
behaviour similar to CAI. This new clinical staging system for hospitalized patients with
infection needs to be further validated in different settings and geographical areas before
being used in clinical practice.
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